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 La trombina è una proteasi serinica appartenente, per omologia di sequenza, alla 
famiglia della chimotripsina dalla quale differisce per la presenza di numerosi loop
d’inserzione, che le conferiscono una peculiare specificità di substrato. Essa si presenta come 
un ellissoide caratterizzato da due β-barrels, alla giunzione dei quali si colloca la cavità che 
ospita il sito attivo. Il riconoscimento molecolare dei diversi effettori, invece, è mediato da 
due regioni superficiali elettropositive, diametralmente opposte e circondanti la cavità 
catalitica. Queste sono definite, rispettivamente, esosito-I (Anion Binding Exosite-I o 
Fibrinogen Recognition Site) ed esosito-II (Anion Binding Exosite-II o Heparin Binding Site). 
L’esosito-I è coinvolto nel legame della trombina al fibrinogeno, al recettore piastrinico PAR-
1, alla trombomodulina, e a inibitori endogeni, come il fattore eparinico II, ed esogeni come la 
coda C-terminale dell’irudina. L’esosito-II rappresenta il sito di legame per l’eparina, per il 
frammento F2 della pro-trombina e per inibitori fisiologici come l’antitrombina III e la 
nexina-I. A differenza della chimotrispsina, l’attività proteolitica della trombina è aumentata 
dal binding del Na+ che stabilizza l’enzima in una conformazione più aperta e rigida. 
 La trombina è una proteasi multifunzionale: da una parte gioca un ruolo importante 
nella cascata coagulativa, dall’altra interviene in modo fondamentale nei processi 
infiammatori a carico del sistema nervoso centrale. Infatti, la trombina svolge un ruolo chiave 
all’interfaccia tra coagulazione, infiammazione, differenziamento cellulare, angiogenesi e 
malattie neurodegenartive, manifestando così effetti pleiotropici. Studi in vitro hanno 
evidenziato come tale proteina sia in grado di modulare la permeabilità vascolare, la 
formazione di neo-vasi e la ritrazione di neuriti su cellule di neuroblastoma; per di più sembra 
svolgere attività mitogena a carico di cellule muscolari ed endoteliali. Questi effetti si 
realizzano a basse concentrazioni (1-10nM), mentre concentrazioni maggiori (100nM) 
sembrano essere nocive e pro-infiammatorie a livello cerebrale. Allo stesso modo, elevate 
concentrazioni plasmatiche di trombina (100-500nM) portano alla formazione di un clot
compatto di fibrina, non suscettibile a fibrinolisi. Alcuni studi hanno dimostrato come la 
maggior parte delle funzioni non emostatiche si manifestino mediante l’attivazione dei 
recettori piastrinici PAR (Protease Activated Receptors), recettori transmembrana accoppiati 
a proteine-G. Nel dettaglio, il dominio extracellulare del PAR-1, in seguito a proteolisi 
promossa dalla trombina, interagisce col corpo recettoriale favorendo la trasduzione del 
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segnale all’interno di piastrine e macrofagi. Il tutto si traduce in una risposta pro-aggregante e 
pro-infiammatoria. Questi dati suggeriscono la presenza di una stretta comunicazione 
biochimica tra i vari meccanismi che regolano i differenti effetti cellulari della trombina. 
Alla luce di queste considerazioni, l’obiettivo saliente del mio Progetto di Dottorato è 
stato quello di identificare nuovi effettori della trombina, i cui meccanismi di interazione 
possono avere importanti ricadute nella definizione dei processi biochimici che regolano 
l’insorgenza e la progressione delle malattie cardiovascolari, neurodegenerative ed 
autoimmuni. 
Durante il primo anno ho studiato l’effetto della beta2 glicoproteina I (β2GpI) sulle 
funzioni pro- e anti- coagulanti della trombina (Capitolo 2). La β2GpI, identificata come il 
principale antigene della sindrome da anticorpi antifosfolipidi (APS), è in grado di inibire le 
attività procoagulanti (generazione di fibrina ed aggregazione piastrinica) della trombina in 
vitro, senza compromettere l’unica sua funzione anticoagulante, ovvero la generazione di 
Proteina C attiva. I nostri esperimenti, condotti principalmente mediante surface plasmon 
resonance (SPR) hanno permesso inoltre di chiarire il binding mode di interazione delle due 
proteine: la β2GpI si lega agli esositi della trombina, il cui sito attivo rimane quindi 
accessibile al substrato. 
Nel corso del secondo anno ho indagato l’interazione tra l’α-sinucleina (α-Sin) e la 
trombina umana (Capitolo 3). α-sin è una piccola proteina solubile presinaptica, implicata in 
diverse patologie neurodegenerative. Recentemente è stato dimostrato come l’α-Sin sia in 
grado di inibire l’attivazione e quindi l’aggregazione delle piastrine quando stimolate da 
trombina, limitando il rilascio degli α-granuli. Inoltre pazienti affetti dal morbo di Parkinson 
sono meno soggetti ad attacchi ischemici e presentano una velocità di aggregazione 
piastrinica significativamente ridotta. I risultati da noi ottenuti indicano che la porzione acida 
C-terminale dell’α-Sin è in grado di legarsi alla trombina con un’affinità nell’ordine del basso 
micromolare, coinvolgendo i due esositi. Quindi, il complesso [α-Sin - trombina] ostacola 
efficacemente l’aggregazione piastrinica, molto probabilmente in seguito all’ancoraggio del 
dominio N-terminale sulla superficie delle piastrine. 
Infine, durante l’ultimo anno, è stata presa in considerazione la ceruloplasmina umana 
(CP), quale possibile binder della trombina (Capitolo 4). Elevati livelli di CP sono stati 
individuati in pazienti affetti da artrite reumatoide, malattia infiammatoria cronica 
autoimmunitaria a carico delle articolazioni sinoviali. Come osservato per la CP, i livelli di 
trombina sono notevolmente aumentati in tessuti infiammati e, in modo particolare, nel fluido 
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sinoviale di pazienti affetti da artrite reumatoide. Difatti, la trombina agisce come mediatore 
pro-infiammatorio e chemiotattico. In nostri dati indicano che la trombina è in grado di 
ostacolare, in seguito a proteolisi, l’attività antiossidante della ceruloplasmina. Queste 
evidenze sperimentali sono state confermate dal fatto che in presenza di irudina il cleavage
della CP è inibito e l’infiammazione articolare nei soggetti con artrite reumatoide è ridotta.
4 
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 Thrombin is a serine protease of the chymotrypsin family. Compared to chymotrypsin, 
thrombin displays several insertion loops, responsible for the unique substrate specificity of 
the enzyme. Two different insertions shape and narrow the access to the active site, while the 
interaction of binders involves allosteric sites, called exosite-I (Anion Binding Exosite-I or 
Fibrinogen Recognition Site) and exosite-II (Anion Binding Exosite-II or Heparin Binding 
Site). These contain electropositive amino acid residues and are localized at opposite poles of 
the active site, representing two potential exosites for the binding of macromolecular ligands. 
Exosite-I is involved in binding to fibrinogen, platelet receptor PAR-1, thrombomodulin, and 
to endogenous (i.e. heparin cofactor II) and exogenous (i.e. C-terminal tail of hirudin) 
inhibitors. Exosite-II interacts with heparin, F2 prothrombin fragment, and physiological 
inhibitors such us antithrombin III and protease nexin-I. Contrary to chymotrypsin, the 
proteolytic activity of thrombin is enhanced upon binding of Na+, that stabilizes the enzyme 
into a more open and rigid conformation. 
 Thrombin is a multifunctional enzyme that plays a key role at interface between 
coagulation, inflammation and nervous system. The protease is involved in numerous 
physiological and pathological processes, including haemostasis and thrombosis, 
inflammation and chemotaxis, cellular proliferation and tumor growth, angiogenesis and 
neurodegenerative diseases, manifesting pleiotropic effects. For example, low concentrations 
of thrombin (i.e. 1-10nM) can influence glia cell mitosis and neuronal out-growth, acts as 
mitogen. Conversely, higher concentration of the enzyme (100nM) has been shown to induce 
apoptosis in motor neurons and to determine in the brain a pro-inflammatory state. Instead, in 
vivo, the dynamic concentration of free thrombin during coagulation cascade reactions is 
estimated to vary from 1nM to over 100 – 500nM. Typically low concentration are associated 
with platelet activation and loosely organised fibrin strands susceptible to fibrinolysis; higher 
concentration produce tightly packet fibrin strands capable of forming a stable clot. Some of 
these effects are mediated by activation of Protease Activated Receptors (PARs). The general 
mechanism by which proteases activate PARs is the same: enzymes cleave at specific sites 
within the extracellular amino terminus of the receptors; this cleavage exposes a new amino 
terminus that serves as a tethered ligand domain, which binds to conserved regions in the 
second extracellular loop of the cleaved receptor, resulting in the initiation of signal 
Abstract 
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transduction. All these observations argue in favor of a biochemical communication between 
the different mechanisms regulating the cellular effects of thrombin. 
 The general aim of my PhD project was to identify novel effectors of thrombin, whose 
interaction may have important implications in defining the biochemical processes that 
regulate the onset and progression of cardiovascular diseases, neurodegenerative and 
autoimmune diseases. 
 During the first year, I studied the effect of beta2-glycoprotein I (β2GPI) on the 
procoagulant (i.e. fibrin generation and platelet aggregation) and anticoagulant (i.e. generation 
of activated protein C) functions of thrombin (Chapter 2). β2GPI, identified as the major 
antigen of antiphospholipid syndrome (APS), functions as a physiologic anticoagulant by 
inhibiting the key procoagulant activities of the protease, without affecting its unique 
anticoagulant function. Our experiments, conducted by surface plasmon resonance (SPR), 
clarify the binding mode of interaction: β2GPI binds to thrombin exosites, while the active 
site remains free and accessible for substrate binding. 
 In the second year of my PhD course, I have investigated the interaction between α-
synuclein (α-Syn) and human thrombin (Chapter 3). α-Syn is a small soluble presynaptic 
protein implicated in different neurodegenerative disorders. Recent studies indicated that α-
Syn is able to inhibit platelets degranulation, upon thrombin stimulation. In addition, clinical 
studies indicated that the incidence of ischemic stroke in patients with Parkinson disease is 
lower than in controls, and platelet aggregation is also significantly decreased. Our results 
suggest that the acidic C-terminal portion of α-Syn binds to thrombin exosites (Kd ~ µM). 
Consequently, we speculate that the complex [α-Syn – thrombin] effectively hinders platelet 
aggregation, due to the interaction of the N-terminal domain on the platelets surfaces. 
 During the last year, I studied human ceruloplasmin (CP) as a possible binder of 
thrombin (Chapter 4). The plasma level of CP is an important diagnostic indicator of 
inflammatory disease, such as Rheumatoid Arthritis (RA), a chronic systemic inflammatory 
autoimmune disorder. As observed with CP, thrombin concentration is markedly increased in 
inflamed tissues and specifically in the synovial fluid of RA patients. We conclude that the 
anti-inflammatory function of CP is regulated by thrombin: the enzyme, in fact, 
proteolytically hinders the antioxidant activity of CP. These results are confirmed in RA 
patients treated with hirudin that have clinical symptoms ameliorated. These data are 
unprecedented and set the basis for elucidating the biochemical mechanisms underlying the 
progression of inflammation in RA patients. 
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 Human α-thrombin is a serine protease, described in 1982 by Alexander Schidmdt, 
and first identified by Buchanan in 1845 (1). The sequence of heavy chain of human thrombin 
is related to trypsin and chymotrypsin with 35 % sequence identity and 49 % sequence 
similarity; consequentently thrombin sequence numbering follows the numeration of 
chymotrypsynogen (Appendix B) (2). In vivo, thrombin is produced by the enzymatic 
cleavage of prothrombin, a vitamin K-dependent zymogen. Prothrombin (70 kDa), or 
coagulation factor II, is a glycoprotein with 579 aminoacid residues, produced in the liver 
parenchymal cells and secreted into the blood. In the penultimate step of the coagulation 
cascade, prothrombin is converted to thrombin by the prothrombinase complex comprising 
factor Xa and cofactor Va, assembled on the surface of platelets in the presence of calcium 
ions (3) 
Molecular Structure of Human
 α-Thrombin: the Active Site
 Human α-thrombin (36 kDa) is a heterodimer consisting of two polypeptides called 
chain A and B (2) (Fig. 1.1). The light chain A, consisting of 36 residues, is linked by a single 
disulfide bound to heavy chain B, 250 aminoacid residues, that contains three intra-chain 
disulfide bonds. The B chain carries the functional epitopes of the enzyme and has the typical 
fold of serine proteases, in which the catalytic triad for activity is representative by His57, 
Asp102 and Ser195. Briefly, the C atom is converted into a tetrahedral intermediate in the 
transition state, which is stabilized by hydrogen bonds between the charged carbonyl O atom 
of the peptide group of the scissile bond and the amide hydrogen atoms of Gly193 and Ser195 
which form the oxyanion hole. The substrate is then acylated by the O atom of Ser195 after 
transfer of a proton to His57 and its C-terminal fragment is released. A molecule of water, by 
nucleophilic attack, catalyses deacylation and releases the carboxylic acid product and the N-
terminal fragment of the substrate. Subsequently, Asp102 anchors His57 in the correct 
orientation for proton transfer from and to Ser195, which compensates for the developing 
positive charge (4). 
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Figure 1.1 Crystallographic structure of thrombin. Thrombin (1PPB.pdb) structure is shown in the 
standard Bode orientation, in ribbon (A) and surface (B) mode. The active site containing the catalytic 
triad (H57, D102, and S195, yellow) is covered by the hydrophobic loop W60d (red) and by the 
hydrophilic loop 148 (magenta). Exosite 1 (blue) and 2 (green) are two electropositive patches that 
flank the active site and coordinate substrates/inhibitors recruitment. As for exosites, the Na+-binding 
site (cyan) is located about 15-20 Å away from the catalytic triad, too.  
 Numerous insertions are present in thrombin, relative to trypsin and chymotrypsin, 
shaped as loops connecting -strands in the B chain. Two different insertions shape and 
narrow the access to the active site. The Trp60d loop defines the upper rim of the active site 
and screens His57 and Ser195 from the solvent. The loop contains an insertion of nine 
residues, from Tyr60a to Ile60i, and protrudes into the solvent with the bulky side chain of 
Trp60d providing most of the steric hindrance (5). Opposite to the Trp60d loop, the autolysis 
148-loop forms the lower rim of the active-site cleft. The 148-loop is strategically positioned 
in human α-thrombin (2)and is crucial for fibrinogen recognition (5).  
 In between the two insertion loops, the active-site residues are nestled in the centre of 
a narrow cleft framed. The trypsin-like specificity for basic residues at P1 (6) is conferred to 
thrombin by the presence of Asp189 at the S1 site occupying the bottom of the catalytic 
pocket. However, differently from trypsin pocket, thrombin increased flexibility allows 
accommodation of more hydrophobic or even uncharged P1 groups and confers a strong 
preference for P1-Arg over Lys residues (7). Relatively unique to thrombin is the acidic 
Glu192 residue positioned at the entrance to this pocket. The negatively charged of Glu192 is 
not compensated by hydrogen bonds or ion pair interactions with neighbour residues. The 
uncompensated charge plays an important role in discriminating against substrates carrying 
acidic groups near the scissile bond, like protein C and the platelet protease activated receptor 
1 (PAR-1) (8). Based on the Trp215 indole moiety, a hydrophobic surface groove extends on 
top of the S1 pocket, which is partially delimited by the 60 loop. The conjunction of 

Exosite I
Exosite 2
Loop 148 
Loop W60d 
Na+ binding site 
ACTIVE 
SITE
15-20 Å
10-15 Å
A B
A B
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hydrophobic residues together with the pavement of the active-site forms an apolar binding 
site, which is subdivided into the S2 cavity and the aryl binding site/S4 groove. This latter site 
hosts P4 side chain of all L-amino acids substrates, whereas the P3 side chain extends 
alongside Glu192, away from the active site. The S1’ site of thrombin, positioned to the right 
of the active site, is limited in size by the Lys60f side chain, and therefore particularly suited 
to accommodate small polar P1’ side chain. The S2’ subsite is of medium size and mainly 
hydrophobic, so that bulky hydrophobic P2’ residues are preferred. The S3’ site, instead, is 
open and slightly acidic, so prefers basic P3’ side chains (Table 1). 
On these bases, a P4 to P3’ consensus sequence of an optimal thrombin polypeptide substrate 
should contain a P4-Phe/Leu, any P3 residue, a P2-Pro/Val, a P1-Arg, a P1’-Ser/Gly, a P2’-
Phe, and a P3’-Arg residue. Although the majority of thrombin natural substrates follows the 
consensus scheme proposed, important exceptions are found with fibrinogen A (FA), factor 
XIII, protein C, and heparin cofactor II (HCII) (5, 9). Consequently, the interaction of binders 
Table 1: Cleavage sequences of thrombin substrates or inhibitors around the scissile peptide bond 
and the reactive-centre loop, respectively. 
 P4 P3 P2 P1 P1’ P2’ P3’  Ex- Cofactor 
Fibrinogen A Gly Gly Val Arg Gly Pro Arg I 
Fibrinogen B Phe Ser Ala Arg Gly His Arg I 
FV (709) Leu Gly Ile Arg Ser Phe Arg I, II 
FV (1018) Leu Ser Pro Arg Thr Phe His I, II 
FV (1545) Trp Tyr Leu Arg Ser Asn Asn I, II 
FVIII (372) Ile Gln Ile Arg Ser Val Ala I, II 
FVIII (740) Ile Glu Pro Arg Ser Phe Ser I, II 
FVIII (1689) Gln Ser Pro Arg Ser Phe Gln I, II 
FXIII Gly Val Pro Arg Gly Val Asn None 
PAR-1 Leu Asp Pro Arg Ser Phe Leu I 
PAR-4 Pro Ala Pro Arg Gly Tyr Pro None 
FXI Ile Lys Pro Arg Ile Val Gly I 
PC Val Asp Pro Arg Ile Val Gly TM 
TAFI Val Ser Pro Arg Ala Ser Ala TM 
AT Ile Ala Gly Arg Ser Leu Asn Heparin 
HCII Phe Met Pro Leu Ser Yhr Gln I, Heparin 
AT, antithrombin; F, factor, HC, heparin cofactor, TAFI, thrombin-activable fibrinolysis inhibitor 
1.1. Human α-Thrombin 
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to the active site of human α-thrombin also involves allosteric sites, called exosite I and 
exosite II. These contain electropositive amino acid residues and are localized at opposite 
poles of the active site, representing two potential exosites for the binding of macromolecular 
ligands. 
Exosite-I or ABE-I 
The prominent loop centred on Lys70 is called exosite-I and is homologous to the Ca2+
binding loop of the cognate proteases trypsin and chymotrypsin (10). Exosite-I is located 
about 10-15 Å away from the active site and is mainly placed on the Arg67 to Ile82 loop and 
bordered by the 37-loop and segment Lys109-Lys110. In this domain, four charged residues 
(Arg67, Lys70, Glu77 and Glu80) form a salt bridge cluster, which is buried well below the 
surface of the exosite, substantially contributing to the rigidity of the loop (2). Over this 
buried charged spot, several not compensated cationic residues (Arg73, Arg 75 and Arg 77a) 
form a strong electropositive field. 
Electrostatic forces generated by the exosite-I charge have an important influence on the 
biomolecular association of thrombin with some ligands. In fact, exosite-I represents the 
recognition site for many macromolecular ligands, such as fibrin, fibrinogen (11), 
thrombomodulin (12), protease activated receptor-1 (PAR-1) (13), HCII, hirudin, coagulation 
factor V, VIII and XIII (14-16). It is hypothesized that the electrical field of exosite-I could 
pre-orient the enzyme for a productive interaction, so the hydrophobic stacking components 
can subsequently stabilized the various adducts.  
In addition, exosite-I can communicate changes to the catalytic moiety of the enzyme. In 
fact, peptides derived from the physiological inhibitor HCII (17), PAR-1 (13) or hirudin C-
terminal domain (18, 19) influence the active site of human α-thrombin allosterically.  
Exosite-II or ABE-II 
On the other side of the enzyme, opposite exosite-I, a prominent C-terminal helix hosts a 
number of positively charged residues that provide the anion binding exosite-II. Exosite-II is 
the template for interaction with polyanionic ligands such as heparin and glycosaminoglycans. 
At this surface, a small hydrophobic Leu234-based groove is delimited by basic residues 
Arg93, Arg101, Arg 165, Arg 233, Arg 126, Lys236, Lys235, Lys240 and His91 with most of 
their side chain charges not compensated by adjacent negative charges. This assignment was 
confirmed in the presence of exosite-II thrombin mutant, measuring the heparin-catalyzed 
1.1 Human α−Thrombin 
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thrombin inhibition by anti-thrombin III (ATIII) (20). Exosite-II binds, also, to platelet 
receptor GpIb (21) and to fibrinogen-elongated ’ chain (22).  
Na
+
 Binding Site and Allosteric Effect  
Sodium ion has been found to be an important allosteric modulator of human -thrombin. 
The binding of this monovalent cation to thrombin plays a relevant role in the allosteric 
control of the protease activities, as it causes a conformational transition from a Na+-free 
form, referred to as slow, to a Na+-bound form, referred to as fast. The slow and fast forms are 
significantly (2:3 ratio) populated under physiologic conditions because the Kd for Na+
binding is 80-110mM at 37°C and physiologic NaCl concentration (140mM) is not sufficient 
for saturation (8, 23). The two forms exhibit different relative activities toward 
macromolecular substrates. The fast thrombin form cleaves fibrinogen and PAR-1 more 
efficiently and displays procoagulant, prothrombotic, and prosignaling properties. Notably, 
the slow form activates protein C with an efficiency similar to that of the fast form (Table 2).  
Table 2. Effect of Na
+
 on the catalytic activity of thrombin towards some relevant 
physiological substrates. 
 kcat/Km (M
-1 s-1) r 
 Fast  Slow   
    
(D)FPR-pNA 88.9 ± 4 3.5 ± 0.5 26 
Fibrinopeptide A release 35 ± 4 1.5 ± 0.1 23 
Fibrinopeptide B release 17 ± 1 0.73 ± 0.03 23 
PAR-1a 54 ± 2 1.4 ± 0.1 39 
Protein C 0.21 ± 0.001 0.32 ± 0.01 0.7 
All measures were performed in buffer that stabilized either the fast (0.2M NaCl) or the slow (0.2M ChCl) 
form. Kinetic constants were adapted from (5). 
Na+ binds 16–20 Å away from residues of the catalytic triad (His57, Asp102, Ser195) and 
within 5 Å from Asp189 in the primary specificity pocket, nestled between the 220- and 186-
loops and coordinated octahedrally by the backbone O atoms of Arg221a and Lys224 and 
four buried water molecules anchored to the side chains of Asp189, Asp221 and the backbone 
atoms of Gly223 and Tyr184a. Na+ binding to thrombin has been studied in great detail in 
terms of mutagenesis, structure, kinetics, and functional components (24). Currently available 
data suggest that Na+-bound (fast) thrombin form is more stable and exhibits a more open 
accessible and rigid active site cleft, whereas the Na+-free (slow) form possesses a more 
closed, flexible substrate binding region (8). In fact, Na+ increases the catalytic activity of the 
1.1. Human α-Thrombin 
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enzyme toward synthetic and physiological substrates, with the exception of the anticoagulant 
protein C (25). However, the affinity of Na+ is strongly temperature dependent, with a large 
heat capacity change and enthalpy that cause the Kd to become comparable to the [Na+] in the 
blood under physiological conditions (26). 
Human
 α-Thrombin in the Vascular System 
 Human α-thrombin is the final protease generated in the coagulation cascade, in which 
plays a vital role encountering a large number of potential procoagulant and anticoagulant 
substrates (Fig. 1.2). The major procoagulant effect, the conversion of soluble fibrinogen to 
insoluble fibrin, is amplified by activation of factor XIII that covalently stabilises the fibrin 
clot (27, 28). Following this activation, factor XIII induces soluble fibrin monomers to 
interact end-to-end and side-to-side, causing it to become a soluble cross-linked fibrin 
monomer (29). Also, the inhibition of fibrinolysis via activation of thrombin-activable 
fibrinolysis inhibitor (TAFI) and the proteolytic activation of factors V, VIII and XI 
contribute to the procoagulant activity of thrombin (30, 31). In addition thrombin activates 
platelets through the cleavage of two protease platelet receptors, PAR-1 and PAR-4, 
promoting blood clotting (32). 
Figure 1.2 Antagonizing actions of thrombin in coagulation cascade. Thrombin is the final protease 
generated in the bloodstream, where it experts both procoagulant and anticoagulant functions. The figure 
was adapted from (66). 
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 By contrast, regarding thrombin function as anticoagulant, activation of protein C (PC) 
is very important. The activation depends on the binding to thrombomodulin (TM), a member 
receptor on endothelia cells (14, 33, 34). The reaction is further enhanced by the presence of a 
specific endothelial cell protein C receptor (14). Activated protein C (aPC) cleaves and 
inactivates FVa and FVIIIa, essential for coagulation, and FXa and FIXa, required for 
thrombin generation, thereby down-regulating both the amplification and progression of the 
coagulation cascade. Notably, in the microcirculation the system thrombin-thrombomodulin-
protein C constitutes the natural anticoagulant pathway that prevents massive intravascular 
conversion of fibrinogen into a soluble clot upon thrombin generation (14).  
Efficient regulation of thrombin activity is essential to prevent excessive or improperly 
localized clot formation. The serine protease inhibitor (serpin) superfamily inhibits the 
catalytic activity of thrombin, reaction greatly accelerated in the presence of 
glycosamminoglycans such as heparin, heparan sulphate and dermatan sulphate (35). The 
most important serpins responsible for thrombin inhibition are antithrombin (originally called 
antithrombin III), heparin cofactor II (HCII) and protease nexin I (PNI) (36). Antithrombin is 
abundant in the blood (2.3 M), inhibits a variety of serine proteases involved in blood 
coagulation and appears to be the main inhibitor limiting intravascular clot formation. In 
contrast, HCII is highly specific for thrombin and appears to regulate thrombin activity in 
extravascular tissues following vascular injury; whereas PNI is likely to inhibit thrombin at or 
near the surface of a variety of cell types but especially in the brain (36). In addition to these 
endogenous thrombin inhibitors, several potent thrombin inhibitors have been isolated from 
hematophagous organisms, including hirudin and haemadin from the leeches Hirudo 
medicinalis and Haemadipsa sylvestris, respectively (37). 
Recent studies in vitro indicated that human α-thrombin modulates multiple processes in 
the vascular system including vascular permeability, vascular tone and neovessel formation 
(35). It was reported that thrombin activates angiogenesis and decreases the ability of 
endothelial cells to attach to basement membrane proteins via cyclic adenosime 
monophosphate (38). Thrombin also potentiates vascular endothelial grow factor (VEGF), by 
up-regulation of the expression of VEGF receptors (38). In addition, the enzyme increases 
vascular permeability, resulting in plasma protein leakage and the development of a 
proangiogenic matrix (39, 40). 
In vivo, the dynamic concentration of free thrombin during coagulation cascade reactions 
is estimated to vary from 1nM (0.1 U/ml) to over 100 – 500nM, depending on detection 
methods and experimental conditions (41). Typically low concentration (< 10nM) are 
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associated with platelet activation and loosely organised fibrin strands susceptible to 
fibrinolysis; higher concentration produce tightly packet fibrin stands capable of a stable clot 
(28, 42). Furthermore, some studies in vivo indicate that thrombin administrated as a bolus 
causes microembolism, as well as the protein infused slowly at steady-state conditions (1.6 
U/kg/min) leads to bleeds, but not to intravascular clotting. Beside, large quantity of thrombin 
infused at low rate (0.05 U/kg/min) increases the vascular permeability leading to tissue 
damage (35). Nevertheless, the true enzyme concentration in tissues is unknown; whether the 
serine protease can reach such an extraordinary concentration in vivo remains an un-answered 
question. 
In conclusion, human α-thrombin is the central protease in the coagulation cascade and 
one of the most extensively studied of all enzyme. In addition to its essential role in the 
coagulation cascade and haemostasis, thrombin displays multiple pleiotropic effects through 
interaction with different targets localized at the level of platelets, endothelia, heart, neurons, 
leukocytes and tumor cells. 
Human
 α-Thrombin in the Nervous System 
 Human α-thrombin is a promiscuous molecule that plays a key role at interface 
between coagulation, inflammation and nervous system. The serine protease dynamically 
modulates cell growth, development and response to injury in the central and peripheral 
nervous system, so this protein results important in the mediation of pain sensations (43). In 
fact, concentration of thrombin as low 1 -10nM can influence glia cell mitosis and neuronal 
out-growth (44), induces retraction of neuritis in neuroblastoma cells, acts as mitogen and 
provokes alteration in astrocytes morphology (45). All these effects seem to have a protective 
role in neurons and astrocytes and are mediated through activation of protease activating 
receptors (PARs) (45). Conversely, higher concentration of the enzyme (100nM) has been 
shown to induce apoptosis in motor neurons (46) and to determine in the brain a pro-
inflammatory state (47). In addition, thrombin inhibits development neurite outgrowth from 
the dorsal root ganglion (DRG) in vitro (48). 
 Recent studies suggest that thrombin is also involved in neurodegenerative diseases. 
The protein accumulates in the brains of Alzheimer’s diseases (AD) patients, both in vessel 
walls and senile plaques. In these regard, thrombin is directly toxic to neurons and can also 
potentiate neuronal injury indirectly via activation of neighboring microglia and astrocytes. 
Immunofluorescent analysis of the cerebrovasculature in AD mice demonstrates significant 
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increases in thrombin, interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), 
matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) compared to controls 
(49). Furthermore, the serine protease is able to induce production of amyloid precursor 
protein (APP) and to hydrolyze APP, generating fragment of amyloid peptide similar to those 
found in fibrils of AD patients (50, 51). In Parkinson’s disease (PD), instead, thrombin 
contributes directly to neuronal degeneration, by a toxic effect on dopaminergic neurons in 
the substantia nigra (52). 
 Numerous alterations in morphology and platelets aggregation have been found in AD 
and PD. Platelets degranulation induced by thrombin, thought PAR-mediated activation, is 
impaired by α-synuclein, an acid protein expressed in presynaptic neuron terminals and in a 
number of blood cells (53). α-Synuclein is also the major component of fibrillar deposits of 
AD and PD (54, 55). In fact, clinical studies have shown that PD patients are less susceptible 
to ischemic stroke and have reduced platelet aggregation (56). 
Human
 α-Thrombin in the Inflammation Response 
 Inflammation and coagulation constitute two host defense systems with 
complementary roles in eliminating pathogens, limiting tissue damage and restoring 
homeostasis. Between these systems exists a reciprocal relationship: inflammation leads to 
activation of coagulation and coagulation considerably affects inflammatory activity (57). 
Thrombin has the ability to stimulate production and secretion of inflammatory cytokines like 
interleukin-1β (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF-), and this is 
primarily accomplished through nuclear factor kappa B (NF-B) signaling pathways. With 
monocytes or monocyte-derived macrophages, thrombin enhances their adhesiveness and 
increases their production (58). The enzyme also stimulates production of platelet-activating 
factor (PAF) whose role is to attract neutrophils and contribute to their adhesion (59). As 
regards, several studies show the importance of IL-6 in the initiation of coagulation 
activation, and the role of IL-1 and TNF- in the regulation of physiological anticoagulation 
(60). 
 Inflammation induced the activation of coagulation by dysfunction of the normal 
anticoagulant mechanisms, such as antithrombin and protein C systems (61), and by improve 
the tissue factor-mediated thrombin generation. Tissue factor (TF) plays a central role in the 
initiation of inflammation that promotes coagulation. Some data indicated that blocking TF 
activity completely inhibits inflammation-induced thrombin generation in models of 
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experimental endotoxaemia or bacteraemia (62). Inflammatory cells in atherosclerotic plaques 
produce abundant TF and upon plaque rupture there is extensive TF exposure to blood (63). 
In fact, in inflamed tissues thrombin concentration is markedly increased, especially in the 
synovial fluid of rheumatoid arthritis patients (64). 
 Summarizing, communication between inflammation and coagulation is bidirectional; 
coagulation proteases and protease inhibitors not only interact with coagulation protein 
zymogens, but also with specific cells receptors to induce signaling pathways. The pivotal 
mechanism by which thrombin modulates inflammation is binding to PARs, that are localized 
in the vasculature on endothelia cells, mononuclear cells, platelets, fibroblasts and smooth 
muscle cells (65). 
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 Proteolytic enzymes are estimated to comprise 2% of the human genome: proteases 
participate in different biological processes where, anchored to the plasma membrane or free 
in the extracellular fluid, can cleave ligands or receptors to either initiate or terminate signal 
transduction (1). The pivotal mechanism by which coagulation proteases modulate nervous 
system and inflammation is by binding to protease activated receptors (PARs). The PARs 
family (PAR-1, PAR-2, PAR-3 and PAR-4) consists of four members of G-protein coupled 
receptors found on endothelia cells, monuclear cells, platelets, fibroblasts and smooth muscle 
cells (2, 3). 
 The general mechanism by which proteases cleave and activate PARs is the same: 
enzymes cleave at specific sites within the extracellular amino terminus of the receptors; this 
cleavage expose a new amino terminus that serves as a tethered ligand domain, which binds to 
conserved regions in the second extracellular loop of the cleaved receptor, resulting in the 
initiation of signal transduction (1) (Fig. 1.3). PAR-1, PAR-3 and PAR-4 are thrombin 
receptors, and PAR-1 can also serve as receptor for the tissue factor-factor VIIa complex and 
factor Xa. PAR-2 cannot bind thrombin, but can be activated by the tissue factor-factor VIIa 
complex, factor Xa and by trypsin (4). 
 Structurally, PAR-1 is a protein of 425 amino acid residues with 7 hydrophobic 
domains. The deduced sequence of human PAR-1 contained an amino-terminal signal 
sequence, and extracellular amino-terminal domain of 75 residues and a potential cleavage 
site for thrombin within the amino-tail (LDPR41S42FLLRN, where  denotes cleavage). 
PAR-2 contains 395 residues with 30% amino acid identity to human PAR-1. The 
extracellular amino terminus of 46 residues contained a putative trypsin cleavage site 
SKGR34 S35LIGKV. PAR-3 was found to share 28% sequence homology to human PAR-1 
and PAR-2. Like PAR-1 and PAR-2, PAR-3 has a thrombin cleavage site within the 
extracellular amino terminus at LPIK38T39FRGAP, while PAR-4, 385 amino acid residues, 
presents a potential cleavage site for thrombin and trypsin in the extracellular amino-terminal 
domain: PAPR47G48YPGQV (1) (Fig. 1.4).  
1.2 Protease Activated Receptors  
26 
Figure 1.3 Structural and functional domains of PARs. The figure shows alignment of domains of 
human PAR-1, PAR-2, PAR-3 and PAR-4. (A) and (B): mechanism of cleavage and interaction of the 
tethered ligand with extracellular binding domains. (C): functionally important domains in the amino 
terminus, second extracellular loop, and carboxyl terminus. This figure was adapted from (1). 
Protease Signaling in the Cardiovascular System 
 Serine proteases of the coagulation cascade are the most efficient activators of PARs 
(2, 5, 6). Human α-thrombin activates PAR-1, PAR-3 or PAR-4 at the surface of platelets, 
resulting in aggregation and granular secretion, which are essential for haemostasis. PAR-1 is 
the primary thrombin receptor on human platelets, while PAR-4 mediate the late phase of 
clotting activation (7). In addition, PAR-4 could act as a platelet receptor for other proteases, 
such as cathepsin G (8). Activation of PAR-1 by thrombin reduce vascular endothelial barrier 
function through signaling cascade that allow calcium influx, nitric oxide release and 
endothelia cell retraction (9). Moreover, proteolysis of PAR-1 stimulates proliferation of 
endothelial (10) and vascular smooth muscle cells (11) by up-regolaton of expression of 
vascular endothelial growth factor (VEGF). Similarly, thrombin activation of PAR-4 induces 
proliferation of vascular smooth muscle cells (12).
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Figure 1.4 Mechanisms of activation and intermolecular cooperation of PARs. (A) Thrombin 
activates PAR-1 and PAR-3 in a two-step process. First, thrombin binds to a hirudin-like domain; 
second, thrombin cleaves to expose the tethered ligand, which binds and activates the cleaved 
receptor. (B) PAR-3 is a cofactor for PAR-4 in murine platelets. Thrombin binds to the hirudin site of 
PAR-3, but PAR-3 does not signal in mouse platelets. The PAR-3-bound thrombin then cleaves and 
activates PAR-4. (C) Intermolecular signalling of PAR-2 and PAR-1 in endothelial cells. The exposed 
tethered ligand domain of PAR-1 can bind and activate PAR-2, resulting in intermolecular signalling. 
This figure was adapted from (1). 
 The tissue factor-factor VIIa-factor Xa complex signals by cleaving PAR-1 and PAR-
2 on a variety of cell types, including endothelia cells (13). Indeed it was reported that 
activation of PAR-2 can be stimulate proliferation of endothelial cells (14). 
Protease Signaling in the Nervous System 
 The effects of thrombin on the nervous system are mediated through activation of 
PARs: these receptors have been linked to the development and regrowth of central nervous 
system pathway related to memory, neurodegenerative diseases and dopaminergic reward 
pathway. PAR-1 mRNA is expressed in the neocortex, cingulate/retrosplenial cortex, 
subiculum, nuclei within the hypothalamus and thalamus, and in discrete layers of the 
hippocampus, cerebellum, and olfactory bulb. PAR-1 is also expressed at low levels in glial 
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cells throughout the brain and by ependymal cells of the choroid plexus and ventricular lining; 
in addition, PAR-1 is present in the peripheral nervous system (15). PAR-2 expressed within 
the brain, at the level of neurons and glial cells of the hypothalamus (16); in the periphery, 
PAR-2 is expressed in primary spinal afferent neurons (17). 
 Activation of PARs by thrombin or other ligands has been associated with increased 
apoptosis of dopaminergic neurons in the substantia nigra and degeneration of hippocampal 
cells (18). The serine protease potentiates the activity of N-methyl-D-aspartate (NMDA) 
receptors in hippocampal cells through PAR-1, impacting synaptic and neuronal development 
and neuroprotection during early injury (19). Similarly, in the presence of thrombin, 
neuroexcitability and neuronal cells damage after injury are increased (20). In addition, both 
PAR-1 and PAR-2 have been implicated in neurogenic inflammation in the peripheral 
nervous system, whose clinical manifestations are vasodilatation, edema and pain responses 
(21). These receptors, in fact, exist on sensory afferent nerve endings in the peripheral 
nervous system. Their activation results in indirect release of substrate P and calcitonin 
peptide in vivo, two kinds of neuropeptides that mediate edema through loosening of the 
epithelial gap junctions (22). 
Protease Signaling in the Inflammatory Response 
 Recent studies have shown that binding of tissue factor-factor VIIa to PAR-2 results in 
up-regulation of inflammatory mediators in endothelial cells (23). In this scenario the events 
that follow are production of reactive oxygen species, expression of major histocompatibility 
complex II (MHC II) and cell adhesion molecule, neutrophil infiltration and pro-inflammatory 
cytokine expression (4). The in vivo relevance of PARs has been confirmed in various 
experimental studies using PAR inhibitors or PAR-deficient mice. For example, observations 
on PAR-2 - deficient mice suggest a role for this receptor in inflammation of the airway, 
joints and kidney (1). 
 The role of PARs was investigated is some inflammatory disease, such as rheumatoid 
arthritis (RA). RA is a chronic inflammatory condition that is associated with inflammation of 
the synovium and hyperplasia. There is also elevated expression of tissue factor and thrombin 
in the synovium and the deposition of fibrin in the inflamed joint, indicating activation of the 
coagulation system (24). Immunization and subsequent challenge of mice with chicken 
collagen results in arthritis, and administration of the thrombin inhibitor hirudin reduces the 
severity of the inflammation, assessed by clinical scoring and measurement of expression of 
pro-inflammatory cytokines, providing direct evidence for the involvement of thrombin in the 
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inflammation (25). Evidence for a role of PAR-2 in arthritis has been provided from 
observations of PAR-2 - deficient animals, which are protected against arthritis induced by 
intra-articular and periarticular injection of adjuvant. This inflammation is accompanied by an 
up-regulation of PAR-2 expression, which is normally confined to the vasculature of the 
joints (26). 
Figure 1.5 Summary of the potential physiological and pathophysiological roles of proteases and 
PARs in different cell types. This figure was adapted from (1). 
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2-Glycoprotein I (2GpI), or apolipoprotein H (ApoH), is a 50 kDa protein, 
synthesized in the liver and placenta, abundantly present in human plasma (50–500 µg/ml) 
second only to fibrinogen, among the plasma proteins involved in clotting (1, 2). The plasma 
level of the protein may be increased in chronic infections, hyperlipidaemia, smoking, male 
gender and increasing age (3). β2GpI is highly conserved in all mammals: human, bovine, 
canine and mouse proteins have 60-80% amino acid sequence homology (4). 
Molecular Structure of β2-Glycoprotein I: Different Conformations 
 The mature sequence of human β2GpI is heavily glycosylated and consists of 326 
amino acids arranged into four repeating units (domains I-IV) and a distinctly folded C-
terminal domain V, which is responsible for the binding to phospholipids membrane (5) (Fig. 
2.1). Domains I to IV belong to the Complement Control Protein (CCP) family and contains 
about 60 amino acids each, sharing a common elliptically β-sandwich structure, stabilized by 
two conserved disulfide bonds (2, 6). These domains are also characterized by the presence of 
high proline content (i.e. 8-15%), a conserved Cys-Pro peptide bond in the N-terminal region 
of each domain and a single Trp-residue stacked against the disulfide bond connecting the 
first and third cysteine. Conversely, domain V is aberrant because it contains 82 amino acids 
that fold into a central β-spiral structure flanked by two small helices. In addition, it contains 
three disulfide bonds, has a relatively low proline content (i.e. 3.5%) and the single Trp-
residue is not structurally conserved. Besides, the fifth domain contains a conserved positively 
charged (multiple lysine) region between cysteine 281 and 288 (Fig. 2.1) that is critical for 
phospholipid binding (7). Many of the positively charged side chains are located in a 
particular surface region of domain V, consisting of three loops (8). To the phospholipid 
binding region in domain V, a secondary interaction between domain I and phospholipid has 
also been suggested, which occurs only at low ionic strengths (9). Thus, 2GpI binding to 
anionic phospholipids could result either from the combined interaction of the lysine-rich 
region with the hydrophobic loop or from a two step process involving domains V and I. In 
summary, the structure of 2GpI suggests a lipid membrane insertion area on the fifth 
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domain, two domains (III and IV) protected from proteolysis by glycosylation and two further 
domains (I and II) projecting away from the lipid surface into the extracellular space, and thus 
able to interact with other proteins and/or antibodies. Hence, both hydrophobic and 
electrostatic interactions appear necessary for 2GpI binding to anionic phospholipids (4). 
 The crystallographic structure of human β2GpI (Fig. 2.2A) show that the five domains 
are arranged like beads on a string to form an elongated J-shaped molecule (10), whereas 
small-angle X-ray scattering analysis (Fig. 2.2B) indicates that β2GpI in solution assumes a 
predominantly S-shaped conformation, resulting from a tilt between domain II and III (11). 
Recent electron microscopy data (Fig. 2.2C), instead, show that β2GpI can assume either a 
closed circular or an open conformation, similar to the crystallographic structure (2, 12). In 
these case, plasma purified β2GpI assumes a circular conformation whereby domain I 
interacts with domain V and after interaction with anionic surface (i.e. phospholipids 
membranes and lipopolysaccharides) the protein elongates in a J-shaped open conformation. 
In addition, the interaction of domain V with lipopolysaccharides (LPS), the major 
constituents of the outer membrane of Gram-negative bacteria, results in a conformational 
change from the closed to the open conformation (12).  
Figure 2.1 Schematic representation of the interaction of 2GpI with phospholipid membranes.
The four glycosylation sites in domain III and IV (i.e. Asn143, Asn164, Asn174, Asn243) are 
indicated by orange hexagons. Zooming on domain five shows the stereoview structures of the 
phospholipid binding domain (1QUB.pdb). In pink the C-terminal hydrophobic loop (i.e. 
313LAFW316) is indicated, while in green is shown the multiple lysine sequence 
(281CKNKEKKC288). Under oxidative conditions, the carboxyl-terminal amino acid, Cys326, forms 
a disulfide (S-S) bridge with Cys288 in domain V, while Cys32 in domain I binds to Cys60. In this 
manner it forms the oxidized-immunogenic species present in APS Patients (31). 
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β2-Glycoprotein I in the Coagulation Cascade 
2GpI has been shown to interact with a number of steps of the coagulation and 
fibrinolytic pathways, in fact both pro-coagulant and anti-coagulant activities in vitro have 
been reported for these protein over the last 30 years (2, 4). Few data show that β2GpI hinders 
the contact activation in the intrinsic blood coagulation pathway and impairs platelet 
aggregation by inhibiting the effect of adenosinephospate (13). More recent results indicate 
that β2GpI binds with low affinity to the A1 domain of vWF and reduce the ability of the co-
factor to promote platelet adhesion and agglutination (14). In the presence of dextran sulfate, 
β2GpI binds to zymogen factor XI and inhibits its activation by thrombin and factor XII, with 
a resulting down-regulation of factor Xa and thrombin generation (15). β2GpI has also been 
shown to bind platelet factor 4, a small protein released from platelet α-granules, displaying 
both pro- and anti- coagulant functions (16). Contrasting data has been reported for the effect 
of β2GpI on the activation of the zymogen protein C (PC) and on the inhibition of activated 
PC (aPC) (17-19). Finally, the protein might also exert pro-coagulant functions by protecting 
thrombin from inactivation by heparin cofactor II (20). 
Figure 2.2 Different proposed conformation of 2GpI. (A) Elongated J-shaped form obtained from 
crystallographic structure (1QUB.pdb). (B) S-shaped conformation resulting by small-angle X-ray 
scattering analysis in solution. (C) Dynamic equilibria between closed circular and open conformation, 
suggest by electron microscopy data. In this case, plasma purified β2GpI assumes a circular 
conformation whereby domain I interacts with domain V and only after interaction with anionic 
surface the protein elongates in a J-shaped open conformation. 
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 Recently, mice lacking 2GpI have been produced by gene targeting. Plasma from 
these knockout mice exhibited impaired thrombin generation in vitro. In heterozygous mice, 
thrombin generation was not as impaired as in the knockouts. This suggests a correlation 
between thrombin generation and 2GPI levels (21, 22). In fact, it was reported that in vitro 
β2GpI in circular-native conformation does not affect the biochemical parameter of thrombin 
generation. Preincubation with phospholipids, thereby inducing a conformational change from 
its native to an open J-shaped conformation revealed anticoagulant properties for the protein 
to thrombin generation (23). Nevertheless, the exact role of 2GpI in the clotting cascade is 
not fully elucidated. 
The Antiphospholipid Syndrome 
2GpI has been identified as the major antigen in the antiphospholipid syndrome 
(APS), a severe thrombotic autoimmune disease that can affect both the venous and arterial 
circulations (2, 4, 24). Clinical features of APS mainly include recurrent thrombosis, 
thrombocytopenia, recurrent spontaneous miscarriages and various neurological syndromes. 
The syndrome may occur alone (primary APS) or in association with systemic lupus 
erythematosus (SLE), other autoimmune diseases, and rarely with infections and drugs 
(secondary APS). In addition, the catastrophic antiphospholipid syndrome is characterized by 
clots in multiple small vascular beds and leads to multi-organ failure with high mortality, is 
generally developed in a small subgroup of patients (24, 25). The other major clinical 
manifestations of the APS are obstetrical. They include the unexplained death of fetuses at or 
beyond the 10th week of gestation, the premature birth of neonates before the 34th week of 
gestation and the spontaneous abortions before the 10th week of gestation (26). 
 The antiphospholipid syndrome is associated with the presence of antiphospholipid 
antibodies (aPLAb) (26, 27). These antibodies are directed against either anionic 
phospholipids or phospholipid-binding protein epitopes localized, for example, at the level of 
β2GpI. In fact, it was demonstrated that β2GpI binds to anionic phospholipid membranes 
using positively charged patches in domain V (Fig. 2.1) (28), while it interacts with 
pathogenic aPLAb by the N-terminal domain I (DmI) (1, 29). Of note, high plasma levels of 
aPLAb recognizing DmI strongly correlate with thrombosis, whereas aPLAb recognizing 
other different regions of β2GpI do not seem to be pathogenic. Mutagenesis studies indicate 
that the antigenic epitope of β2GpI in DmI is discontinuous in nature and comprises amino 
acid residues Asp8 and Asp9 and the Arg39-Arg43 segment (2). It is possible that aPLAb 
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directly bind to the constitutive epitope in DmI or, alternatively, to the cryptic epitope that 
becomes exposed in DmI only after β2GpI binds to negatively charged surfaces. 
Summarizing, the increase in affinity of 2GpI for anionic phospholipid upon antibody 
binding further supports the pathogenetic role of this molecule in disorders caused by aPLAb, 
maybe through interference with phospholipid-dependent steps in coagulation (30). However, 
the exact mechanism of 2GpI–phospholipid interaction in antibody binding is still 
unresolved. 
 In addition, oxidative stress plays a direct role in the structure and function of 2GpI 
in patients with the antiphospholipid syndrome (24). In healthy persons, the free thiol -non 
immunogenic- form of 2GpI predominates in the plasma (i.e. Cys32, Cys60, Cys288 and 
Cys326). Under conditions of oxidative stress, disulfide bonds form at these sites, in 
correspondence of DmI (Cys32-Cys60) and DmV (Cys288-Cys326) (31). It was 
demonstrated that in patients with APS the major species of 2GpI is the oxidized -
immunogenic- form (Fig. 2.1). In fact, these patients have decreased levels of plasma nitrite, 
as compared with controls (32). They also have impaired endothelium-dependent vascular 
responses, which suggest that the activity of endothelial nitric oxide synthase is abnormal 
(21). In a murine model, aPLAb decreased bioavailable nitric oxide by antagonizing the 
activity of endothelial nitric oxide synthase, which led to monocyte adhesion to the 
endothelium (33). 
 As regards to the fetal mortality in patients with APS, the exact role of aPLAb is not 
yet fully clarified. One hypothesis suggests that they prevent implantation in vivo, by the 
binding of aPLAb to the trophectoderm of preimplantation embryos (34). Another suggested a 
mechanism in which the placental prostaglandin synthesis is impaired, due to the interaction 
of aPLAb with the 2GpI-mediated activity of lipoprotein lipase on maternal membrane 
phospholipids (35). It has also been suggest that there is an increased macrophage uptake of 
oxidised LDL, secondary to aPLAb binding, inducing placental atherogenesis (36). 
  
The Role of β2-Glycoprotein I in the Thrombotic Events of APS 
 The interference of the physiological interaction between 2GpI and coagulation 
factors by aPLAb could be a possible pathogenic mechanism correlated with thrombosis in 
APS patients. The inhibition of FXa generation on activated platelets by 2GpI has been 
shown to be counteracted by aPLAb, leading to an increased, unopposed FXa generation (37). 
Another mechanism by which aPLAb may predispose an individual with APS to thrombosis 
is by interfering with the fibrinolytic mechanism. It was proposed that the competitive 
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interaction of the complex aPLAb- 2GpI for anionic phospholipid binding sites could hinder 
the protein S - activated protein C (APC) proteolytic system (4). Indeed, the proteolytic 
degradation of both FVa and FVIIIa is mediated by the APC complex and the activation of 
protein C is greatly enhanced by phospholipids (38). 
 The effect of aPLAb in the pathogenesis of APS-associated thrombosis may also be 
considered in relation to protein Z (PZ). PZ is a vitamin-K-dependent plasma protein that 
serves as a cofactor for the inactivation of FXa by protein-Z-dependent protease inhibitor 
(ZPI). Recent studies suggested that 2GpI modestly delayed the FXa inactivation by PZ/ZPI 
and aPLAb were found to further increase the inhibitory potential of 2GPI on PZ/ZPI activity 
(39). So PZ/ZPI system is commonly impaired in APS patients thus probably increasing the 
thrombotic risk. 
 Finally, aPLAb have been shown to exert direct anti-endothelial cell activity in APS 
patients. The binding of aPLAb to 2GPI on the endothelial cell (EC) surface, through the 
specific cell surface receptor annexin II, results in EC activation via the up-regulation of 
adhesion molecules and cytokines. This induces a proinflammatory and procoagulant 
phenotype in endothelial cells. This effect also implies that aPLAb, in the presence of 2GPI, 
may well bind to healthy EC without anionic phospholipid involvement (40). 
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CHAPTER 2.2 
b2-Glycoprotein I Binds to Thrombin 
and Selectively Inhibits the Enzyme Procoagulant Functions 
 
 
INTRODUCTION 
 β2-Glycoprotein (β2GpI)I is abundantly present in human plasma (50–500 mg/ml) and 
highly conserved in all mammals (1). β2GpI has been identified as the major antigen in the 
antiphospholipid syndrome (APS), a severe thrombotic autoimmune disease (2). Despite its 
importance in the pathogenesis of APS, the physiological role of β2GpI is still elusive. In fact, 
both pro-coagulant and anti-coagulant activities in vitro have been reported for β2GpI over 
the last 30 years (1, 3). 
 The crystallography structure of β2GpI shows that it composed of five domains, 
arranged like beads on a string to form an elongated J-shaped molecule (4), whereas small-
angle X-ray scattering analysis indicates that b2GpI in solution assumes a predominantly S-
shaped conformation (5). Recent electron microscopy data have shown that b2GpI can 
assume either a closed circular and an open conformation, similar to the crystallographic 
structure (6). In these case, plasma purified b2GpI assumes a circular conformation whereby 
domain I interacts with domain V and after interaction with anionic surface (phospholipids 
membranes and lipopolysaccharides) the protein elongates in a J-shaped open conformation. 
 Thrombin is the final effector protease in the coagulation cascade (7) and exerts both 
procoagulant and anticoagulant functions in haemostasis. The procoagulant functions mainly 
entail conversion of fibrinogen into fibrin and activation of platelets through cleavage of type 
1 protease activated receptor (PAR-1) (8), whereas the anticoagulant functions of thrombin 
are essentially related to its ability to proteolytically activate the anticoagulant protein C in the 
presence of thrombomodulin (TM) (9). Thrombin has a chymotrypsin-like fold and 
accomplishes most of its activities through the hydrolytic active site, located in a deep crevice 
at the interface between two b-barrels (7). For macromolecular substrate targeting, thrombin 
also exploits two positively charged exosites (exosite-1 and exosite-2) which are located at 
opposite sides from the catalytic cleft (10). In particular, exosite-1 binds fibrinogen, PAR1 
and TM, while exosite-2 binds to the prothrombin F2 fragment, heparin and the elongated g′-
chain of fibrinogen. Furthermore, thrombin uses exosite-2 for interacting with its platelet 
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receptor glycoprotein-Iba (GpIba) and to properly localize on the platelet surface for 
cleaving PAR1 (11, 12). Thrombin functions are also regulated by sodium ion that binds to a 
specific site on the protease and enhances its hydrolytic efficiency (8). 
 Previous qualitative results from Krilis and co-workers, obtained by immobilizing 
β2GpI onto plastic plates after prolonged exposure to high pH, seemed to indicate that β2GpI 
binds to both thrombin exosites (13). However, neither biochemical nor functional data 
pertaining to the proposed β2GpI-thrombin interaction have been reported so far (13). To fill 
this gap, here we have investigated the effect of physiological concentrations of β2GpI on the 
procoagulant (fibrin generation and platelet aggregation) and anticoagulant (generation of 
active protein C) functions of thrombin. 
 
 
MATERIALS AND METHODS 
 
Materials 
Human a-thrombin, PPACK (D-Phe-Pro-Arg-chloromethyl ketone)-inhibited thrombin, 
protein-C, prothrombin, fibrinogen, activated factor-Xa, and thrombomodulin were purchased 
from Haematologyic Technologies (Essex Junction, VT, USA); HD1 and HD22 aptamers 
were obtained from Primm (Milan, Italy); p-aminobenzamidine (PABA); Nα-(2-naphthyl-
sulphonyl-glycyl)-D,L-p-amidinophenylalanyl-piperidine (NAPAP), lypopolysaccharide 
(LPS) and ecarin were from Sigma (St. Louis, USA); hirugen(54-65) peptide, fibrinogen g′-
chain peptide(408-427), hirudin N-terminal domain Hir(1-47), and PAR1(38-60) were 
chemically synthesized (14, 15). 
 
Purification and Characterization of b2GpI 
Natural β2GpI was purified from normal human plasma according to the perchloric acid 
precipitation method (16), followed by affinity chromatography on a heparin-sepharose 
column and cation exchange chromatography on a Mono-S column (GE-Healthcare, 
Piscataway, NJ, USA). The homogeneity and chemical identity of β2GpI preparations 
(e280=47mM
-1·cm-1) was established by SDS-PAGE (4-12% acrylamide), RP-HPLC, and 
mass spectrometry on a 4800 Plus Maldi-Tof instrument (AB-Sciex, Framingham, MA). 
β2GpI purified from three different preparations was used. 
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Production and Characterization of Recombinant Thrombin 
Recombinant wild-type thrombin was expressed and refolded as previously described (17). 
Briefly, pET23(+) plasmid vector containing the cDNA corresponding to wild-type human 
prethrombin-2 (preThb-2) sequence (Dr. J. Huntington, University of Cambridge, UK) was  
used to transform E. coli strain BL21(DE3)pLysS cells. After inducing preThb-2 expression 
with isopropyl β-D-thiogalactoside (IPTG), harvested cells were sonicated and inclusion 
bodies recovered by centrifugation. Refolding of preThb-2 chain was carried out by diluting 
drop wise solubilized inclusion bodies (in 6M Gdn-HCl) into the renaturing solution: 20mM 
Tris-HCl buffer pH 8.5, 0.6M L-arginine hydrochloride, 0.5M NaCl, 1mM EDTA, 10% 
glycerol, 0.2% Brij-58, and1mM L-cysteine. After dialysis and centrifugation, correctly 
folded pThb-2 was purified on a heparin-sepharose column followed by treatment with ecarin 
to generate active thrombin, which was purified on a heparin-sepharose column. Mutations in 
the preThb2 cDNA were introduced by the oligonucleotide-directed mutagenesis method, 
using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The purity of thrombin 
preparations (~98%) was established by SDS/PAGE (12% acrylamide gel) and RP-HPLC on a C4 
analytical column (4.6 x 150 mm, 5 μm particle size, 300 Å porosity) from Grace-Vydac 
(Hesperia, CA, U.S.A.). The column was equilibrated with 0.1% (v/v) aqueous TFA and eluted 
with a linear 0.1% (w/w)-TFA-acetonitrile gradient at a flow rate of 0.8 ml/min. The absorbance 
of the effluent was recorded at 226 nm. The chemical identity of the purified proteins was 
established by ESI-TOF mass spectrometry on a Mariner instrument from Perseptive Biosystems 
(Stafford, TX, U.S.A.). Mutants of human thrombin (i.e. K36A, L65A, K81A, K110A, R165A, 
K169A, D178A, and K235A) were a generous gift of Dr. N. Pozzi (Dep. of Biochemistry and 
Molecular Biology, St. Louis University, USA) and were expressed in baby hamster kidney 
cells, refolded, and purified to homogeneity as previously described (18). 
 
Binding Measurements 
Surface Plasmon resonance (SPR) measurements were carried out on a Biacore X100 
instrument (GE-Healthcare, Piscataway, NJ, USA). Purified β2GpI (50 μg/ml) in 10mM 
ammonium acetate buffer pH 4.5, was injected for 10 min at a flow rate of 5 μl/min and 
covalently immobilized on a carboxymethylated dextran chip (CM5) using the amine 
coupling chemistry, according to the manufacturer’s instructions. The sensor chip was first 
activated with an equimolar (0.2M) mixture of N-ethyl-N′-dimethylaminipropylcarbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) and then reacted with a solution of β2GpI (i.e. the 
ligand). Unreacted carboxymethyl-groups on the sensor chip were blocked by reaction with 
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1M ethanolamine at pH 8.5. Final immobilization levels of 11100 resonance units (RU) were 
obtained, corresponding to approximately 11.1 ng of bound β2GpI/mm2. To avoid 
autoproteolysis, the inactive thrombin mutant S195A was used. When active human or 
thrombin mutants at exosite-I and exosite-II were used, the catalytic site was inhibited after 
incubation with 5-fold molar excess of NAPAP. In competition experiments exosite-I (i.e. 
HD1 and hirugen) and exosite-II (i.e. HD22 and g′-peptide) binders were first incubated with 
thrombin and then injected over the β2GpI-coated sensor chip. All measurements were carried 
out at 25°C in Hepes-EP+ (10mM Hepes pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% 
Tween20 polyoxyethylene sorbitan) at a flow rate of 30 ml/min. Each SPR trace was 
subtracted for unspecific binding (<2% of Rmax) of thrombin. The response units (RU) at the 
steady state were plotted as a function of [thrombin] and fitted to the Langmuir equation 
(eq.1) to yield the dissociation constant, Kd, of thrombin-β2GpI interaction: 
Req = C·Rmax/(C + Kd)         (eq.1) 
where Rmax is the value in RU at complex saturation and Req is the change in RU at each given 
concentration C after reaching equilibrium. 
Studies of the ionic strength dependence of the interaction thrombin- β2GpI were carried out 
by SPR at different concentration of NaCl (i.e. 0.1M, 0.15M, 0.2M, 0.3M, 0.35M, 0.4M, 
0.5M) in Hepes-EP+ buffer at 25°C. The thrombin samples that were injected were prepared 
in each different buffer so that the flowing buffer and the thrombin sample buffer were always 
identical. A total of six different [thrombin] were injected for every salt concentration. The 
data plotted as ln Kd versus ln [salt] were fitted to a straight line according to the following 
expression (eq.2): 
-ln Kd = A0 + Gsalt ln [salt]         (eq.2) 
where Kd is a dissociation constant, the slope Gsalt represents a thermodynamic measure of the effect of 
salt concentration on binding equilibria (19) and provides the minimum number of ionic interaction 
involved, and A0 is the true Kd for the interaction from the intercept at 1M [salt] (20). 
Binding of PABA (e293nm = 15mM
-1·cm-1) and Hir(1-47) (e280nm=2560M
-1·cm-1) to thrombin 
was performed by fluorescence measurements (21, 22) in the absence or presence of 4mM 
β2GpI. Measurements were carried out at 37±0.1°C on a Jasco (Tokyo, Japan) FP-6500 
fluorimeter in Hepes-buffered-saline (HBS, 10mM Hepes pH 7.4, 0.15M NaCl, 0.1% 
PEG6000). For the binding of PABA, the data were corrected for inner filter effect. For PABA 
binding, thrombin samples were excited at 336 nm and the fluorescence intensity was 
2.2 b2-Glycoprotein I Inhibits Thrombin Procoagulant Functions 
 
49 
 
recorded at 375 nm. The data were corrected for inner filter effect (eq.3) (23) and fitted with 
the Langmuir equation (eq.4) using the program Origin 7.5 (MicroCal, Inc.): 
Fcorr = Fobs∙10
–(Aex∙d/2)          (eq.3) 
where Aex is the solution absorbance at the excitation wavelengths and d is the cuvette path-length.  
Fcorr = F0 + {(Fmax∙[I])/(Kd+[I)}        (eq.4) 
where F0 and Fmax are the intensities of PABA fluorescence in the thrombin-free or thrombin-bound 
state, respectively, and Kd is the dissociation constant of thrombin-PABA complex. 
For Hir (1-47) binding, thrombin samples were excited at 295nm and the fluorescence 
recorded at 334nm as a function of inhibitor concentration. The data were analyzed within the 
framework of the tight binding model (eq.5) using the program Origin 7.5 (MicroCal, Inc.): 
DF =  {(DFmax+[I]+Kd) – {(DFmax+[I]+Kd)
2 – 4·DFmax [I]}
1/2
}/2    (eq.5) 
where Kd is the dissociation constant of the inhibitor-thrombin complex and DFmax is maximal 
fluorescence change at saturating [I], such as Hir(1-47). 
 
Clotting Assays 
The turbidity (i.e. absorbance at 350 nm) of a desalted fibrinogen solution was measured after 
addition of thrombin (0.5 - 4 nM) at 37±0.1°C in HBS on a Jasco V-630 spectrophotometer 
(Tokyo, Japan), in the absence or presence of 4mM β2GpI (21). The rate of thrombin-induced 
platelet aggregation was determined by turbidimetric measurements at 350 nm at 37±0.1°C on 
a PACKS-4 aggregometer (Helena Laboratories, Sunderland, UK) (14). Platelets from normal 
donors were obtained by gel filtration of platelet-rich plasma onto a (1×25cm) Sepharose 2B 
column equilibrated with 10mM Hepes buffer pH 7.4, 135mM NaCl, 5mM KCl, 5mM 
glucose, 0.1% BSA. Gel-filtered platelets (220000/µl) were activated with human thrombin 
(1nM) and the velocity (v) of platelets aggregation was estimated as v = DA350/Dt, where 
DA350 is the increase in absorbance at 350 nm and Dt (i.e. 4 min) is the time range in which 
A350 is a linear function of time The IC50 value was estimated by fitting the data points of %vi 
versus [β2GpI] to a logistic equation (eq.6) using the program Origin 7.5 (MicroCal, Inc.): 
v = vmax + {(vmin-vmax)/1+([β2GpI]/IC50)
p
}       (eq.6) 
where vmin and vmax are the asymptotic values that assumes v in the absence or in the presence of 
saturating [β2GpI], p is the slope factor, and IC50 is the concentration of β2GpI inhibiting by 50% 
thrombin-induced platelet aggregation.  
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The effect of β2GpI on the thrombin-induced clotting in whole blood was determined at 37°C 
by Multiple Electrode Aggregometry (MEA) using a Multiplate analyzer (Dynabyte, Munich, 
Germany). The Area Under the aggregating Curve (AUC) was calculated over 6-min reaction 
(24). Citrate-treated blood samples were taken from three healthy donors, two males and one 
female, 23-28 years of age, and non-smokers. The donors gave written informed consent for 
participation to this study, approved by the institutional ethics committee. Ecarin clotting time 
(ECT) and thrombin clotting time (TCT) assays were carried out at 25°C with normal and 
β2GpI-deficient plasma (Affinity Biologicals, Ancaster, Canada) using an ACL-Top300 
coagulometer (Instrumentation Laboratory, Milan, Italy) according to the manufacturer’s 
procedures. 
 
PAR-1 Hydrolysis and PC Activation 
Measurement of thrombin-mediated PAR-1 hydrolysis on gel-filtered platelets was carried out 
by immunocytofluorimetry on FACScan flow-cytometer (Becton Dickinson, Mountain View, 
CA) (11, 14), using a SPAN-12 mAb recognizing intact PAR-1. Briefly, gel-filtered platelets 
(10000/µl) were activated at 37±0.1°C with human thrombin (0.2nM) in the presence of 
β2GpI (0-2mM). The presence of intact PAR-1 molecules on the platelet membrane after 
thrombin stimulation was measured by adding saturating concentrations (2 mg) of SPAN12 
monoclonal antibody (mAb) (Immunotech, Monrovia, CA, USA), a phycoerythrin (PE)-
conjugated anti-PAR-1 mAb recognizing the N-terminal portion of PAR-1 segment 35–46 
35
NATLDPR↓SFLLR
46, exclusively in the intact, uncleaved form. Data points were fitted to a 
logistic equation (eq.7) to obtain the IC50 value, using the program Origin 7.5 (MicroCal, 
Inc.): 
F = F0 + {(F1-F0)/1 + ([β2GpI]/IC50)
p
}               (eq.7) 
where F0 and F1 are the fluorescence of PE-conjugated anti-PAR-1 mAb at [β2GpI] = 0 and 2mM, 
respectively, p is the slope factor, and IC50 is the concentration of β2GpI inhibiting by 50% thrombin-
mediated cleavage of PAR-1 on platelets. Fluorescence data are expressed as the per cent of the 
maximum emission recorded by incubating platelets with SPAN12 mAb. 
Hydrolysis of PAR-1(38-60) peptide (1mM) by thrombin (0.1nM) was carried out at 25°C in 
Tris-buffered-saline (TBS) and monitored by RP-HPLC (14). The peptide PAR-1(38-60) 
38LDPR↓SFLLRNPNDKYEPFWEDEE60 was synthesized in our laboratory by solid phase 
techniques, using the fluorenylmethyloxycarbonyl chemistry, purified to homogeneity by RP-
HPLC, and its chemical identity established by MS. The effect of β2GpI (1mM) was 
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investigated by pre-incubating the enzyme with the protein. At time intervals, aliquots of the 
reaction mixture was blocked with aqueous formic acid (10%) and the time course of PAR-1 
(42-60) release was monitored by RP-HPLC, onto a (4.6x150mm) Vydac C18 column eluted 
(0.8 ml/min) with a linear acetonitrile-0.1% TFA gradient from 5 to 45% in 45 min, by 
recording the absorbance of the effluent at 214 nm. When substrate concentrations are lower 
than Km values of thrombin (E) for PAR-1 (>10mM) (25) the concentration of product [P] 
[i.e. PAR-1(42-60)] can be measured as a function of time (t) according to the pseudo first-
order kinetic equation (eq.8), using the program Origin 7.5 (MicroCal, Inc.): 
[P] = [P] ∞ [1 – exp(-t∙kobs)]                 (eq.8) 
where [P]∞ is the concentration of the product at t=∞ and kobs is the observed kinetic constant given by 
kobs = [E]s, in which [E] is the enzyme concentration and s is the specificity constant kcat/Km. The s 
values were analyzed as a function of the inhibitor concentration, [I] (i.e. β2GpI) using the linkage 
equation (25). 
Protein C (PC) activation by thrombin alone or in the presence of 4mM β2GpI was monitored 
with or without thrombomodulin at 37°±0.1C in TBS, containing 5mM CaCl2, according to 
the quenching method described elsewhere (24). At time intervals, aliquots of the reaction 
mixture were added to a TBS solution containing the aPC substrate S2366 (200μM) 
(Chromogenix, Milan, Italy), and hirudin HM2 (1μM) to selectively inhibit thrombin. The 
initial velocity, vi, of S2366 hydrolysis was determined by measuring the release of p-
nitroanilide at 405 nm, using a Victor3 plate reader (Perkin-Elmer, Norwalk, CA) and 96-well 
polystyrene plates (Sigma, St. Louis, MO, USA). At each time point, the concentration of the 
newly generated aPC was determined from a standard curve of vi versus [aPC], obtained with 
aPC solutions of known concentration. The kcat/Km. value of PC hydrolysis was obtained 
from the time-course of aPC generation, using the pseudo first-order kinetic model (eq.8). 
 
Modelling 
Docking was performed with Ultrafast-FFT GPU-based HEX 6.3 software (26), run on 
nVidia GeForce GTX680, starting from the structures of β2GpI (1C1Z.pdb) (4) and inhibitor-
free thrombin (1PPB-pdb) (7). Simulations were run using default parameters, without 
introducing any geometric/energetic constrain. One hundred poses were generated and ranked 
according to the HEX scoring function (26). The top three poses were almost identical and 
selected for data analysis. 
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RESULTS 
 
Chemical Characterization of Purified b2GpI 
Natural β2GpI was purified from normal human plasma by means of perchloric acid 
precipitation. This procedure yields highly homogenous (> 95%) β2GpI preparations, as 
obtained from RP-HPLC and SDS-PAGE (Fig. 2.3).Under reducing conditions, β2GpI 
migrates as a single band at ׽53 kDa, in agreement with the known lower electrophoretic 
mobility of glycosylated proteins. Malti-tof mass spectrometry analysis of purified β2GpI 
yields an average molecular mass of 44957 ± 20 a.m.u. 
 
Figure 2.3 Analytical characterization of purified b2GpI (30 mg) by RP-HPLC. The material eluted in 
correspondence of the major chromatographic peak was collected, lyophilized and analyzed by Maldi-tof mass 
spectrometry. Inset: SDS-PAGE (4-12% acrylamide) analysis of b2GpI under reducing conditions. Lane 1, 
purified b2GpI (4 mg); lane 2 molecular weight protein standards (Std). 
 
 
b2GpI-Thrombin Interaction Probed by SPR 
Increasing concentrations of the inactive mutant S195A (Fig. 2.4A) or recombinant wild-type 
a-thrombin (Fig. 2.4B), pre-treated with the active-site inhibitor NAPAP (Kd = 7nM), were 
injected over a CM5 sensor chip loaded with purified β2GpI up to 11´100 resonance units 
(RU). Our data (Fig. 2.4A) show that S195A and the NAPAP-inhibited wild-type thrombin 
bind to immobilized β2GpI with the same affinity (Kd = 37nM and 34nM, respectively), 
suggesting that the active-site of thrombin is not (or only loosely) involved in β2GpI 
interaction. This conclusion was further supported by the lack of any significant effect of 
β2GpI on the affinity of thrombin for structurally different active-site inhibitors, like PABA 
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(Fig. 2.4D) and Hir (1-47) (Fig. 2.4E). While PABA is a small molecule interacting with the 
primary specificity site of trypsin-like proteases (27), Hir (1-47) is a globular polypeptide 
encompassing the N-terminal domain of hirudin and extensively penetrating into the enzyme 
subsites (15). Interestingly, β2GpI does not reduce and even slightly enhances the affinity of 
the inhibitors for thrombin (Fig. 2.4). Control experiments, carried out with unmodified CM5 
sensor chip, unequivocally demonstrate that β2GpI does not interact with the negative surface 
of the carboxymethyldextran-coated sensor chip, either in the absence of soluble 
carboxymethyldextran (1 mg/ml). 
 
Mapping b2GpI-Thrombin Interaction Sites 
The role of thrombin exosites in β2GpI binding was assessed by:  
1. competition experiments with ligands specific for exosite-I (hirugen, HD1 aptamer and 
TM) or exosite-II (fibrinogen g′-peptide and HD22 aptamer);  
2. binding with thrombin mutants having exosite-I or exosite-II partially compromised by 
point mutations; 
3. binding with thrombin zymogens prothrombin (ProT) and prethrombin-2 (Pre2) and 
nicked thrombin (bT-thrombin) having one or both exosites variably compromised. 
 In competition experiments (Fig. 2.5A, 2.5B, 2.5C) exosite-I or exosite-II were 
blocked with saturating concentrations of ligands specific for either one of the two exosites. 
The resulting thrombin-ligand solutions were injected over the β2GpI-immobilized sensor 
chip and the decrease in the SPR signal was interpreted as an indication that the blocked 
exosite was involved in the interaction with β2GpI. SPR analyses indicate that blockage of 
either exosite-I or exosite-II results in 40-60% decrease of RU, while the simultaneous 
blockage of both exosites with hirugen and g′-peptide completely abrogates binding. In 
addition, linkage-experiments with increase concentration of inhibitors (0-2mM for hirugen 
and 0-160 mM for fibrinogen g′-peptide) confirm that both exosites are involved in the 
interaction: Kd, in the presence of saturating concentration of exosite-I or exosite-II binders, 
increases of 3-5 fold. 
 Perturbations of thrombin exosites by point mutations indicate that Ala-shaving of 
R73 in exosite-I or R101 in exosite-II slightly reduces affinity for β2GpI (Fig. 2.5D). Data 
obtained with a small library of mutant of human thrombin (Exosite-I: K36A, L65A, K81A, 
K110A; Exosite-II: R165A, K169A, D178A, K235A) suggest that the ionic interaction plays  
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Figure 2.4 Surface plasmon resonance analysis of b2GpI-thrombin interaction. (A) Binding of the 
inactive recombinant S195A thrombin mutant. (B) Binding of wild-type thrombin inhibited with NAPAP 
(1mM). (C) Plot of RU/RUmax ratio as a function of [Thrombin], where RUmax is the RU value extrapolated at 
[Thrombin]→∞. Data fitting yields a Kd = 37 ± 4 nM for S195A mutant (○,Δ) and Kd = 34 ± 4 nM for 
NAPAP-inhibited wild-type thrombin (●). 
Effect of β2GpI on the affinity of active-site inhibitors for thrombin. (A) PABA binding: thrombin samples 
(25nM) in the absence (○) and presence (●) of 4mM β2GpI were excited at 336 nm and the fluorescence of 
PABA was recorded at 375 nm. Kd for PABA binding was calculated as 256 ± 6mM and 187 ± 9mM in the 
absence or in the presence of β2GpI. (B) Hir(1-47) binding: thrombin samples (50nM) in the absence (○) and 
presence (●) of 4 mM β2GpI were excited at 295 nm and the fluorescence was recorded at 334 nm. Kd values for 
Hir(1-47) binding were calculated as 151 ± 8nM and 145 ± 7nM in the absence or in the presence of β2GpI. The 
error on fluorescence measurements was <5%. 
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Figure 2.5 Surface plasmon resonance analysis of b2GpI binding to thrombin exosites. (A) Exosite-I: 
thrombin (T, 250nM) inhibited with NAPAP (5mM) was incubated for 5 min with 1mM HD1 or 20mM hirugen 
(Hir) and the resulting complex injected over the bound β2GpI. In the case of TM, the cofactor alone (10nM) or 
an equimolar (10nM) TM-thrombin solution was loaded. (B) Exosite-II: NAPAP-inhibited thrombin (250nM) 
were separately incubated with 1mM HD22 and 270mM fibrinogen g'-peptide or with a solution of 20mM 
hirugen+200mM g'-peptide. (C) %RU measured for the binding of thrombin to immobilized β2GpI in the 
presence of exosite binders, as obtained in A and B. (D) Interaction of recombinant wild-type (●) and mutant 
thrombins R73A (○) and R101A (■) to bound β2GpI. Data fitting yields Kd value of 72 ± 8 nM for R73A, 91 ± 
10 nM for R101A, and 45 ± 4 for wild-type. (E) Interaction of mutant human thrombin to bound β2GpI; D178A 
displays incremental of affinity by 4 fold. (F) Localization of amino acid residue substituted by point mutations 
in the thrombin structure (1PPB.pdb). 
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a relevant role in the binding. In fact, all the above mutations did not significantly influence 
the affinity for β2GpI immobilized on sensor chip; the only exception is D178A (Fig.2.5E). In 
this case, the substitution on negative charge of Asp residue with Ala residue comport an 
incremental of affinity by 4 fold. 
Binding measurements with thrombin zymogens (Fig. 2.6A) show that full-length 
ProT does not significantly bind to β2GpI, whereas the shorter zymogen intermediate Pre2 
interacts with β2GpI with an affinity 7-8 fold lower than that of mature a-thrombin, Kd = 264 
± 15 nM (Fig.2.6A, 2.6B). These results can be rationalized considering that in ProT both 
exosites are heavily compromised, whereas in Pre2 only exosite-1 is perturbed while exosite-
2 is still functional. Consistently with these findings, the affinity of bT-thrombin (17) is 
dramatically reduced (Fig. 2.6A), as a result of tryptic cleavage of Arg77a-Asn78 bond, 
causing disruption of exosite-I and perturbation of exosite-II (28). Conversely to thrombin, 
immobilized β2GpI does not bind to activated factor X (FXa) (Fig. 2.6B), the serine protease 
immediately upstream to thrombin in the coagulation cascade. 
 
 
 
Figure 2.6 Surface plasmon resonance analysis of b2GpI binding to thrombin zymogens. (A) RU/RU0 ratio 
measured for the binding of Pre2 (10nM) and ProT (1mM), b-thrombin (10nM) and FXa (10nM) to bound 
β2GpI. RU0 is the signal obtained with thrombin S195A alone (10nM). (B) SPR analysis of the interaction of 
Pre2 to immobilized β2GpI. After data fitting (Inset), a Kd = 264 ± 15 nM was obtained. 
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Electrostatic Steering of b2GpI-Thrombin Interaction  
The effect of the salt (i.e. 0.1M, 0.15M, 0.2M, 0.3M, 0.35M, 0.4M, 0.5M Na+) in the 
interaction of β2GpI with thrombin (Fig.2.7A) can be further quantified by plotting the data as 
ln Kd, at different concentration of NaCl, verses ln [salt] on a straight line according to eq. 2. 
The value of Gsalt for this interaction was calculated from the slope of the line as -2.36 ± 0.15 
(Fig. 2.7B). The value of Gsalt for β2GpI-thrombin interaction is compared with the Gsalt values 
calculated for the enzyme and other exosite-I and exosite-II ligands obtained from the 
literature (19). Thrombin ligands that bind at its exosite-I (i.e. fibrinogen and hirudin) have 
little salt dependence and values of Gsalt around 1.0, whereas known exosite-II binders (i.e. 
heparin and thrombomodulin) are characterized by Gsalt values around 4-5 (19). In this respect, 
β2GpI is behaving as a thrombin exosite-I – exosite-II binding ligand. In addition, if the 
association between β2GpI and thrombin is solely due to an electrostatic association, the 
values of Gsalt will also indicated the minimum number of ionic bound involved in the binding 
(20). Thus, it might be expected that a minimum of two-three ionic bonds contribute to this 
interaction. 
 
Figure 2.7 Salt dependence of b2GpI-thrombin interaction. (A) Interaction of thrombin to immobilized 
β2GpI at different concentration of NaCl: 0.1M ●●, 0.15M ○○, 0.2M ▲▲, 0.3M ΔΔ, 0.35M ■■, 0.4M □□, 
0.5M ♦♦. (B) The dissociation constant, Kd, for the b2GpI-thrombin interaction derived from the curves in A 
were plotted as a function of the respective Na+ ion concentration on a ln-ln scale, and fitted by linear regression 
according to eq.2. After data fitting a Gsalt = -2.36 ± 0.15 was obtained. 
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b2GpI Prolongs the Clotting Time in Fibrin Generation Assays 
Fibrin generation was started by addition of thrombin to a solution of purified human 
fibrinogen at increasing [β2GpI] and monitored by turbidimetry at 350nm. The resulting 
clotting curves were analyzed to extract the values of DAmax, tmax, tc, and Dtc=tc-t∞, where 
DAmax is the maximum slope of the clotting curve, tmax is the time needed to reach DAmax, tc 
(i.e. the clotting time) is the lag-time and t∞ is the value that assumes tc at [Thrombin]→∞ (21). 
The value of t∞ was calculated as 33 ± 4 sec and found identical to that previously determined, 
t∞ = 32.5 ± 1.4sec (18). Of note, tmax and tc are correlated quantities: tmax = 26.4 + 1.11∙tc (21). 
 
 
Figure 2.8 Effect of b2GpI on fibrin generation (A) Representative clotting curves for the generation of fibrin 
in the absence and presence of b2GpI. To a human fibrinogen solution (0.44mM) in HBS at 37°C was added 
plasma thrombin (1nM), with or without b2GpI (4mM) and the increase in turbidity (Abs350 nm) was recorded 
over time. (B) Plot of Dt = tc-t∞ as a function of [β2GpI]/[thrombin] ratio. The concentration of b2GpI is kept 
constant at 4mM while thrombin concentration is varied in the 0.5-4nM range. (C) Effect of [LPS] on fibrin 
generation. Reaction was started by addition of thrombin (1nM) in the presence of b2GpI (4mM). The tmax/t
0
max 
ratio is plotted as a function of [LPS], where t0max is the value of tmax at [LPS] = 0. (D) Effect of b2GpI on ECT 
(●) and TCT (○) in b2GpI-deficient plasma. Increasing concentrations of b2GpI were added to diluted (1:1 in 
TBS) b2GpI-deficient plasma samples (100ml) and the clotting time was determined by measuring the 
absorbance at 671 nm from the addition of ecarin (0.25 EU/ml) or human thrombin (0.5 NIH units/ml). 
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Our data show that addition of a physiological concentration of β2GpI to the clotting reaction 
significantly prolonged tc (Fig. 2.8A), compared to thrombin alone, and that Dtc increases 
linearly by increasing the [β2GpI]/[thrombin] ratio (Fig. 2.8B). Interestingly, the data in Fig. 
2.8C indicate that bacterial LPS dose-dependently opposed the effect of β2GpI by reducing 
tmax by 60%. Finally, the data obtained with isolated fibrinogen favourably correlate with 
ecarin (ECT) and thrombin clotting time (TCT) measurements carried out on β2GpI-deficient 
plasma (Fig. 2.8D). 
 
b2GpI Hinders Thrombin-Induced Platelet Aggregation by Inhibiting PAR-1 Hydrolysis 
Turbidimetric measurements (Fig. 2.9A, 2.9B) indicate that β2GpI inhibits aggregation of gel-
filtered platelets with IC50 = 0.36 ± 0.1μM. A similar IC50 value of 0.32 ± 0.1μM was obtained 
by immunocytofluorimetric determination of PAR-1 cleavage on gel-filtered platelets (Fig. 
2.9C). 
 The effect of β2GpI on platelet aggregation was also determined on whole blood, by 
Multiple Electrode Aggregometry (MEA) (29) (Fig. 2.9D). MEA exploits the increase of 
electric impedance measured in the measure cell and proportional to the amount of platelets 
sticking on the electrodes. Our data indicate that β2GpI dose-dependently inhibits platelet 
aggregation in whole blood and that this effect is partially opposed by LPS. Notably, IC50 
values estimated from MEA curves on whole blood are approximately ten-fold lower than 
those obtained with gel-filtered platelets. Likely, this is predominantly caused by the intrinsic 
higher sensitivity of platelets in whole blood (29) and to a minor extent by the contribution of 
fibrin generation to the increase of the measured electric impedance. In the presence of 80mM 
LPS (Fig. 2.9E) the inhibitory effect of β2GpI on platelet aggregation was partially reversed.  
This finding is consistent with recent results showing that LPS binds β2GpI domain V (6) and 
therefore can impair the β2GpI-thrombin interaction. 
Finally, the inhibitory effect of β2GpI on PAR-1 cleavage was explored with the 
synthetic peptide PAR-1(38-60), chemically synthesized by solid phase techniques. With 1 
µM β2GpI, a concentration four-fold lower than that found in vivo (1, 2), the efficiency of 
PAR-1(38-60) hydrolysis is almost halved (Fig. 2.9F). 
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Figure 2.9 Inhibition of thrombin-induced platelet aggregation and PAR-1 hydrolysis by b2GpI 
(A-B) Gel-filtered platelets (220000/µl) in HBS were activated at 37°C with human thrombin (1nM) and the 
change in transmittance at 350 nm with time (A) was recorded to determine the rate (v) of platelet aggregation 
(B) Data fitting yields IC50 = 0.36 ± 0.1μM. (C) Inhibition of thrombin-induced PAR-1 hydrolysis by b2GpI on 
intact platelets. Gel-filtered platelets (10000/µl) were activated at 37°C with human thrombin (0.2nM) in the 
presence of β2GpI. Uncleaved PAR-1 was quantified by immuno-cytofluorometry, adding saturating amounts (2 
mg) of SPAN12 mAb which selectively recognizes intact PAR-1. Data fitting yields IC50 = 0.32 ± 0.1μM. (D-E) 
Effect of b2GpI on platelet aggregation on whole blood (D), induced by addition of thrombin (6nM), in the 
presence (○) or in the absence (●) of LPS (80mM) (E). The data are expressed as the AUC/AUC0 ratio, where 
AUC0 is the Area Under the aggregation Curve at [b2GpI]=0. (F) Time-course cleavage of PAR-1(38-60) 
peptide by thrombin(0.1nM) in the absence (●) and in the presence (○) of β2GpI (1µM) at 25°C. The release of 
PAR-1(42-60) was quantified by RP-HPLC. The data were analyzed with the pseudo-first order kinetic model 
and the values of kcat/Km were calculated as 35.8 ± 0.1 and 19.7 ± 0.1 µM
-1 s-1 in the absence and presence of 
1µM β2GpI, respectively. The error on the quantification of cleaved PAR1 was <5%. 
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b2GpI Does Not Influence PC Activation by Thrombin 
The effect of physiological concentrations of β2GpI on activated PC (aPC) generation was 
investigated in the absence or presence of TM (Fig. 2.10). Without TM, β2GpI does not alter, 
or even slightly enhances (by 3-fold) the efficiency with which thrombin hydrolyses PC. With 
TM, the efficiency of aPC generation is dramatically increased, as expected (9), but in the 
presence of the cofactor the effect of β2GpI is negligible. The slight increase of kcat/Km 
observed with β2GpI likely reflects the widening of thrombin active site that might be 
induced allosterically by interaction of β2GpI with exosite-I, as already observed with other 
exosite-I binders (7, 30). With TM, this enhancing effect is masked by the overwhelming 
affinity of the co-factor for thrombin, compared to that of β2GpI. 
 
Figure 2.10 Effect of b2GpI on the generation of aPC by thrombin in the presence or absence of 
thrombomodulin. Effect of β2GpI on PC activation with (○,●) or without (Δ,▲) TM. To a solution of PC 
(200nM) was added human thrombin (5nM) in the absence (Δ) or in the presence (▲) of β2GpI (4mM) at 37°C. 
Under conditions of pseudo-first reaction, the values of kcat/Km and [aPC]∞ were determined as follows: -β2GpI, 
kcat/Km= 0.30 ± 0.2 mM
-1·s-1 and [aPC]∞ = 194 ± 9 nM; +β2GpI, kcat/Km= 1.00 ± 0.2 mM
-1·s-1 and [aPC]∞ = 213 ± 
2n M. The effect of β2GpI on PC activation in the presence of 50nM TM (○,●) was determined as above, with 
[thrombin] = 10nM: -β2GpI, kcat/Km = 215 ± 1 mM
-1·s-1 and [aPC]∞ = 202 ± 3nM; +β2GpI, kcat/Km = 280 ± 3mM
-
1·s-1 and [aPC]∞ = 212 ± 5nM. 
 
 
DISCUSSION 
b2GpI Function as an Anticoagulant Protein 
 β2GpI was described for the first time about 50 years ago and since that time no clear 
physiological function has been identified for this protein (1, 3). The results of these study 
provide experimental evidence that β2GpI may function as an anticoagulant protein. In fact, it 
inhibits key procoagulant activities of thrombin in vitro, such as fibrin generation (Fig. 2.8) 
and platelet aggregation either (Fig. 2.9), without affecting its unique anticoagulant function, 
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i.e. PC activation (Fig. 2.10). In particular, β2GpI dose-depend impairs thrombin-mediated 
generation of fibrin from purified fibrinogen (Fig. 2.8A, 2.8B) or from β2GpI-deficient 
plasma, as shown by the significant prolongation of the clotting time observed after the 
addition of fully active thrombin in the TCT assay or the direct prothrombin activator ecarin 
in the ECT assay (Fig. 2.8D) Likewise, β2GpI inhibits the thrombin-induced aggregation of 
platelets, by impairing thrombin cleavage of PAR-1 (Fig. 2.9C, 2.9F), either when they are 
isolated from blood by gel filtration (Fig. 2.9B) or when they are in the complex matrix of 
whole blood (Fig. 2.9E). It is noteworthy that β2GpI binding is specific for the newly 
generated active thrombin, and does not involve the inactive zymogene ProT or FXa, the 
protease immediately upstream in the coagulation cascade (Fig. 2.6A). 
 
Mechanism of Β2GpI-Thrombin Interaction 
 Using several different molecular probes, we have demonstrated that β2GpI affects 
thrombin functions by binding to protease exosites, while leaving the active site accessible 
(Fig. 2.4, 2.5, 2.6). The picture of β2GpI-thrombin interaction derived from experimental data 
is fully compatible with the theoretical model of the β2GpI-thrombin complex shown in Fig. 
2.11. The model shows a clear geometric and electrostatic complementarity between the 
positively charged exosites of thrombin and the large negatively charged surface distributed 
over the concave face of β2GpI, within domains DIII, DIV and DV (15 Asp+Glu). Notably, 
DV has an asymmetric charge distribution, with a negative region (6 Asp+Glu) on the upper 
face pointing towards thrombin exosite-I and a positive region (9 Lys+Arg) on the lower face, 
amenable to interact with negatively charged surfaces (phospholipid membranes and LPS) (1, 
6). Importantly, the model shows that thrombin active site is fully accessible for 
substrate/ligand binding after β2GpI binding.  
 In addition, the binding of β2GpI to thrombin appears to be in part salt-dependent (Fig. 
2.7). The value of Gsalt (i.e. -2.36 ± 0.15) exceeds the values reported for fibrinogen and 
hirudin (19) and signals a electrostatic contribution to the binding of β2GpI to thrombin. 
Moreover, it is likely that a minimum of two-three ionic bonds are involved in this 
interaction. 
SPR data show that ligand saturation of a specific thrombin exosite does not 
completely abolish binding of β2GpI, with a significant residual signal being still measurable 
(Fig. 2.5A, 2.5B, 2.5C). Nevertheless, the concomitant saturation of both exosites with 
hirugen and g′-peptide completely abrogates binding (Fig. 2.5B). Likewise, structural 
perturbation of exosite-I in Pre2 (31) results in a 7-8 fold decrease in affinity (Fig. 2.6A, 
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2.6B), whereas inactivation of both exosites, as in ProT (7) and bT-thrombin (17, 28), almost 
completely abrogates interaction (Fig. 2.6A). These results can be interpreted according to a 
dynamic binding model in which the conformationally flexible β2GpI molecule (1, 4-6) 
exploits different sites on DIII, DIV and DV domains to interact with exosite-I and -II on 
thrombin surface (Fig. 2.11) and suggest that the strong affinity measured for β2GpI binding 
to thrombin (Kd = 34nM; DGb= -10.6 kcal/mol) is distributed over several different interacting 
sites and it is fully expressed only when both thrombin exosites are available for binding. 
According to the model, in fact, when one of the two exosites is already occupied by a given 
ligand present in solution, β2GpI can still interact with thrombin, albeit with lower affinity, at 
the other exosite available on the protease surface to form a ternary complex. Hence, the 
binding properties of β2GpI can be dynamically regulated by the specificity and affinity of the 
ligand that can contact thrombin at either one of the two exosites. This simple model explains 
why β2GpI hinders binding of ligands displaying moderate affinity for exosite-I like 
fibrinogen (Kd = 1.1mM) (30) (Fig. 2.8), whereas it is not able to compete with a much 
stronger exosite-I binder like TM (Kd = 0.5nM) (9) (Fig. 2.8). 
 
 
 
Figure 2.11 Theoretical Model of b2GpI-thrombin interaction. The docking model was obtained using the 
HEX software, starting from the coordinates of isolated β2GpI (1C1Z.pdb) and thrombin (1PPB.pdb). β2GpI is 
shown as a ribbon drawing (pink) while thrombin is shown as an surface (grey). The approximate position of 
active site, exosite-I and -II on thrombin surface is indicated in yellow. 
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 In this study a collection of thrombin mutants was used to provide a structural 
mapping of the key residues involved in the thrombin-β2GpI binding. Our results indicated 
that the point mutations at exosite-I or exosite-II, involving positive charged amino acid 
residue (Arg→Ala, Lys→Ala), are not sufficient for hinder the interaction. However, if a 
negatively charged amino acid is replaced (Asp→Ala) the affinity changes drastically (Fig. 
2.5E). Perhaps, the loss of the negative charge Asp178 is more significant than the deficiently 
of a positive charge residue, because thrombin has an extensive electropositive surface area 
(200 Å2) whose residues are well exposed to the solvent. So, the lack of Arg or Lys can be 
compensated by other positively charged residues, localized principally at the level of 
exosites. This may be in agreement with the demonstrated salt-dependency in the formation of 
thrombin-β2GpI complex. 
 
Effect of b2GpI on Coagulation 
 As expected from the involvement of exosite-I in thrombin-β2GpI interaction (Fig. 
2.5) β2GpI inhibits hydrolysis of those procoagulant substrates, like fibrinogen (Fig. 2.6) and 
PAR-1 (Fig. 2.9C, 2.9F), that use exosite-I as a hot spot for binding to thrombin (30). 
Likewise, participation of exosite-II in β2GpI binding (Fig. 2.5) highlights the possibility that 
β2GpI hinders exosite-II mediated anchoring of thrombin on its platelet receptor GpIba (11, 
12) with a resulting inhibition of platelet aggregation, as shown in Fig. 2.9. Notably, the data 
also indicate that β2GpI does not fully impair platelet aggregation, even at the highest 
concentrations tested. Probably this effect arises from the presence on platelet surface of 
PAR-4 a receptor that, contrary to PAR-1, is cleaved by thrombin independently of exosite 
binding (30). Importantly, both experimental and theoretical data herein reported seem to 
indicate that β2GpI binds to thrombin without covering the catalytic site. This distinctive 
feature of β2GpI-thrombin interaction is fully consistent with the observation that β2GpI does 
not alter the efficiency with which thrombin hydrolyses PC (Fig. 2.10), a zymogen which is 
known to interact with the thrombin exclusively at its active site (32).  
Our data show that β2GpI is quite specific for active a-thrombin and does not bind 
neither to ProT nor to FXa (Fig. 2.6A), the serine protease immediately upstream to thrombin 
in the coagulation cascade. This effect likely arises from the markedly different distribution of 
surface charges in the two enzymes (28). Like thrombin, FXa has a positively charged 
exosite-II, although more dispersed than the corresponding patch on thrombin. Conversely, 
the region on FXa topologically equivalent to exosite-I on thrombin, is highly negative and 
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this might cause electrostatic repulsion with the negative surface on β2GpI. Additional results 
indicate that bacterial LPS seem to oppose the inhibitory effects of β2GpI on fibrin generation 
(Fig. 2.8C) and platelet aggregation on whole blood (Fig. 2.9E). β2GpI has been recently 
shown to act as a scavenger of LPS, which tightly binds (Kd = 62nM) to β2GpI domain V (6). 
Hence, we speculate that the effect of LPS on β2GpI function results from masking/alteration 
of β2GpI binding sites for thrombin. 
To address the possible role of β2GpI in the regulation of haemostasis in vivo, one 
should consider that the haemostatic process is the result of a delicate equilibrium between 
opposing procoagulant and anticoagulant systems, variably operating in different vascular 
compartments (e.g. large vessels and capillaries). Down-regulation of blood coagulation is 
accomplished mainly on the vascular endothelium by tissue factor pathway inhibitor (TFPI), 
heparin-like proteoglycans (HP), and TM. TFPI acts in the initiation phase, whereas HP and 
TM function in the attenuation-phase of blood coagulation (33). In the macrovasculature, 
where the concentration of TM is too low (0.2nM) for efficient PC activation, thrombin 
inhibition is mainly exerted by the HP-antithrombin III system. In the microvasculature, 
instead, where the concentration of TM increases up to 300nM, due to the higher 
surface/volume ratio of the capillaries compared to large vessels (34), the major anticoagulant 
function is accomplished by TM. Endothelial cell-bound TM interacts with thrombin exosite-I 
and shifts the substrate specificity of the protease by preventing binding of fibrinogen and 
PAR-1. In addition, TM dramatically enhances thrombin activation of PC by bringing 
thrombin and PC close together and inducing conformational changes both in the protease and 
substrate (9, 33). Intriguingly, while present on most endothelial cells, TM is absent in the 
vasculature of human brain (35). 
All these considerations and the high plasma concentration of β2GpI (up to 10mM ~ 
0.5 mg/ml) (1) allow us to speculate that under physiological conditions β2GpI may function 
as a plasma-soluble anticoagulant protein acting in those vascular compartments where the 
more potent TM-thrombin pathway poorly functions, as in the large vessels, or is even absent, 
as in the brain vasculature. Further, indirect support to our proposal is given by clinical 
studies showing that significantly reduced β2GpI levels are found in patients with stroke and 
in elderly patients with thrombotic disorders (36), whereas high circulating levels of β2GpI 
appear to be associated with a reduced risk of myocardial infarction (37). In addition, there is 
a positive correlation between the presence of auto-antibodies against β2GpI and thrombotic 
manifestations in APS patients (1, 3). 
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In conclusion, the results herein reported highlight the unique anticoagulant properties 
of β2GpI, selectively inhibiting the procoagulant functions of thrombin without altering its 
anticoagulant activity. These findings are unprecedented and pave the way to the discovery of 
a novel physiological anticoagulant pathway. 
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α-synuclein (α-Syn) is a small (14.5 kDa, 140 amino acids) soluble presynaptic 
protein that is highly conserved in vertebrates and has been implicated in different 
neurodegenerative disorders, called “synucleinopathies”. These disorders include, among 
others, Parkinson’s disease (PD) and Alzheimer’s disease (AD). PD is the most common 
movement disorder, whereas AD is the most common form of dementia (1). PD is 
characterized by eosinophilic cytoplasmatic inclusion, called Lewy bodies (LB), found in 
dopaminergic neurons of the substantia nigra and composed of α-Syn extensively 
ubiquitinylated (2). AD is characterized by intracellular neurofibrillary tangles that are 
composed of the hyperphosphorylated protein τ and extracellular β-amyloid plaques (3). It 
was reported that the central region of α-Syn, known as the non Aβ component of amyloid 
plaques, seems to be responsible for its aggregation process in the neurodegenerative status. 
In fact, the term “synucleinopathies” was introduced after found filamentous α-syn deposits 
(4). 
Structure and Conformational Properties of α-Synuclein: a Protein Chameleon 
α-synuclein is a small highly acidic natively unfolded protein that is abundantly 
expressed in the brain, where it is concentrated in presynaptic nerve terminals (5). Its primary 
sequence can be divided into three regions (Fig. 3.1). The N-terminal region (residues 1–60) 
includes 7 imperfect 11-residues repeats, each containing a highly conserved hexameric motif 
(KTKEGV) necessary to form amphipathic α-helices, typical of the lipid-binding domain of 
apolipoproteins (6). The central region (residues 61–95) comprises the non Aβ component of 
amyloid (NAC) sequence that seems to be responsible for the ability of α-Syn to form a single 
cylindrical β-sheet and to form Aβ-like protofibrils and fibrils (1, 5). The C-terminal region 
(residues 96–140), instead, is extremely enriched in acidic residues and prolines. 
α-Syn is a typical intrinsically disordered (or natively unfolded) protein, which 
possesses little or no ordered structure under physiological conditions in vitro (7). These 
proteins have recently been recognized as a new protein class, due to their capacity to perform 
numerous biological functions although the lack of unique structure. In fact, intrinsically 
3.1 α-Synuclein 
72 
disordered proteins exist as dynamic and highly flexible ensembles that undergo a number of 
distinct inter conversions on different timescales. Recent studies, obtained by small angle X-
ray scattering, shown that α-Syn has a radius of gyration of ~40 Å, larger than that predicted 
for a folded globular protein of 140 residues (i.e. 15Å), but significantly smaller than that for 
a fully unfolded random coil (i.e. 52 Å). In fact, a high-resolution NMR analysis reveled that 
α-Syn is largely unfolded in aqueous solutions, but exhibits a region between residues 6 and 
37 (N-terminal lipid - binding domain) with a preference for helical conformation (8, 9). 
 Nevertheless the structure of α-Syn is extremely sensitive to its environment and can 
be easily modulated by a change in conditions. α-Syn can acquire a pre-molten globule state 
in several conditions such as low pH, high temperature and presence of metal ions (4, 7). In 
organic solvent the protein forms α-helical species (10), as well as in the presence of synthetic 
lipid vesicles and detergent micelles (11). Upon binding to negatively charged surface, the N-
terminal domains adopts a highly helical structure (extended-helix state), instead the micelle-
bound form of α-Syn consists of two non-contacting antiparallel helices in the N-terminal 
region, with a short-break around residues 38-44 and a flexible conformation in the C-
terminal domain (broken-helix state) (Fig. 3.2) (12). α-Syn can form several morphologically 
different types of aggregates, including dimers, oligomeric protofibrillar species and insoluble 
amorphous aggregates. Hence, the conformational/functional properties of the protein are 
highly environment-dependent and therefore α-synuclein is now regarded as a protein-
chameleon (4). 
Figure 3.1 Schematic representation of the primary structure of -Syn. The three different regions 
that compose the protein are indicated. The N-terminal amphipathic region (in blue) contains most of 
the repeats and the three point mutations linked to autosomal dominant early-onset PD. The central 
region (NAC) (in green), which encompasses the most hydrophobic residues, promotes aggregation, 
while the acidic C-terminal portion (in red) of the protein tends to decrease protein aggregation.  
Physiological Functions of α-Synuclein 
 Presently the normal function of α-synuclein remains poorly understood, although 
numerous biological roles and possible interactions have been proposed for this protein. α-
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Syn has been estimated to account for as much as 1% of total protein in soluble cytosolic 
brain fractions and has been linked with synaptic plasticity (13), learning (14) and 
maintenance of synaptic vesicle pools (15). Indeed, the protein is involved in the vesicular 
transport: α-Syn knockout mice exhibit enhanced dopaminergic release at nigro striatal 
terminals only in response to paired electrical stimuli, suggesting that it is an activity-
dependent, negative regulator of dopaminergic neurotransmission (16). In addition, some 
studies reveal that α-Syn regulates catecholamine release from the synaptic vesicles, and its 
over-expression inhibits a vesicle ‘priming’ step that occurs after secretory vesicle trafficking 
to ‘docking’ sites but before calcium-dependent vesicle membrane fusion (17). 
Figure 3.2 Different tridimensional organization of α-synuclein. Structured protein regions are 
depicted as solid lines (in violet), while helical regions are depicted as filled bars or cylinders (in light 
blue). Membrane bilayers are indicated as double black lines with hashes. The unbound, intrinsically 
disordered state of α-Syn is depicted as existing in equilibrium between less compact and more 
compact conformations, which are also in equilibrium with the vesicle-bound extended-helix state. 
The latter can convert to the broken-helix state upon approach of the vesicle to another membrane, 
such as the pre-synaptic plasma membrane. Transitions between these conformations are indicated by 
black double arrows. The potential activity of the broken helix state in modulating membrane 
properties during membrane fusion is indicate by the green color of the linker region and the dotted 
lines between the vesicle and plasma membranes. Either the extended- or broken-helix states may be 
able to convert to a membrane-bound partially helical intermediate by the release of the C-terminal 
region of the lipid-binding domain from the membrane surface. Intermolecular association of these 
intermediates, driven by the membrane-associated N-terminal helices, may bring the disordered 
regions into close proximity, facilitating intermolecular β-sheet formation leading to amyloid oligomer 
and fibril formation. These transitions, which are considered to occur as part of the pathological 
behavior of α-Syn, are indicated by orange double arrows. This figure was adapted from (12). 
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 Other studies have proposed a putative function of α-Syn as a chaperone protein, 
based on its abundance in the cytosol, its natively unfolded structure, and its prevention of 
protein aggregation induced by heat shock or chemical treatment (18). In vivo the protein can 
protect the nerve terminals against injury via cooperation with cysteine string protein α
(CSPα) and soluble N-ethylmaleimide sensitive factor (NSF) attachment receptor proteins on 
the presynaptic membrane interface (19). 
α-Syn interacts stably with synthetic phospholipid vesicles containing negatively 
charged groups, phospholipid membrane, fatty acid and detergent micelles (4). It is proposed 
that α-Syn plays a role in modulating the organization of membrane lipid components: the 
protein, in the presence of negatively charged membrane of multilamellar vesicles, has a 
profound effect on the integrity of these bilayers, causing the formation of non-bilayer or 
small vesicular structures (20). Finally, it has been found that monomeric α-Syn bound to 
lipid membrane can prevent lipid oxidation (21). 
α-Syn has been shown to interact with at least 50 proteins and other ligands (21, 22). 
The protein acts as a high affinity inhibitor of phospholipase D2, which catalyzes the 
hydrolysis of phosphatidylcholine to phosphatidic acid (23). These results suggest that α-Syn 
influences the membrane remodeling processes involved in vesicle fusion or budding. At last, 
α-Syn interacts whit several polyvalent metal cations including Fe2+, Al3+, Zn2+, Cu2+, Mg2+
and Ca2+ (4). 
α-Synuclein in the Cardiovascular System
α-synuclein was ubiquitously expressed in various hematopoietic cells including T 
cells, B cells, NK cells and monocytes (24). Recent studies identify red blood cells as the 
major source of α-Syn (25). Almost all (> 99%) of the protein in blood is present in red blood 
cells; only minor amount were measured in peripheral blood mononuclear cells (0.05%) and 
platelets (0.2%) as well as in the plasma (0.1%). Nevertheless, if the amount of synuclein is 
normalized to the amount of cellular protein, platelets have the highest amount of α-Syn (i.e. 
264 ± 36 α-syn/protein ng/ml for platelets, 131 ± 23 α-syn/protein ng/ml for red blood cells) 
(26). In addition immune-gold electron microscopy of platelets showed that α-syn is loosely 
associated with the plasma membrane, the endomembrane system and, occasionally, with the 
membrane of secretory -granules. These findings suggest that the protein may play a critical 
role during hematopoietic cell differentiation and vesicle release (27). In this context, the 
hematopoietic system may be regarded as exceptional populations since expression of -Syn 
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in adult stage has been demonstrated in some lineages, including lymphocytes and platelets 
(28). 
It was reported that -Syn functions as a negative regulator of Ca2+-dependent -granule 
release from human platelets (29), and that the protein can be able to penetrate in platelet only 
in the presence of NAC region, as well as in neuronal cells (30). Moreover, α-Syn play a role 
as a negative regulator in Weibel-Palade body exocytosis in endothelia cells (31). Clinical 
studies indicated that the incidence of ischemic stroke in patients with PD is lower than in 
controls, and platelet aggregation is also significantly decreased (32). In fact, it seems that the 
platelets from PD patients have defect in their secretory pathways: the intracytoplasmatic 
vacuoles are larger and contain numerous granular molecules around the open canalicular 
system (33). All these results suggest that α-synuclein functions might not be restricted to 
neurons. 
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INTRODUCTION 
α-synuclein (α-Syn) is a small soluble presynaptic protein that is highly conserved in 
vertebrates and has been implicated in Parkinson’s disease (PD). Several mutations (i.e. 
A53T, A30P, and E46K) in the human α-Syn gene have been found to be associated with rare 
familial PD (1). In addition, protein deposits in PD’s brain, called Lewy body, are composed 
by β-sheet rich α-Syn amyloid fibrils (2). Presently, the normal function of α-Syn remains 
poorly understood, although it has been linked with synaptic plasticity (3) and learning (4), 
neurotransmitter release and maintenance of synaptic vesicle pools (5). α-Syn was found to 
localize to the presynaptic membrane and was ubiquitously expressed in various 
hematopoietic cells including T cells, B cells, NK cells, monocytes, red blood cells and 
platelets (6). In fact, the protein is able to penetrate the platelets and constitute the major 
component of protein deposits in PD (2). At the level of platelets, α-Syn is loosely associated 
with the plasma membrane, the endomembrane system and, occasionally, with the membrane 
of secretory α-granules (7). 
 Thrombin is the final effector protease in the coagulation cascade (8) and plays a key 
role at the interface between blood coagulation, inflammation, and physiological and 
pathological cell proliferation (9). Moreover, it seems to be also involved in 
neurodegenerative diseases (10) due to its expression in a number of cells in the nervous 
system (NS) (11). The effects of thrombin on the NS are mediated by activation of Protease 
Activated Receptors (PARs), that have been linked to the development and regrowth on 
central NS related to memory, neurodegenerative diseases and dopaminergic reward pathway 
(12-14). It was reported that thrombin, at low concentration, induces retraction of neuritis in 
neuroblastoma cells, acts as mitogen and induces alterations in astrocytes morphology: all 
these effects seem to have a protective role in the NS (15). Conversely, in the presence of 
higher concentration of the enzyme, has been shown to induce apoptosis in motor neurons 
(16) and to determine in the brain a pro-inflammatory state (17). Interestingly, numerous 
alterations in morphology and platelets aggregation have been found in PD. Furthermore, α-
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Syn has been shown to impair thrombin-induced platelets degranulation, through PAR-
mediated activation (18). It was reported, in fact, that -Syn functions as a negative regulator 
of Ca2+-dependent -granule release from human platelets (18), and it plays as a negative 
regulator in Weibel-Palade body exocytosis in endothelia cells (19). Besides cell biology data, 
clinical studies indicated that the incidence of myocardial infarction and ischemic stroke in 83 
patients with PD is significantly lower than in controls, and that this effect seems to be 
correlated with the reduction of platelet aggregation (20). It seems that the platelets from PD 
patients have altered secretory pathways (21), owing to the presence of numerous large 
intracytoplasmic vacuoles formed from the open canalicular system. All these data suggest a 
possible implication of α-Syn in downregulating thrombin-induced platelets activation 
through binding to the protease. 
In this study we investigated the possible interaction of the acid α-Syn with the basic 
thrombin molecule using biochemical and spectroscopic techniques. In particular, we 
investigated the effect of α-Syn on the procoagulant (i.e. fibrin generation and platelet 
aggregation) and anticoagulant (i.e. generation of active PC) functions of thrombin. These 
results might contribute to shed light on the possible cross-talk between 
coagulation/differentiation/inflammation pathways regulated by thrombin and Parkinson’s 
disease. 
MATERIALS AND METHODS 
Materials 
Human α-thrombin, protein-C, fibrinogen, and thrombomodulin were purchased from 
Haematologyic Technologies (Essex Junction, VT, USA); HD1 and HD22 aptamers were 
obtained from Primm (Milan, Italy); p-aminobenzamidine (PABA) and chromeogenic 
substrates (i.e. S-2238 D-Phe-Pip-Arg-p-nitroanilide; S-2366 pyroGlu-Pro-Arg-p-nitroanilide) 
were purchased from Sigma (St. Louis, MO, USA) and from Chromogenix (Milan, Italy), 
respectively; hirugen(54-65) peptide, fibrinogen γ-chain peptide(408-427), and hirudin N-
terminal domain Hir(1-47) were chemically synthesized (22, 23).  
Production and Characterization of Recombinant α-Synuclein 
Recombinant wild-type full length α-Syn (1-140), and his-tagged α-Syn (1-140), were 
expressed and refolded as previously described (24). Briefly, pRSETB expression vector 
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(Invitrogen, Carlsbad, CA, USA) was used to transform E. coli strain TOP10 and BL21pLysS 
cells. After inducing protein expression with isopropyl -D-thiogalactoside (IPTG), harvested 
cells were sonicated in 40mM Tris-HCl pH 8.0, 0.5M NaCl buffer, and boiled for 10 minutes. 
The soluble fraction, containing α-Syn, was dialyzed over-night at 4°C in 40mM Tris-HCl pH 
8.0, 0.1M NaCl, 2mM EDTA buffer, and purified by RP-HPLC on a C18 semi-preparative 
column (4.6 x 250 mm, 5 m particle size, 300 Å porosity) from Grace-Vydac (Hesperia, CA, 
U.S.A.). The column was equilibrated with 0.1% (v/v) aqueous TFA and eluted with a linear 
0.1% (w/w) TFA-acetonitrile gradient (30 - 55% in 30 minutes) at a flow rate of 1.5 ml/min. 
The absorbance of the effluent was recorded at 226 nm. The chemical identity of the purified 
proteins was established by ESI-TOF mass spectrometry (MS) on a Mariner instrument from 
Perseptive Biosystems (Stafford, TX, USA), while the purity of α-Syn preparations was 
established by SDS/PAGE (12% acrylamide gel). In addition, to confirm the correctness of 
amino acid sequence, a peptide mass fingerprint analysis was conducted. In details, to a 
solution of purified α-Syn (500 µl, 0.1 mg/ml) in 50mM Tris-HCl pH 7.8, 1mM CaCl2 buffer 
was added trypsin, in protease/protein ration of 1:50 (w/w); the reaction was carried out for 3 
hours at 37±0.1°C. The tryptic digest was then analyzed by RP-HPLC and MS spectrometry. 
Chemical Synthesis and Characterization of C-terminal α-Syn Peptides 
The peptides corresponding to residues (103-140), (103-121) and (122-140) of -Syn were 
chemically synthesized by the solid-phase Fmoc method (25) using a model PS3 automated 
synthesizer from Protein Technologies International (Tucson, AZ, USA). N-Fmoc protected 
amino acids, solvents and reagents for peptide synthesis were purchased from Applied 
Biosystems (Foster City, CA, USA) or Bachem AG (Bubendorf, Switzerland). All other 
reagents and solvents were of analytical grade and purchased from Fluka-Sigma (St. Louis, 
MO, USA). The peptide chain was assembled stepwise on a ChemMatrix resin (Matrix 
Innovation, Quebec, Canada) derivatized with Fmoc-Ala (0.47 mequiv/g) or Fmoc-Asp (0.45 
mequiv/) in the case of α-Syn (103-121). The crude peptides were fractionated by RP-HPLC 
on a C18 column (4.6 x 150 mm, 5 m particle size, 300 Å porosity) from Grace-Vydac 
(Hesperia, CA, U.S.A.). The absorbance of the effluent was recorded at 226 nm. The peptide 
material was analyzed by mass spectrometry on a Mariner ESI-TOF instrument from 
Perseptive Biosystems (Stafford, TX, USA). 
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Spectroscopic Characterization of Monomeric α-Syn 
Purified α-Syn (1-140) was subjected to alkaline treatment to obtain the monomeric form 
(26). Briefly, aliquots of lyophilized protein (2 mg) were dissolved immediately before use in 
2mM NaOH (100 µl); the pH was adjusted to 11.0 with 1M NaOH (10 µl), and the protein 
was incubated for 10 min at room temperature (to dissolve any seeds). The pH was readjusted 
to 8 with 100mM Tris-HCl pH 7 buffer (200 µl). Solutions were centrifuged at 15000 rpm for 
15 minutes to remove large aggregates. α-Syn (1-140) concentration was determined by UV 
absorption at 280 nm on a Jasco V-630 spectrophotometer (Tokyo, Japan) using a molar 
absorptivity value of 5960 M-1·cm-1. For DLS measurements, polystyrene cuvettes (1-cm 
pathlength, 100l) (Hellma, Müllheim, Germany) were used. Each measurement at 25°C 
consisted of a subset of runs determined automatically, each being averaged for 10 seconds. 
Scattering data were analyzed with the multimodal algorithm, as implemented in the Nano-
6.20 software, and expressed as percentage mass size distribution. α-Syn (1-140) samples 
were filtered at 0.22µm on Vivaspin 500 filters (Sartorius, Germany) for 2 minutes at 8000 
rpm and equilibrated for 1 min before analysis. The concentration of synthetic peptide was 
determined by UV absorption at 280 nm, using a εM280nm for α-Syn (103-140) and α-Syn 
(122-140) of 4470 M-1 cm-1. For α-Syn (103-122), the protein concentration was determined 
at 205nm, according to the method previously described by Scopes and co-workers: c mg/ml = 
Abs205nm / 31b (28), because the peptide does not contain Trp or Tyr residues. 
Binding Measurements of α-Synuclein – Thrombin Interaction 
The interaction of full-length α-synuclein and its synthetic peptides to thrombin was studied 
by spectroscopic techniques (i.e. fluorescence and circular dichroism) and surface plasmon 
resonance. The affinity (Kd) was estimated by recording the increase of tryptophan 
fluorescence of thrombin at the max (i.e. 334 nm) as a function of protein/peptide 
concentration. The interaction was monitored by adding, under gentle magnetic stirring, to a 
solution of thrombin (1.5ml, 70nM) in HBS buffer (20mM HEPES pH 7.4, 0.15M NaCl, 
0.1% PEG8000) at 37±0.1°C, aliquots (2, 5, 10l) of a suitable stock solution of ligand. 
Fluorescence spectra were recorded on a Jasco spectrofluorimeter model FP-6500, equipped 
with a Jasco ETC-223T Peltier system (Tokyo, Japan). Excitation and emission wavelengths 
were at 295 and 334 nm, using an excitation/emission slit of 3/10 nm, respectively. Under 
these conditions, Trp-photobleaching was always lower than 2%. The optical density of the 
solution at both 295 and 334 nm was always lower than 0.05 units and therefore no inner filter 
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effect occurred during titration experiments. Fluorescence intensities were corrected for 
dilution (<5% at the end of the titration) and subtracted for the contribution of the ligand, at 
the indicated concentration. The fluorescence values, measured in triplicate, were analyzed as 
a function of the peptide concentration by a single site binding isotherm equation (eq. 1) using 
the program Origin 7.5 (MicroCal Inc.):  
(F-F0)/∆Fmax = [RL]/[R] = [L]/(Kd + [L])       (eq.1) 
where the fluorescence intensity, F, of thrombin , R, at a given concentration of α-Syn ligand, L, is 
linearly related to the concentration of the complex [RL], according to the equation F = [RL]·Fbound + 
[R]free·Ffree. F-F0 is the change in thrombin fluorescence in the absence, F0, and presence, F, of the 
ligand, ∆Fmax is the maximum signal change at infinite concentration of ligand, [L]∝, and Kd is the 
dissociation constant of the complex, RL.
Surface Plasmon resonance (SPR) measurements were carried out on a Biacore X100 
instrument (GE-Healthcare, Piscataway, NJ, USA), using a NTA sensor chip 
(carboxymethylated dextran pre-immobilized with nitrilotriacetic acid, NTA), according to 
the manufacturer’s instructions. The sensor chip was first washed with EDTA scavenger 
solution (0.35M, 50µl), nickel solution (NiCl2 500µM, 50µl), and EDTA wash solution 
(3mM, 31µl). Then, an equimolar mixture of N-ethyl-N-dimethylaminipropylcarbodiimide 
(EDC, 0.2M, 85µl) and N-hydroxysuccinimide (NHS, 0.2M, 85µl) was loaded; unreacted 
carboxymethyl-groups on the sensor chip were blocked by reaction with  ethanolamine (1M, 
126µl) at pH 8.5. Purified his-tagged α-Syn (1-140) (i.e. the ligand; 200nM, 90µl) was 
theninjected for 600 sec at a flow rate of 5 l/min. Final immobilization levels of 224 
resonance units (RU) were obtained. To avoid autoproteolysis, the inactive thrombin mutant 
S195A, produced in our laboratory, was used (29). All measurements were carried out at 
25°C in Hepes-EP+ (10mM Hepes pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% Tween20 
polyoxyethylene sorbitan) at a flow rate of 30 µl/min. Each SPR trace was subtracted for 
unspecific binding (<2% of Rmax) of thrombin. The response units (RU) at the steady state 
were plotted as a function of [thrombin] and fitted to the Langmuir equation (eq.2) to yield 
the dissociation constant, Kd, of thrombin - his-tagged α-syn interaction: 
Req = C·Rmax/(C + Kd)         (eq.2) 
where Rmax is the value in RU at  saturating ligang concentration and Req is the change in RU at each 
given concentration C after reaching equilibrium. 
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Thrombin-α-Syn interaction was also probed by circular dichroism (CD), in the 
presence (i.e., fast form) and absence (i.e., slow form) of Na+ and under physiological 
conditions. Far-UV CD spectra were recorded on a Jasco J-810 spectropolarimeter equipped 
with a thermostatted cell holder and a Peltier PTC-423S temperature control system (Tokyo, 
Japan), using a 1 mm-pathlength quartz cell. Each spectrum was the average of four 
accumulations, after base line subtraction. Under physiological  conditions, the spectra were 
recorded in PBS (10mM Na2HPO4 pH 7.4, 0.15M NaCl) at 37±0.1°C, while in fast and slow 
conditions the signals were monitored at 25±0.1°C in 10mM Tris-HCl pH 7.4 buffer, 
containing NaCl (0.2M) and choline (0.2M), respectively (30).  
Probing the Accessibility of Thrombin Active Site after α-Syn Binding 
Binding of PABA (ε293nm = 15mM
-1·cm-1), S2238 (D-Phe-Pip-Arg-para-Nitroanilide) (ε342nm
= 8270M-1·cm-1) and Hir(1-47) (ε280nm=2560M
-1·cm-1) to thrombin was performed by 
fluorescence measurements in the absence or presence of 20µM α-syn. Measurements were 
carried out at 37±0.1°C in HBS buffer. For PABA binding (31), thrombin samples were 
excited at 336 nm and the fluorescence intensity was recorded at 375 nm. The data were 
corrected for inner filter effect (eq.3) (31): 
Fcorr = Fobs10
–(Aexd/2)          (eq.3) 
where Aex is the solution absorbance at the excitation wavelength and d is the cuvette path-length.  
Data points were then fitted to the Langmuir equation (eq.4) using the program Origin 7.5 
(MicroCal, Inc. (32): 
Fcorr = F0 + {(Fmax[I])/(Kd+[I)}        (eq.4) 
where F0 and Fmax are the intensities of PABA fluorescence in the thrombin-free or thrombin-bound 
state, respectively, and Kd is the dissociation constant of thrombin-PABA complex. 
For S228 binding, thrombin samples were excited at 295nm and the fluorescence recorded at 
334nm as a function of substrate concentration; fluorescence data were fitted to the equation 
describing a simple one-site binding mechanism (eq.1). For Hir(1-47) binding, thrombin 
samples were excited at 295nm and the fluorescence recorded at 334nm as a function of 
inhibitor concentration. The data were analyzed within the framework of the tight binding 
model (eq.5) using the program Origin 7.5 (MicroCal, Inc.): 
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∆F =  {(∆Fmax+[I]+Kd) – {(∆Fmax+[I]+Kd)2 – 4·∆Fmax [I]}1/2}/2    (eq.5) 
where Kd is the dissociation constant of the inhibitor-thrombin complex and ∆Fmax is maximal 
fluorescence change at saturating Hir(1-47) concentrations, [I]. 
Probing the involvement of Thrombin Exosites  
Binding of hirugen (exosite-I binder) and γ-peptide (exosite-II binder) to thrombin, in the 
presence of 20µM α-Syn, were carried out by fluorescence measurements (λ excitation / λ emission
: 295nm/334nm), in HBS buffer at 37±0.1°C. The data were analyzed by eq. 1. In SPR 
competition experiments, exosite-I (i.e. HD1 and hirugen) and exosite-II (i.e. HD22 and γ-
peptide) binders were first incubated with thrombin mutant S195A and then injected over the 
his-tagged a-Syn (1-140) -coated NTA sensor chip, using the same experimental condition 
reported above. 
Clotting Assays 
The turbidity (i.e. absorbance at 350 nm) of a desalted fibrinogen solution was measured after 
addition of thrombin (1nM) at 37±0.1°C in HBS on a Jasco V-630 spectrophotometer (Tokyo, 
Japan), in the absence or presence of 0, 0.5, 1, 10µM α-Syn (1-140) (33). The effect of full-
length α-Syn (1-140) and α-Syn (103-140) on whole blood clotting induced by thrombin, 
TRAP (Thrombin Receptor Activating Peptide: Ser-Phe-Leu-Leu-Arg-Asn) (34), and ADP in 
was estimated at 37°C by Multiple Electrode Aggregometry (MEA) using a Multiplate 
analyzer (Dynabyte, Munich, Germany). The Area Under the aggregating Curve (AUC) was 
calculated over 6-min reaction (35). Citrate-treated blood samples were taken from three 
healthy donors, 23-28 years of age, and non-smokers. The donors gave written informed 
consent for participation to this study, approved by the institutional ethics committee.  
PC Activation 
Protein C (PC) activation by thrombin alone or in the presence of 20µM α-syn (1-140) was 
monitored with or without thrombomodulin at 37°±0.1C in HBS, containing 5mM CaCl2, 
according to the quenching method described elsewhere (36). At time intervals, aliquots of 
the reaction mixture were added to a HBS solution containing the aPC substrate S2366 
(pyroGlu-Pro-Arg-p-nitroanilide) (200M), and hirudin HM2 (1M) to selectively inhibit 
thrombin. The initial velocity, vi, of S2366 hydrolysis was determined by measuring the 
release of p-nitroanilide at 405 nm, using a Victor3 plate reader (Perkin-Elmer, Norwalk, CA) 
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and 96-well polystyrene plates (Sigma, St. Louis, MO, USA). At each time point, the 
concentration of the newly generated aPC was determined from a standard curve of vi versus 
[aPC], obtained with aPC solutions of known concentration. The kcat/Km value of PC 
hydrolysis was obtained from the time-course of aPC generation, by the pseudo first-order 
kinetic model (eq.6), using the program Origin 7.5 (MicroCal, Inc.): 
[P] = [P][1 – exp(-tkobs)]                 (eq.6) 
where [P] is the concentration of the product at t= and kobs is the observed kinetic constant given by 
kobs = [E]s, in which [E] is the enzyme concentration and s is the specificity constant kcat/Km.  
RESULTS 
Chemical Characterization of Recombinant α-Synuclein 
Wilde type α-Syn (1-140) were expressed in E. coli cells and purified by RP-HPLC. The 
chromatogram shows a major peak (Fig. 3.3A) having a mass of 14458.8 ± 0.1 a.m.u. 
(Fig.3.3B), very close  to the average theoretical value deduced from the primary structure of 
α-Syn (1-140) (i.e. 14460.1 a.m.u.). In Fig. 3.3B-Inset SDS-PAGE analysis (12% acrylamide 
gel) of α-Syn (1-140) shows an apparent molecular weight of 20kDa, which is larger than the 
theoretical value of the protein, i.e. 14kDa. The abnormal slow mobility can be attributable to 
the poor binding of SDS by negative C-terminal region of α-Syn (37). Chemical 
characterization of the proteolytic fragments, resulting from limited proteolysis of α-Syn (1-
140) with trypsin, allowed us to cover ~99% of protein sequence (Table 1), establishing that 
recombinant protein corresponds to the natural  human protein. 
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Figure 3.3 Chemical characterization of recombinant α-synuclein (1-140). (A) RP-HPLC analysis of purified 
α-Syn (1-140) (10µg) by a C18 column eluted with an acetonitrile-0.1% TFA gradient (---). (B) Deconvoluted 
ESI-TOF mass spectrum of RP-HPLC purified α-Syn (1-140). (Inset) SDS-PAGE (4-12% acrylamide) analysis 
of purified α-Syn (1-140) under reducing conditions. Lane 1: soluble fraction, containing crude α-Syn (1-140), 
after sonication; lane 2: purified α-Syn (1-140) (2µg). The molecular weight markers are indicated on the right. 
Table 1: Peptide mass fingerprint analysis of α-synuclein (1-140)
Peak 
Experimental  
MW 
(u.m.a.) 
Theoretical 
MW 
(u.m.a.) 
∆
MW 
Sequence 
Deduced 
1 403.24 403.48 0.24 
7GLSK10
2 829.44 830.92 1.48 
24QGVAEAAGK32   
3 872.46 873.98 1.52 
13EGVVAAAEK21
4 1071.60 1073.23 1.63 
11AKEGVVAAAEK21
5 1294.72 1296.47 1.75 
46EGVVHGVATVAEK58
6 1523.88 1525.75 1.87 
46EGVVHGVATVAEKTK60
7 950.50 952.09 1.59 
35EGVLYVGSK43
8 769.35 770.98 1.63 
1MDVFMK6
9 1609.50 1607.85 1.65 
81TVEGAGSIAAATGFVKK97
10
2156.12 
1477.74 
2158.46 
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α-Synuclein in Monomeric Form 
To study the interaction with thrombin, α-synuclein should be in the momoneric form. For 
this purpose, α-Syn (1-140) has been subjected to different experimental conditions: 
- HBS buffer 
- 5M Guanidine Chloride 
- 7% DMSO (dimethyl sulfoxide) v/v 
- 2mM NaOH – 1M NaOH  
Spectroscopic analytical techniques are usually used for protein aggregate detection (38), so 
the process has been validated by UV-Visible (UV-Vis) absorption and fluorescence 
emission. The UV-Vis spectra suggest that the protein after alkaline treatment is in the 
momoneric form (Fig. 3.4A). In fact the ratio Abs275nm / Abs250nm is equal to 2.6 ± 0.2 (i.e. 
characteristic value Tyrosine amino acid residue), and in the range 300-340 nm is not 
observed a significant scattering of light, possibly due to aggregation phenomena. 
Furthermore, the fluorescence emission spectroscopy indicates that the protein is not 
aggregated (Fig. 3.4B): the variation of the spectroscopic signal as a function of [analyte] is 
compatible with that obtained in the presence of a solution of N-Acetyl-Tyrosine amide (i.e. 
in α-Syn there are 4 Tyr, aromatic chromophores). It was previously reported that 
fluorescence and circular dichroism (CD) analyses allow investigating α-Syn fibrils formation 
(27). CD studies demonstrated that lower values of pH facilitate the aggregation process, 
probably by reducing the negative charge of α-Syn (present in physiological conditions). 
Consequently, it was proposed that hydrophobic interactions play a crucial role in α-Syn 
aggregation mechanism (39). 
 Dynamic light scattering measurements indicate in alkaline treated-α-Syn (1-140) the 
presence of a predominant specie (99%) having a hydrodynamic radius (Rh) of 3.6 ± 0.3 nm 
(Fig. 3.4D). The DLS data, expressed as the per cent of size distribution by mass, suggest that 
the sample is essentially monodispersed (Fig. 3.4C: no inflections observed) and essentially 
free of aggregates (Fig. 3.4C: baseline does not display significant noise beyond the logsec
10000), and that the count rate is appropriate for a protein-like material (i.e. 342.3 kcps). 
Therefore, we can conclude that the alkaline treatment (2mM NaOH-1M NaOH) (26) is a 
conveninet method for obtaining full-length α-Syn in the monomeric form. 
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Figure 3.4 Characterization of monomeric α-synuclein (1-140). (A) UV-Vis absorption spectra of α-Syn (1-
140) (2mg) in HBS buffer (), 5M Guanidine Chloride (), 7% DMSO (), and 2mM NaOH – 1M NaOH 
(). The spectra were reordered at 25±0.1°C, using a 0.5-cm pathlength cuvette (B) Variation of the 
fluorescence signal as a function of [α-Syn (1-140)] at 25±0.1°C, under different experimental conditions, as in 
panel A. Protein samples were excited at 300 nm using an excitation/emission slit of 5/10 nm and a 1-cm 
pathlength cuvette. In black is reported the model solution of N-Acetyl-Tyrosine amide. (C) Correlation curve of 
dynamic light scattering analysis of alkaline treated-α-Syn (1-140). (D) DLS data expressed as per cent mass. 
The samples (100µl) were centrifuged at 13000 r.p.m. for 5 min at 20°C and filtered at 0.22 µm. 
α-Synuclein - Thrombin Interaction Probed by Fluorescence and SPR 
The dissociation constants (Kd) of the interaction between α-Syn (1-140) and thrombin was 
determined by exploiting the decrease of the intrinsic fluorescence (ex 295 nm, em 334 nm) 
of the protease upon complex formation (Fig. 3.5A). In fact, the binding of α-Syn (1-140) to 
thrombin results in a decrease of the fluorescence quantum yield by about 30% (Fig. 3.5B), 
without any significant variation of the λmax. Recent studies conducted in our laboratory 
contribute to elucidate the allosteric regulation of the thrombin active site (AS) by exosite 
specific lingands. In particular, exosite-I binders trigger a more open and accessible 
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conformation of the AS, increasing both the affinity for substrates/inhibitors and the catalytic 
efficiency of the enzyme. Conversely, exosite-II ligands do not significantly perturb the 
molecular recognition properties of thrombin. In this study, all tested peptide binders cause an 
increase in fluorescence intensity by 20-30%, whereas the λmax remains unchanged. This 
suggests an overall conformational change of thrombin in which the chemical environment of 
tryptophan residues becomes more rigid. Most notably, our results are fully consistent with 
previous data reported in the literature showing that binding of  allosteric modulators, such as  
Na+ and exosite-I or exosite-II ligands, induces long-range effects on the structure of the 
enzyme (40-43). 
 In the case of α-synuclein, the decrease of fluorescence intensity can be attributed to 
quenching effect of carboxyl groups localized in the C-terminal portion on Trp-residues of  
thrombin. α-Syn (1-140) binding displays a saturable dose-dependent behaviour with a 
calculated stoichiometry of 1:1 and a Kd of 1.7 ± 0.5 µM. 
 The system α-synuclein - thrombin was also studied by surface plasmon resonance 
(SPR). Increasing concentrations of the inactive mutant S195A (Fig. 3.5C) were injected over 
a NTA sensor chip, loaded with purified his-tagged α-Syn (1-140), via Ni2+/NTA chelation. 
Notably, the S195A mutant is catalytically inactive but retains the structural and molecular 
recognition properties of the wild type enzyme (44). Under the experimental conditions 
employed, the binding process was too fast to allow estimation of the rate constants and for 
this reason only equilibrium affinity analysis was performed to measure the Kd of thrombin 
binding (45). Our data (Fig. 3.5D) show that S195A binds to immobilized his-tagged α-Syn 
(1-140) with the same affinity (Kd = 2.4 ± 1.0 µM) obtained by spectroscopic technique (i.e. 
Kd = 1.7 ± 0.5 µM).  
Mapping α-Synuclein - Thrombin Interaction Sites  
A deeper understanding of the mechanism of α-synuclein binding to thrombin was achieved 
by studying the effect of α-Syn (1-140) on the affinity of competitive inhibitors of thrombin 
(i.e. PABA, S2238, and Hir (1-47)), which display different chemical complexity at enzyme 
catalytic pocket. PABA is a small inhibitor of trypsin-like serine proteases and forms a tight 
salt bridge with Asp189 at the bottom of their primary specificity site S1 (31). S2238 (D-
Phe-Pip-Arg-p-nitroanilide) is a fibrinogen-like substrate and therefore it portrays on the 
procoagulant activity of thrombin. The substrate orients its bulky aromatic aminoacid D-
Phe1 into the aryl binding site S3, pipecolyc acid in position 2 (Pip2) contacts Tyr60a and 
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Trp60d in the S2 site, while Arg3 harbours Asp189 in the S1 site of thrombin. S-2238 also 
interacts with S1 primed site downstream to the scissile bond, where the pNA-group points 
to. Hir (1-47), the N-terminal domain of hirudin HM2 (23), binds to the active site (AS) of 
thrombin forming a parallel β-sheet, and through its first three amino acids extensively 
penetrates into the specificity pockets (46). In particular, Val1 on the inhibitor points to the 
S2 site, while Ser2 covers (but does not penetrate) the S1 site, and Tyr3 fills the apolar 
cavity of the S3 site (8). Binding of these inhibitors to thrombin was monitored by 
fluorescence spectroscopy in the absence or in the presence of 20µM α-Syn (1-140). The 
results indicate that α-Syn (1-140) does not influence the affinity of the inhibitors for 
thrombin AS (Table 2); therefore it is likely that the AS remains free and accessible for 
inhibitor/substrate binding. 
 The role of thrombin exosites in α-synuclein binding was assessed by studying the 
effect of 20µM α-Syn (1-140) on the affinity of specific exosites binders. For exosite-I, was 
used hirugen, corresponding to the C-terminal sequence of HV1 hirudin (54-65) (47, 48) 
whereas for exosite-II fibrinogen γ-peptide, corresponding to the 408-427 sequence of the 
elongated fibrinogen γ-chain (40). Our data (Table 2) suggest that, in the presence of 20µM 
α-Syn (1-140), is selectively reduced only the affinity of thrombin for the exosite II binder γ-
peptide, with an increased Kd value of 4 fold. 
 The involvement of thrombin exosite-II in α-Syn binding was qualitatively confirmed 
by SPR, saturating exosite-I (i.e. hirugen and HD1 aptamer) or exosite-II (i.e. fibrinogen γ-
peptide and HD22 aptamer) of S195A thrombin with different specific binders. The thrombin-
ligand solutions were injected over his-tagged α-Syn (1-140) immobilized sensor chip and the 
decrease of the SPR signal (∆RU) of the ternary complex was taken as an indication of 
compromised binding. SPR data indicate (Fig. 3.5E) that blockage of exosite-I results in 20-
30% decrease of RU, while in the presence of exosite-II binders the response was completely 
abolished. In addition, the simultaneous blockage of both exosites with hirugen and γ-peptide 
completely abrogates binding of S195A to his-tagged α-Syn (1-140). 
 These results confirm that both exosites are involved in the α-Syn (1-140)-thrombin 
interaction, suggesting that the role exosite-II is more important in promoting α-Syn binding 
to thrombin. 
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Figure 3.5 Analysis of α-Synuclein-thrombin interaction. (A) Interaction studied by tryptophan fluorescence: 
the intrinsic fluorescence of thrombin () decreases by about 20-30% () after adding α-Syn (1-140) (). 
Fluorescence spectra were recorded at 37±0.1°C by exciting the sample at 300 nm, using an excitation/emission 
slit of 5/10 nm and a 1-cm pathlength cuvette. (B). Plot of the fluorescence values, measured in triplicate, as a 
function of the protein concentration. The solid lines represent the least square fit with Kd of 1.7 ± 0.5 µM. (C)
SPR signals relative to the binding of S195A to his-tagged α-Syn (1-140) loaded chip. (D) Plot of response 
signal (RU) as a function of [S195A]. Data fitting yields a Kd= 2.4 ± 1.0 µM. (E) Exosite-I: S195A (T, 1µM) 
was incubated for 30 min with 500nM HD1 or 20µM hirugen (Hir). Exosite-II: S195A (T, 1µM) was incubated 
with 1µM HD22 and 50µM fibrinogen γ'-peptide (γ’pep) or with a solution of 20µM hirugen + 50µM γ'-peptide. 
The resulting complexes were injected over the bound his-tagged α-Syn (1-140).
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Conformational Study of α-Synuclein - Thrombin complex 
To investigate whether the interaction of α-synuclein with thrombin alters the secondary 
structure of the protein we performed far-UV circular dichroism (CD) measurements. In fact, 
CD provides very convenient means of detecting such changes (49).  
 The shape of far-UV CD of human α-thrombin (Fig.3.6A) under physiological 
conditions (i.e. 0.15M NaCl, 37±0.1°C) resembles that of a protein possessing α-helical 
content (30). Indeed, the contribution of aromatic amino acids (i.e. Phe, Tyr, and Trp) and 
disulphide bonds induce a red shift in the typical bands of the helical conformation (220-222 
nm and 208 nm 	 210 nm and 225 nm) (30). The far-UV CD spectra of α-syn (1-140) 
(Fig.3.6A) presents a strong negative peak at 202 nm and a small shoulder at about 222 nm, 
indicating a random coil structure, possibly with the presence of some nascent and  
marginally stable -helix content (37). In the presence of thrombin, the far-UV CD spectra is 
characterized by two minima, one at around 225 nm and one at 200 nm, with a substantial 
increase in the CD signal (Fig.3.6A). The signal for [α-syn (103-140)-thrombin] complex 
(Fig. 3.6B) is similar in shape but not in intensity, because the spectra are not normalized to 
molar concentration or Mean Residue Weight (MRW) (49). The difference between the 
experimental and the theoretical spectra suggests a weak conformational change of α-
synuclein, after interaction with the serine protease. Interestingly, under “fast” conditions 
Table 2: Effect of 
 α-synuclein on affinity* of SA/Exosite  
thrombin binders 
Probe -  α-syn (1-140) +  α-syn (1-140) 
Active Site 
PABA 114 ± 9 µM 96 ± 8 µM  
S2238 0.82 ± 0.02 µM  0.71 ± 0.09 µM  
Hir (1-47) 43 ± 4 µM  30 ± 5 µM  
Exosite -I
 Hirugen 2.04 ± 0.01 µM  2.75 ± 0.04 µM  
Exosite -II
’ peptide  4.4 ± 0.4 µM  19.5 ± 0.9 µM  
*Kd values were calculated in HBS at 37±0.1°C in the presence or absesence of 20µM α-syn 
(1-140). 
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(Fig. 3.6C; ∆Ellipticity ~ 17%), i.e. with 0.2 M NaCl, this difference is greater than under the 
“slow” (Fig. 3.6D; ∆Ellipticity ~ 11%), i.e. 0.2 M ChCl, demonstrating that the interaction is 
influenced by the initial conformation of thrombin, whereby the “fast” form has a more open 
and rigid conformation and exosite-I is completely structured and therefore more competent 
for ligand binding. Conversely, in the absence of Na+, thrombin has a more flexible and 
collapsed conformation and exosite I is not fully expressed. Partial disruption of exosite-I in 
the “slow” form can dramatically reduce the affinity of α-Syn for thrombin. 
Figure 3.6 CD Analysis of α-synuclein-thrombin interaction. Far-UV CD spectra of: α-Syn (1-140) (), α-
Ssyn (103-140) (), human thrombin (), [α-Syn – thrombin] complex (), and theoretical sum of α-Syn and 
thrombin’s Far-UV CD spectra (). (A-B) Physiological conditions: 37±0.1°C in PBS, using a 1 mm pathlength 
quartz cell. (C) Fast conditions: 25±0.1°C in Tris buffer containing 0.2M NaCl, using a 1 mm pathlength quartz 
cell. (D) Slow conditions: 25±0.1°C in Tris buffer containing 0.2M Choline, using a 1 mm pathlength quartz 
cell.
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Effect of α-Synuclein on Thrombin Functions 
Thrombin plays a pivotal role in the coagulation cascade, encountering a large number of 
different substrates. Here we investigated the effect of α-synuclein on pro-coagulant (i.e. 
fibrin generation and platelet aggregation) and anti-coagulant (i.e. protein C activation) 
functions of the serine protease. The effect of α-Syn (1-140) on the sol-gel transition 
associated with fibrin formation was monitored as an increase in turbidity (i.e. Abs350nm) with 
time due to the light scattered by fibrin aggregates. Fibrin generation was started by addition 
of thrombin to a solution of purified human fibrinogen at increasing [α-Syn (1-140)]. The 
resulting clotting curves were analyzed to extract the values of ∆Amax, tmax, and tc, where 
∆Amax is the maximum slope of the clotting curve, tmax is the time needed to reach ∆Amax, and 
tc (i.e. the clotting time) is the lag-time. Of note, tmax and tc are correlated quantities: tmax = 
26.4 + 1.11tc (33). Our data show that in the presence of α-Syn (1-140) the clotting time is  
not significantly influence (Fig. 3.7A). Conversely, α-syn seems to affect ∆Amax, in a dose-
dependent manner. Probably α-Syn (1-140) might influence the structure of fibrin clot; indeed 
∆Amax is a parameter linked to the aggregation steps leading clot formation (33).  
 The effect of α-syn (1-140) on platelet aggregation was determined on whole blood, 
by Multiple Electrode Aggregometry (MEA) (35). MEA exploits the increase of electric 
impedance due to the adhesion and aggregation of platelets on the electrodes, upon addition 
of exogenous agonist (i.e. thrombin, TRAP, and ADP). Our results indicate that α-Syn (1-
140) dose-dependently inhibits thrombin- and TRAP- induced platelet aggregation in whole 
blood (Fig 3.7B), by about 80% and 70% respectively. In the presence of ADP, instead, the 
effect is lower and the AUC value (Area Under the aggregating Curve) decreases by only 
30%. These data were also confirmed by preliminary studies with PRP (Platelet Rich Plasma) 
in the presence of 20µM α-Syn (1-140), showing that thrombin-induced platelet aggregation 
is significantly slowed (Fig. 3.7C). 
 The effect of α-Syn (1-140) on the generation of activated PC (aPC) was investigated 
in the absence or presence of TM. The time-course of aPC generation was monitored by 
recording the release of pNA from the substrate S-2366, after thrombin inhibition (Fig. 3.7D). 
With or without TM, α-Syn (1-140) does not alter the efficiency with which thrombin 
hydrolyses PC. This trend confirms our conclusion that the active site of thrombin is not (or 
only marginally) involved in the formation of α-synuclein – thrombin complex. 
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Figure 3.7 Effect of α-synuclein on thrombin functions. (A) Representative clotting curves for the generation 
of fibrin in the presence of α-Syn (1-140). To a human fibrinogen solution (0.44µM) in HBS at 37°C was added 
plasma thrombin (1nM), with different concentration of α-Syn (1-140) (0, 3, 5, and 10 µM) and the increase in 
turbidity (Abs at 350 nm) was recorded over time. (B) Effect of α-Syn (1-140) on platelet aggregation on whole 
blood, induced by addition of thrombin (6nM, ), TRAP () and ADP (). The data are expressed as the 
AUC %, where AUC0 = 100% is the Area Under the aggregation Curve at [α-Syn (1-140)] = 0. (C) Effect of α-
Syn (1-140) (20µM) on thrombin- (6nM) platelet aggregation on PRP. The aggregation was performed at 
37±0.1°C with stirring of 1000 r.p.m., monitoring the transmittance at 650 nm. In (E) is reported the platelet 
aggregated on PRP in presence (left) and in the absence (right) of 20µM α-Syn (1-140). (D) Effect of α-syn (1-
140) on PC activation with (
,) or without (,) TM. To a solution of PC (200nM) was added human 
thrombin (5nM) in the absence () or in the presence () of α-Syn (1-140) (20µM) at 37°C. Under conditions 
of pseudo-first reaction, the values of kcat/Km and [aPC] were determined as follows: - α-Syn (1-140), kcat/Km= 
0.3 ± 0.2 mM-1·s-1 and [aPC] = 194 ± 9 nM; + α-Syn (1-140), kcat/Km= 0.31 ± 0.2 mM
-1· s-1 and [aPC] = 196 ± 
5n M. The effect of α-Syn (1-140) on PC activation in the presence of 50nM TM (
,) was determined as 
above, with [thrombin] = 10nM: - α-syn (1-140), kcat/Km = 215 ± 1 mM
-1·s-1 and [aPC] = 198 ± 4nM; + α-Syn 
(1-140), kcat/Km = 212 ± 3mM
-1·s-1 and [aPC] = 200 ± 3nM.
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Effect of C-terminal α- Synuclein Peptides on Platelet Aggregation  
The peptides corresponding to residues (103-140), (103-121) and (122-140) of -Syn were 
chemically synthesized by solid-phase Fmoc method (25), and their identities were confirmed 
by MS analysis (Table 3). The affinity for thrombin was studied by spectroscopic technique, 
recording the variation of enzyme tryptophan fluorescence. The data were analyzed by the 
Langmuir equation and yields a Kd (Table 3) comparable to that obtained for the full-length 
protein (i.e. Kd =1.7 ± 0.5 µM). These data suggest that the C-terminal region is important for 
the formation of [α-synuclein - thrombin] complex. 
 Surprisingly, studies of platelet aggregation on whole blood show that the C-terminal 
peptide does not inhibit platelet aggregation induced by thrombin, TRAP or ADP (Fig. 3.8). 
This finding is consistent with recent results showing that the deletion mutant of α-Syn, 
which completely lacks C-terminal acidic tail, does not function as a negative regulator of α-
granule release in platelets (18). In fact, it seems that only the intact protein plays a critical 
role in membrane translocation and platelet degranulation.  
Figure 3.8 Effect of α-syn (103-140) on platelet aggregation on whole blood. The aggregation was induced by 
addition of thrombin (6nM, ), TRAP () and ADP () on whole blood in the presence of different 
concentrations of α-Syn (103-140) (0, 0.1, 0.3, 0.7, 1, 5, 10, and 20µM). The data are expressed as the AUC %, 
where AUC0 = 100% is the Area Under the aggregation Curve at [α-Syn (103-140)] = 0.
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Table 3: Small library of C-terminal α- synuclein peptides 
Peptide 
Experimental  
MW (u.m.a.) 
Theoretical  
MW (u.m.a.) 
∆
MW 
Kd thrombin
α-syn (103-140) 4289.5 4288.4 1.1 1.41 ± 0.05 µM 
α-syn (103-121) 2055.1 2055.2 0.1 1.12 ± 0.10 µM 
α-syn (122-140) 2251.2 2249.9 1.3 1.99 ± 0.09 µM 
DISCUSSION 
α-Synuclein Interacts with Thrombin 
 Previous studies have indicated that α-Syn may penetrate into platelets and 
subsequently affects α-granule release (18). The protein is also expressed in hematopoietic 
cells (6) and is implicated in the differentiation of megakaryocytes (50), suggesting that the 
biological function of α-Syn is not restricted to neuronal cells. The results of this study 
provide evidence that α-Syn binds to thrombin, inhibiting thrombin-mediated platelet 
aggregation (Fig. 3.7B). Using different molecular probes, we have demonstrated that α-Syn 
interacts with protease exosites, leaving the active site accessible (Fig. 3.5), thus displaying 
physiologically relevant affinity (Kd~2µM). 
 The theoretical model implies that the micromolar affinity of α-Syn for thrombin, 
expressed as the free energy change of binding (Kd~2µM; ∆Gb~-8.13kcal/mol), is distributed 
over the two interacting sites (∆Gb=∆Gb1+∆Gb2) and that it is fully manifested only when both 
thrombin exosites are available for binding. According to the model, in fact, when one of the 
two exosites is already occupied by a given ligand present in solution, α-Syn can still interact 
with thrombin, albeit with lower affinity (Kd~10mM), at the other exosite accessible on the 
protease surface to form a ternary complex. Hence, the binding properties of α-Syn can be 
dynamically regulated by the specificity and affinity of the ligand present in solution for 
either one of the two thrombin exosites. This simple model explains why in the presence of 
exosite ligands the interaction is not completely abolished (Table 2), while the concomitant 
blockage of both exosite abolishes binding (Fig. 3.5E). This interpretation is consitent with 
the observation that in the absence of Na+, i.e. the slow form, the affinity of α-Syn for 
thrombin is much lower (Fig. 3.6D). In the slow form, in fact, exosite-I is not completely 
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formed and competent for ligand binding. In addition, the C-terminal region, α-Syn (103-
140), appeared to interact with the serine protease (Table 3), suggesting that the acidic region 
of α-Syn is directly involved in the [α-Syn - thrombin] complex formation. 
Effect of α-Synuclein on Platelet Aggregation 
 Multiple pathways contribute to platelet activation, involving different agonist such us 
thrombin, ADP, tromboxane, collagen, serotonin and epinephrine (51). Thrombin- platelets 
activation is mediated primarily by PAR-1, while PAR-4 expresses a lower sensitivity to the 
enzyme (52). Activation by thrombin results in cross linked platelet aggregation as fibrinogen 
strands bind to glycoprotein IIb/IIIa receptors. Adenosine diphosphate (ADP) is a nucleotide 
that is stored in the dense granules of platelets. Upon activation, platelets undergo shape 
change and release the contents of their α- and dense- granules. The release of internal stores 
of ADP promotes the activation of local free circulating platelets by binding to purinergic 
receptors, P2Y1 and P2Y12 on platelet membranes (53). 
 Our results suggest that full-length α-Syn inhibits thrombin-platelet aggregation, while 
the effect in the presence of ADP is less noticeable (Fig. 3.7B). Conversely, α-Syn (103-140) 
does not affect platelets activation (Fig. 3.8). The data reported here seem to indicate that the 
C-terminal region of α-Syn interacts with thrombin exosites, without influencing the catalytic 
activity of the protease. The observation that the C-terminal region of  α-Syn (103-140) is 
able to interact with thrombin, but is not capable of inhibiting platelets aggregation can be 
explained according to a model in which α-Syn, secreted upon thrombin stimulation, localizes 
on the negatively charged surface of activated platelets (18), rich in phosphatidyl serine, 
likely through its highly electropositive N-terminal domain. Next, platelet-bound α-Syn 
would harbor thrombin exosite through its disordered negatively charged C-terminal domain, 
thus limiting  further (useless) activation of platelets by thrombin (Fig. 3.9). 
 This model is consistent with the fact that, among cellular components of blood, α-
Syn is most abundant in platelets (i.e. 264 ± 36 ng/ml), compared to leukocytes and 
erythrocytes (54), and that patients with Parkinson’s disease have significantly lower 
incidence of myocardial infarction and ischemic stroke, compared to normal subjects and that 
the reduction of thrombotic events is caused by a reduced tendency of platelets to aggregate. 
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In conclusion, the results reported in this work allow us to propose a plausible 
molecular mechanism through which higher expression of α-Syn can affect the coagulation 
process in neurodegenerative diseases. 
Figure 3.9 Schematic representation of interaction between α-synuclein and thrombin on the platelets 
surface. Upon thrombin activation platelets secret α-syn from α-granules; the protein interacts by C-terminal 
portion to thrombin exosites, while the N-terminal region binds to membrane surface in the vicinity of platelet 
receptors. 
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 Human ceruloplasmin (CP) is a protein from the 2-globulin fraction of human blood 
serum. This protein belongs to the family of multicopper oxidases (MCO), that includes 
ascorbate oxidase and laccase, and accounts for 95% of plasma copper (1). Copper ions in the 
CP molecule provide a large number of enzymatic activities. It was first isolated in 1944 (2) 
and has a molecular weight of some 132 kDa, being comprised of a single polypeptide chain 
of 1046 amino acid residues with a carbohydrate content of 7-8% (3). Serum CP is 
synthesized in the liver; however, its gene is also expressed in the brain, lungs, spleen, testis 
and some other organs of mammals (1). 
Structure of Human Ceruoloplasmin 
 The first X-ray structural study of CP was reported in 1996 (i.e. 3.1 Å) (4) and shows 
that the molecule is comprised of six cupredoxin-type domains arranged in a triangular array. 
It is also shown that there are six integral copper ions, three of which form a trinuclear cluster 
at the interface of domains 1 and 6, whilst the remainder are arranged in three monuclear 
sites, one each in domains 2, 4 and 6 (Fig. 4.1). Each of the monuclear copper ions is 
coordinated to a cysteine and two histidine residues and those in domains 4 and 6 also 
coordinate weakly to a methionine residue; in domain 2, methionine is replaced by leucine at 
a van der Waals distance from the cation. Chemically, in domain 6 there are one type I Cu2+, 
one type II Cu2+ and one type III Cu2+, whereas the remaining type III Cu2+ is coordinated by 
ligands of domain 1. Two additional type I (or ‘blue’) coppers are set apart from the catalytic 
centre, i.e. in domains 2 and 4 (4). Moreover, the lower surface of the molecule is relatively 
flat and positively charged, whereas the upper surface presents three large protuberances and 
is strongly negatively charged. 
 The arrangements of the trinuclear center and the mononuclear copper ion in domain 6 
are essentially the same as that found in ascorbate oxidase and other members of the laccase 
family, strongly suggesting an oxidase role for CP in the plasma(5). 
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Figure 4.1 Overall organization of the human ceruloplasmin molecule (4ENZ.pdb). Left: side view; right: 
top view. β-sheets are colored in cyan, while helices are in red; copper (pink) and Ca+2 (green) ions are also 
shown. Below it is reported the distribution of copper ions. In domain 6 there are one type I Cu2+, one type II 
Cu2+ and one type III Cu2+, whereas the type III Cu2+ is coordinated by ligands of domain 1. Two more type I 
coppers are set apart from the catalytic centre, in domains 2 and 4. 
Physiological Functions of Human Ceruloplasmin: a Moonlighting protein 
 Despite intensive studies of CP in the last 60 years, it is believed that only some of its 
most visible functions have been disclosed. CP is nowadays regarded as a “moonlighting” 
protein, because the protein can change its function in response to changes in substrate, 
localization and expression (6, 7). 
 CP plays a key role in copper storage (i.e. > 95% of plasma copper is bound to CP) 
and transport, as well as in iron metabolism and homeostasis. CP oxidizes Fe+2 to Fe+3, which 
is then transferred in the plasma to apo-transferrin for delivery (8), and then holo-transferrin 
transports Fe3+ to haemoglobin of reticulocytes. Thus CP acquired its systematic name “ferro–
O2 oxidoreductase”, although it is often termed “ferroxidase” (9). Importantly, the ferroxidase 
activity of CP reduces the concentration of free Fe+2 available for initiating Fe+2–catalyzed 
lipid peroxidation, with a resulting marked antioxidant effect (6, 7, 10). Indeed, CP oxidizes 
highly toxic ferrous ions to the ferric state for further incorporation into, catalyzes Cu(I) 
oxidation (11) and promotes the oxidation of biogenic amines (norepinephrine, serotonin), 
synthetic amines (p-phenylenediamine (p-PD) and o-dianisidine (o-DA) (12). 
 Further, CP is the only plasma protein demonstrating the activity of NO-oxidase, NO2-
syntase (13), glutathione-linked peroxidase (14) and superoxide dismutase (15). These 
Side view Top view
1                2                3                4               5                6 
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properties make CP an effective antioxidant, able to prevent oxidative damage to proteins, 
DNA and lipids (16). The protein, in fact, can reduce the concentration of superoxide radical 
(O2•-) and nitric oxide (NO•) available for generating peroxynitrite (ONOO-) (13), a highly 
potent and tissue harmful oxidant (17). 
Interaction of Human Ceruloplasmin with Other Proteins 
CP seems to have an antioxidant-protective function. Recent studies indicated that the 
protein inhibits lipoxygenase (18) and several other leukocyte proteins/enzymes related to 
inflammatory and septic processes (19, 20). In vitro incorporation of Fe3+ into ferritin was 
shown to depend on the formation of CP-ferritin complex (21). In addition, the ability of CP 
to interact with myeloperoxidase (MPO) and to inhibit its pro-oxidant properties (22) likely 
imparts it with additional antioxidant activity in vivo: CP potently inhibits (Kd = 130 nM) 
leukocyte myeloperoxidase (MPO) both in vitro (23-26) and in vivo (23). In fact, the low-
resolution crystallographic structure of MPO-CP complex shows that CP covers the enzyme 
active site, thus hindering MPO function (27). The protein interacts with the iron-binding 
protein lactoferrin (LF) (28, 29), and in the presence of MPO e LF forms a triple complex, 
under physiological conditions (23). CP may also be involved in regulating inflammation by 
interacting with macrophage migration inhibitory factor (30).  
 The interaction of CP with neuropeptide PACAP (31) probably plays a certain role in 
neuroregulation processes. Due to complex formation with ferroportin I, the membrane-bound 
CP found in astrocytes participates in regulation of iron levels in the central nervous system 
and in the prevention of free radical reaction. Finally, CP is suggested to participate in the 
regulation of clotting via its competition with blood coagulation factors FV and FVIII for 
protein C binding (32).  
Human Ceruloplasmin in the Rheumatoid Arthritis 
 Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disorder 
causing symmetrical polyarthritis of large and small joints, typically presenting between the 
ages of 30 and 50 years. RA primarily affects joints however it also affects other organs (i.e. 
skin, lungs, kidneys, heart and blood vessels) in 15–25% of individuals. The etiology of RA is 
not fully understood but involves a complex interplay of environmental and genetic factors. 
Complex interactions among multiple immune cell types and their cytokines, proteinases, and 
growth factors mediate joint destruction and systemic complications (33) (Fig. 4.2).  
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 The plasma level of CP is an important diagnostic indicator of neoplastic and 
inflammatory diseases, such us carcinoma, leukemia, primary biliary cirrhosis, systemic lupus 
erythematosus and RA (34). It was observed that in inflamed tissues and in the synovial fluid 
of RA patients CP and thrombin concentrations are markedly increased (35). CP level tend to 
be higher in RA female patients as compared to male, instead there does not seem to be a 
correlation between the protein concentration and the age of subjects (34). In addition, 
significant positive correlation was found between the immunereactive CP, oxidase activity 
and copper in the patients with RA. However, significant correlations were also obtained for 
CP oxidase activity with C-reactive protein and erythrocyte sedimentation rate, which are 
accepted as biological inflammatory markers of RA (36). These results call into question the 
effectiveness with which the modulation of oxidative stress, influenced by CP, might have on 
the progress of disease. 
Figure 4.2 An overview of the cytokine-mediated regulation of synovial interactions. The component cells 
of the inflamed rheumatoid synovial membrane are depicted in innate and adaptive predominant compartments 
of the inflammatory response. Pivotal cytokine pathways are depicted in which activation of dendritic cells 
(DCs), T cells, B cells and macrophages underpins the disregulated expression of cytokines that in turn drive 
activation of effector cells, including neutrophils, mast cells, endothelial cells and synovial fibroblasts. This 
figure was adapted from (37). 
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INTRODUCTION 
Human ceruloplasmin (CP) is a circulating copper-containing glycoprotein (1046 
amino acids, ~ 132 kDa) produced in the liver and first described as a component of 2-
globulin fraction of human plasma (1). CP belongs to the multicopper oxidase family (2) and 
it is nowadays regarded as a “moonlighting” protein, because changes its function as a 
function of in substrate, localization and expression (3, 4). CP plays a key role in copper 
storage and transport, as well as in iron metabolism and homeostasis (2). The ferroxidase 
activity of CP reduces the concentration of free Fe+2 available for initiating Fe+2–catalyzed 
lipid peroxidation, with a resulting marked antioxidant effect (3-5). CP protects tissues form 
damage induced by reactive oxygen and nitrogen species (ROS and RNS) by exerting both 
superoxide dismutase (6) and NO oxidase functions (7), that decrease the concentration of 
superoxide radical (O2· -) and nitric oxide (NO·) available for generating peroxynitrite 
(ONOO-) (7). CP is also a key component of the physiological acute phase response (3, 5), 
i.e. CP plasma concentration is triplicated in acute phase inflammation (8) while its 
disfunction has been associated with cardiovascular and neurodegenerative diseases (4) 
CP structure contains six cupredoxin-type domains, each consisting of 150-190 amino 
acid residues (9-11). The even domains 2, 4 and 6 bind a copper ion each, while the interface 
between domains 1 and 6 hosts a trinuclear copper centre, which is close to a Ca2+-binding 
site in domain 1. The oxygen reductase function of CP has been associated with the trinuclear 
copper center, whereas the ferroxidase activity is accomplished by the copper site in domain 
6. In keeping with its antioxidant/protective function, it was recently reported that CP inhibits 
lipoxygenase and several other leukocyte proteins/enzymes related to inflammatory and septic 
processes (12-14). Furthermore, we and others have discovered that CP potently inhibits (Kd 
=130nM) leukocyte myeloperoxidase (MPO) both in vitro and in vivo (15-19). Interestingly, the 
catalytic pocket of MPO contains heme, which is instrumental for ROS and RNS generation 
(20). The low-resolution crystallographic structure of MPO-CP complex (4ejx) shows that CP 
4.2 Proteolysis of Ceruloplasmin by Thrombin 
116 
covers the enzyme active site, thus hindering MPO function (11). Although MPO represents a 
front-line defense against bacteria in innate immunity, the aberrant production/release of 
MPO from activated neutrophiles, even in the absence of infection, can damage host tissues, 
amplify inflammation and set the basis for the onset of several different diseases (20). In 
particular, compared with healthy controls, plasma MPO concentrations are significantly 
higher in patients with rheumatoid arthritis (RA) (21), a systemic autoimmune disease 
characterized by synovial inflammation and hyperplasia, leading to progressive cartilage and 
bone destruction (22). In this scenario, the potent inhibitory effect of CP on MPO oxidase 
function further emphasizes the role of this cooper-protein in promoting the antioxidant 
response in human plasma (3, 19, 23). 
Thrombin is a serine protease, strategically positioned at the interface of coagulation, 
inflammation and cell proliferation (24-26). Thrombin has a chymotrypsin-like fold (27) and 
accomplishes most of its activities through the hydrolytic active site, located in a deep crevice 
at the interface of two β-barrels, two positively charged exosites (exosite-I and exosite-II) 
located at opposite sides from the catalytic cleft. The procoagulant functions of thrombin 
entail conversion of soluble fibrinogen into insoluble fibrin and activation of platelets through 
cleavage of protease activated receptor 1 (PAR-1). Thrombin also acts as a proinflammatory 
and chemotactic mediator by inducing, via PAR cleavage, the production of inflammatory 
cytokines in monocytes and macrophages (28). As observed with CP, thrombin concentration 
is markedly increased in inflammed tissues and specifically in the synovial fluid of RA 
patients (29). 
 In this study we have demonstrated that thrombin cleaves CP both in vitro and in the 
synovial fluid of RA patients only at two peptide bonds, thus generating a nicked species 
(CP*) formed by a stable non-covalent complex of three proteolytic fragments. Strikingly, 
CP* retains the ferroxidase function of intact CP, but has lost the MPO inhibitory function. 
We conclude that antioxidant/antiinflammatory function of CP is regulated by proteolysis of 
thrombin. These results are unprecedented and set the basis for elucidating the biochemical 
mechanisms underlying the progression of inflammation in RA patients and, hopefully, for 
developing novel therapeutic strategies. 
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MATERIALS AND METHODS 
Materials 
Acrylamide and reagents for electrophoresis were purchased from Medigen Laboratories 
(Novosibirsk, Russia); the reagents for surface plasmon resonance were from GE-Healthcare 
(Piscataway, NJ, USA); phenylmethylsulphonyl fluoride (PMSF), 2,2-azino-bis(3-ethyl 
benzthiazoline-6-sulphonic acid) disodium salt (ABTS), Fe(NH4)2(SO4)2•6H2O, (D)-Phe-Pro-
Arg-chloromethyl ketone (PPACK), thiourea, H2O2, and the chromogenic substrate Z-Ala-
Ala-Arg-pNA•HBr were from Merck (Darmstadt, Germany). All other salts, detergents, 
solvents and reagents were of analytical grade and purcahased from Merck or Fluka. Hirudin 
2 from Hirudinaria manillensis was a generous gift of Dr. Orsini (Farmitalia-Carlo Erba, 
Italy); HD1 and HD22 aptamers were obtained from Primm (Milan, Italy hirugen(54-65) 
peptide, fibrinogen γ-chain peptide(408-427), and hirudin N-terminal domain Hir(1-47) were 
chemically synthesized (30). 
Biological Samples 
Samples of human serum from healthy subjects were obtained from clotted venous blood after 
centrifugation at 5°C for 15 min at 500 g in the presence 0.01% (w/v) gentamycin as a 
bacteriostatic agent. 24 patients (12 males and 12 females) aged between 50 and 70, with 
established diagnosis of rheumatoid arthritis (RA) were examined. The patients enrolled in 
this study were under monitoring at the Institute of Experimental Medicine (St. Petersburg, 
Russia), having a history of RA at a different stage of progression of the disease. The 
protocols for all clinical studies were scrutinized and approved by the Ethical Committee of 
the Institute of Experimental medicine and all subjects gave their informed consent to the 
study. Synovial fluid (5-10 ml) was collected after knee joint puncture. Samples of each 
patient’s synovial fluid were centrifuged at 5°C for 15 min at 500 g or 5 min at 15000 g, 
divided into aliquots (500 µl) and then rapidly placed at -80°C. Frozen samples were thawed 
at 37°C and used for further analyses. 
Determination of the Copper Content in Biological Fluids 
The levels of copper in serum and synovial fluid samples were determined as described (31). 
Briefly, the specimens were treated with threefold excess (w/w) of HClO4:H2SO4 (4:1) 
solution. The mixture was centrifuged at 13000 g for 15 min, and the copper concentration in 
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the supernatant was determined by atomic absorption spectrometry using a PinAAcle 900 
instrument (Perkin-Elmer, USA). 
Purification of CP from Human Plasma 
CP was isolated from human blood plasma by affinity chromatography on protamine-
Sepharose as previously described (14), followed by benzamidine affinity chromatography to 
eliminate traces of contaminant serine proteases. All preparations had Abs 610nm/Abs 280nm
>0.049 and contained more than 95% intact CP, as given by the presence of the 132-kDa 
electrophoretic band. 
Limited Proteolysis of CP with Thrombin 
To a solution of purified, intact hCP (2 mg/ml, 100 µl) in 10mM Tris-HCl  7.4, in 0.1M 
NaCl (TBS) human thrombin was added (50 NIH units/ml, final concentration). At time 
intervals, aliquots (10 µl) were taken, added with an equal volume of reducing sample loading 
buffer, and heated at 100°C for 3 min to stop the proteolytic reaction. Denatured samples 
were then analyzed by SDS-PAGE (4-10% acrylamide) and Coomassie stained. 
Identification of Thrombin Cleavage Sites on CP by Edman Degradation and Peptide Mass 
Fingerprint Analysis 
Electrophoretic bands corresponding to proteolytic hCP fragments were electrotransferred 
onto Immobilon membrane (BioRad, Hercules, CA, USA) using a semi-dry transfer device 
(Hoefer Scientific, Holliston, MA, USA) in Tris-HCl 20%ethanol-containing buffer. 
Coomassie stained bands on the Immobilon sheet were cut and subjected to Edman 
degradation on a Procise-491 automated protein sequencer (Applied Biosystems, Carlsbad, 
CA, USA). Proteolytic fragments were identified by in situ tryptic digestion of the 
corresponding electrophoretic bands followed by peptide mass fingerprint analysis. Briefly, 1-
mm3 pieces of selected  bands were excised from the gel and twice soaked for 30 min at 37°
in 100 µl of 0.1M NH4HCO3 containing 40% (v/v) acetonitrile to extract the dye. The 
aqueous/organic solution was discarded and, to dehydrate the gel, 100 µl of neat acetonitrile 
were added to the gel pieces. After acetonitrile was discarded and the gel air- dried, 4 µl of 
tosyl-phenyl-chloromethylketone(TPCK)-treated trypsin (Promega, Madison, WI, USA) (15 
µg/ml) in 50mM NH4HCO3 were added. Hydrolysis was allowed to proceed for 18 h at 37°
and then 8 µl of peptide extracting mixture were added under gentle stirring. After 
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centrifugation at 2000 rpm for 3 min, the supernatant was collected and analyzed by mass 
spectrometry on an Ultraflex-II MALDI-TOF spectrometer (Bruker, Germany). Routinely, 1 
µl of the supernatant solution was added with 0.3 µl of the matrix 2,5-dihydrobenzoic acid (10 
mg/ml in 0.5% aqueous TFA containing 20% acetonitrile) and the resulting mixture was air- 
dried. Mass spectra were recorded in the reflectron positive ion mode with a mass accuracy of 
50 ppm after internal calibration against the peaks of tryptic autolysis. Protein fragments were 
identified using the MASCOT search software (http://www.matrixscience.com). 
Electrophoresis and Western Blotting 
Polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) and Western 
blotting analyses were performed as described (16).CP bands were detected using a rabbit 
polyclonal anti-hCP antibody (Ab) (1:10000 dilution), as a primary Ab, and a peroxidase-
conjugated goat anti-rabbit IgG (Calbiochem, Darmstadt,Germany) as a secondary Ab 
(1:5000 dilution). When holo- and apo-CP were being analyzed, samples for electrophoresis 
were prepared in the absence of SDS and without heat treatment (32).  
Size-Exclusion Chromatography (SEC) 
The molecular weight of CP and CP* was estimated by SEC. Aliquots of intact and nicked 
CP were loaded on a (1.6 x 30 cm) Superose-12 (GE-Healthcare, Piscataway, NJ, USA) 
column connected to an Äkta-Purifier biochromatography system and eluted at a flow rate of 
0.3 ml/min with 25mM Tris-HCl pH 7.4, 0.15M NaCl. Nicked CP (CP*) was obtained by 
proteolysis of CP with thrombin at 37°C for 5 h. The molecular weight of CP and CP* was 
estimated after calibrating the column with the protein standards BSA (67 kDa), ovalbumin 
(44 kDa), carbonic anhydrase (29 kDa), RNAse (13.7 kDa), and aprotinin (6.5 kDa), 
according to the equation KD = (Ve-V0) (Vi-V0), where KD is the distribution constant, Ve 
is the elution volume of CP or CP*, whereas V0 and Vi are the void and interstitial volume of 
the column. V0 and Vi were calculated by loading blue dextran (2000 kDa) and the 
threepeptide Gly-Tyr-Gly (295 Da), respectively. 
Spectroscopic Techniques 
UV-Vis spectra were recorded on a V-630 spectrophotometer (Jasco, Tokyo, Japan). The 
concentration of thrombin and CP was determined by measuring the absorbance at 280 nm, 
using an extinction coefficient, ε0.1%, of 1.96 and 1.61 mg
-1
cm2 respectively. Fluorescence 
spectra were recorded on a Jasco FP-6500 spectrofluorimeter equipped with a thermostatted 
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cell holder and a Peltier ETC-273T temperature control system. Circular dichroism (CD) 
spectra were recorded on a Jasco J-810 spectropolarimeter equipped with a thermostatted cell 
holder and a Peltier PTC-423S temperature control system. Spectra were recorded on 0.1- or 
1-cm pathlength cuvette in the far- and near-UV region, respectively. Each spectrum is was 
the average of four accumulations, after base line subtraction. Ellipticity data were expressed 
as the mean residue ellipticity, [θ] = (θMRW)/(10lc), where θ is the measured ellipticity in 
degrees, MRW is the mean residue weight, l is the cuvette pathlength, and c is the protein 
concentration in g/ml. 
CP Ferroxidase Activity 
During the time-course proteolysis of hCP (2 mg/ml) with thrombin at increasing time points, 
the ferroxidase activity of the proteolytic reaction was determined at 25°C by recording the 
increase of absorbance at 310 nm, resulting from the formation of Fe+3 complex with N,N-
dimethylformamide (DMF) at a fixed [Fe+2]. Aliquots (10 µl) of the hCP proteolysis mixture 
(0.8 µM, final concentration) was added to solutions of 1% (v/v) DMF in 0.1M sodium 
acetate buffer pH 5.5, containing 30µM thiourea and 200µM ferrous Fe(NH4)2(SO4)2•6H2O. 
The inhibition of hCP ferroxidase activity by thrombin was measured at 37°C in the presence 
of increasing concentrations of human thrombin (0 - 360nM), irreversibly inhibited at the 
active site with equimolar concentrations of phenylmethylsulphonyl fluoride (PMSF). The 
initial rate (v) of Fe+3 generation was plotted as a function of substrate concentration, [Fe+2], 
according to the Hanes-Woolf equation (eq.1): 
[Fe+2]/v = (1/vmax)[Fe
+2] + (Kmapp/vmax)      (eq.1) 
where vmax is the values of the maximum reaction rate and, Kmapp is the apparent Michaelis constant. 
After plotting the values of Kmapp versus [PMSF-thrombin] and fitting the data points to the 
eq.2 the value of the inhibition constant, KI, was extrapolated as the intercept of the straight 
line: 
Kmapp = Km(1 + [I]/KI)         (eq.2) 
where [I] is the concentration of PMSF-thrombin. 
Myeloperoxidase (MPO) Activity 
MPO was purified from the extract of frozen human leukocytes obtained from healthy donors, 
as detailed elsewhere (33). MPO activity in the synovial fluid of RA patients was assayed by 
monitoring the absorbance increase at 414 nm, caused by oxidation of the chromogenic 
4.2 Proteolysis of Ceruloplasmin by Thrombin 

121 
substrate 2,2-azino-bis(3-ethyl benzthiazoline-6-sulphonic acid) disodium salt (ABTS) into 
the ABTS•+ radical. A reference curve was obtained with increasing concentrations (0.05–
0.4µM) of purified MPO in 0.1 sodium-acetate buffer pH 5.5, containing 100µ H2O2 and 
1m ABTS. Upon adding H2O2 to the mixture, the reaction rate was measured as ∆A 
414nm/min on a SF-2000-02 spectrophotometer (OKB Spectr, Russia) using the Kinetics 
software. The concentration of MPO (ng/ml) in the synovial fluid samples was determined 
form the reference curve previously obtained with known concentrations of purified MPO. 
The MPO inhibitory activity of hCP or hCP/CP* mixtures, during proteolysis of hCP with 
thrombin, was determined at 25°C by measuring the rate ABTS•+ formation at 414 nm in the 
same buffer at a fixed [MPO]. 
Thrombin Activity 
The concentration of thrombin (NIH/ml) in the synovial fluid of RA patients was determined 
at 25°C by measuring the rate of p-nitroaniline (pNA) release at 405 nm from the 
chromogenic substrate Z-Ala-Ala-Arg-pNAHBr (0.1 mg/ml) in PBS. A reference curve at 
25°C was obtained with increasing concentrations (0.05 – 2.0 NIH/ml) of purified human 
thrombin. The effect of hCP on the hydrolytic activity of thrombin was determined by 
measuring at 37°C the release of pNA from the substrate S2238 (D-Phe-Pip-Arg-pNA) in 
Hepes buffer pH 7.4, containing 0.1M NaCl and 0.1% PEG-8000, in the presence of 
increasing CP concentrations. 
Production of Recombinant Thrombin 
Recombinant wild-type thrombin was expressed and refolded as previously described. Briefly, 
pET23(+) plasmid vector containing the cDNA corresponding to wild-type human 
prethrombin-2 (preThb-2) sequence (Dr. J. Huntington, University of Cambridge, UK) was  
used to transform E. coli strain BL21(DE3)pLysS cells. After inducing preThb-2 expression 
with isopropyl -D-thiogalactoside (IPTG), harvested cells were sonicated and inclusion 
bodies recovered by centrifugation. Refolding of preThb-2 chain was carried out by diluting 
drop wise solubilized inclusion bodies (in 6M Gdn-HCl) into the renaturing solution: 20mM 
Tris-HCl buffer, pH 8.5, 0.6M L-arginine hydrochloride, 0.5M NaCl, 1mM EDTA, 10% 
glycerol, 0.2% Brij-58, and1mM L-cysteine. After dialysis and centrifugation, correctly 
folded pThb-2 was purified on a heparin-sepharose column followed by treatment with ecarin 
to generate active α-thrombin, which was purified on a heparin-sepharose column. Mutations 
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in the preThb2 cDNA were introduced by the oligonucleotide-directed mutagenesis method, 
using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The purity of thrombin 
preparation (~98%) was established by SDS/PAGE (12% acrylamide gel) and RP-HPLC on a C4 
analytical column (4.6 x 150 mm, 5 	m particle size, 300 Å porosity) from Grace-Vydac 
(Hesperia, CA, U.S.A.). The column was equilibrated with 0.1% (v/v) aqueous TFA and eluted 
with a linear 0.1% (w/w)-TFA-acetonitrile gradient at a flow rate of 0.8 ml/min. The absorbance 
of the effluent was recorded at 226 nm. The chemical identity of the purified proteins was 
established by ESI-TOF mass spectrometry on a Mariner instrument from Perseptive Biosystems 
(Stafford, TX, U.S.A.). 
Binding Measurement 
Dynamic Light Scattering (DLS) measurement were carried out with Zetasizer Nano S 
(Malvern Instruments, Worcestershire, UK); the translational diffusion coefficient (D) was 
obtained experimentally, while the molecular hydrodynamic radius (RH) was calculated from 
the Stokes-Einstein equation: RH = KBT/6piηD, where KB is the Boltzman constant, T is 
the absolute temperature, and η is the solution viscosity. A calibration curve was obtained by 
linear fitting the experimental RH values of monomeric globular protein standards versus 
their known molecular weight (LogMW). Polystyrene cuvettes (1-cm pathlength, 100 	l) 
(ZEN-0117, Hellma) were used for all measurements. Each measurement consisted of a 
subset of runs determined automatically, each being averaged for 10 s. Scattering data were 
analysed with the multimodal algorithm, as implemented in the Nano-6.20 software, and 
expressed as percentage mass size distribution. Protein samples were filtered at 0.22 µm on 
Vivaspin 500 filters (Sartorius, Germany) for 2 minutes at 8.000 rpm and equilibrated for 1 
min before analysis. 
The interaction between CP and inactive S195A thrombin was monitored at 25°C in 5mM 
Tris-HCl pH 7.4, 0.2M NaCl, 0.1% PEG-8000 by a Jasco (Tokyo, Japan) model FP-6500 
spectrofluoriometer, equipped with a Peltier model ECT-327T temperature control system 
(Jasco). Samples were excited at 280 nm and the fluorescence intensity was recorded at 335 
nm, corrected for dilution and subtracted for the signal of S195A at each concentration. The 
data were fitted to the Langmuir equation (eq.3) using the program Origin 7.5 (MicroCal, 
Inc.): 

F = F-F° = (
Fmax·[L])/(Kd + [L])         (eq.3)  
where Kd is the dissociation constant of the complex, RL, and 
Fmax is the maximum fluorescence 
change at infinite concentration of ligand, [L].
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Surface Plasmon resonance (SPR) measurements were carried out on a Biacore X100 
instrument (GE-Healthcare, Piscataway, NJ, USA). Purified CP (50 	g/ml) in 10mM 
ammonium acetate buffer pH 4.0, was injected for 10 min at a flow rate of 5 	l/min and 
covalently immobilized on a carboxymethylated dextran chip (CM5) using the amine 
coupling chemistry, according to the manufacturer’s instructions. The sensor chip was first 
activated with an equimolar (0.2M) mixture of N-ethyl-N-dimethylaminipropylcarbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) and then reacted with a solution of CP (i.e., the 
ligand). Unreacted carboxymethyl-groups on the sensor chip were blocked by reaction with 
1M ethanolamine at pH 8.5. Final immobilization levels of 18500 resonance units (RU) were 
obtained, corresponding to approximately 18.5 ng of bound CP/mm2. To avoid proteolysis, 
the inactive thrombin mutant S195A was used, when active human thrombin was irreversibly 
inhibited at active site with PPACK. In competition experiments exosite-I (i.e. hirugen) and 
exosite-II (i.e γ-peptide) binders were first incubated thrombin-PPACK and then injected 
over the CP-coated sensor chip. All measurements were carried out at 25° in Hepes-EP+ 
(10mM Hepes pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% Tween20 polyoxyethylene 
sorbitan) at a flow rate of 30 µl/min. Each SPR trace was subtracted for unspecific binding 
(<2% of Rmax) of thrombin. The dissociation constant, Kd, of hCP-thrombin complex was 
determined by plotting the value of RU at the steady state as a function of [thrombin] and the 
data were fitted to the Langmuir equation (eq. 4) describing the one-site binding model or to 
eq. 5, describing a two-site nonequivalent binding model: 
Req/Rmax = [Thrombin] / ([Thrombin] + Kd)       (eq.4) 
Req/Rmax = [Thrombin] / ([Thrombin] + Kd1) + [Thrombin] / ([Thrombin] + Kd2)  (eq.5) 
where Req is the RU at a given [Thrombin], after reaching equilibrium, Rmax is the RU value at 
saturating [Thrombin], and Kd1 and Kd2 are the dissociation constants for type 1 and type 2 binding 
sites for thrombin on CP.  
Structural Analysis and Docking Simulations 
Protein structures were visualized with the ViewerPro 4.2 software (Accelerys Inc., San 
Diego, CA, USA) while B-factor flexibility plot was generated with the program What If 
(34). Docking of thrombin into CP structure was performed with Ultrafast-FFT GPU-based 
HEX 6.3 software (35), starting from the structures of CP at 2.6 Å (4ENZ.pdb) (11) and 
PPACK-inhibited thrombin (1PPB.pdb) (27), after removal of the inhibitor coordinates. The 
structure of the ternary complex formed by MPO, CP and thrombin was obtained starting 
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from the structure of the MPO-CP complex (4EJX.pdb) (11). Simulations were run using 
default parameters and “shape + electrostatics” option, without introducing any additional 
geometric/energetic constraint. A hundred poses were generated and ranked according to the 
HEX scoring function. The top three poses were almost identical and used for interpreting 
binding data. 
Treatment of RA Patients with Hirudin-Based Ointment 
A group of 19 patients (11 males and 8 females) were treated with RefludanTM (Leu1,Thr2-
63-desulphohirudin; Bayer Healthcare Pharmaceuticals) prepared as an ointment. The 
treatment lasted for 14 days with applications of the ointment on affected joints every second 
day. Each application contained 200 µg of hirudin. Five additional patients did not receive 
this therapy and were used as controls. For each patient, the swelling of the knee joint was 
measured and taken as an indicator of the arthritis progression. 
RESULTS 
Thrombin Cleaves CP at Two Exposed and Flexible Loops 
Proteolysis (0-120 min) of purified CP by thrombin was carried out under limited proteolysis 
conditions (thrombin:hCP ratio 1:100) and analyzed by SDS-PAGE (lanes 1-8 in Fig. 4.3A). 
Five major bands at 116, 72, 67, 50 and 19 kDa are incrementally generated over time from 
the CP band at 132 kDa. Interestingly, the intensity of the 116-kDa band first increases at 
short reaction times (5-15 min) and then decreases, likely because of further proteolysis. 
Notably, the proteolytic pattern obtained by treatment of CP with thrombin closely resembles 
that resulting from prolonged storage of purified CP preparations kept under sterile conditions 
in buffer solution at 4°C for 3 months (lane 9) or frozen in liquid nitrogen and stored at –70°C 
for one year (lane 10). Western blot analysis in Fig. 4.1B reveals that, upon storage for two 
weeks at 37°C, spontaneous proteolytic degradation of hCP in blood serum (lane 2) is 
abolished in the presence of specific thrombin inhibitors, like full-length hirudin (lane 3) and 
its N-terminal 1-47 fragment (lane 4) (36, 37). 
 Rigorous chemical characterization of the proteolytic fragments, resulting either from 
proteolysis of CP with thrombin or prolonged storage of purified CP, was carried out by 
Edman sequencing on electroblotted bands and by peptide mass fingerprint analysis after in 
situ tryptic digestion of the proteolytic bands. This procedure allowed us to cover ~67% of 
hCP sequence (i.e. 698 out of 1046 amino acids in Fig. 4.4) and establish that: 
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1. the cleavage sites in the two set of experiments (i.e. limited proteolysis with thrombin 
and prolonged storage) are the same; 
2. the bands at 116 and 19 kDa originate from thrombin cleavage of the peptide bond 
Lys887-Val888 in full-length CP, to generate fragments 1-887 and 888-1046, 
respectively; 
3. the bands at 67 and 72 kDa result from cleavage of the peptide bond Arg481-Ser482 in 
CP to generate fragments 1-481 and 482-1046, respectively; 
4. the 67-kDa band (fragment 1-481) results from the proteolytic attack on intact CP (132-
kDa-band) or on fragment 1-887 (116-kDa band); 
5. the 50-kDa accumulates at longer reaction times as the result of proteolysis at both sites 
Arg481-Ser482 and Lys887-Val888, to generate fragment 482-887.  
Figure 4.3 Limited proteolysis of purified CP by thrombin and identification of proteolyzed CP species in 
blood serum. (A) SDS-PAGE analysis of CP proteolysis. Lanes 1-8: proteolysis of plasma purified hCP (2 
mg/ml, 10 µl) with thrombin (50 NIH units/ml) at 25°C, after 0, 5, 10, 15, 30, 45, 60 and 120 min reaction. lanes 
9 and 10: aliquots (10 µl) of purified CP samples (2 mg/ml) undergoing spontaneous proteolytic degradation 
upon prolonged storage under different conditions; lane 11: molecular weight protein standards. (B) Effect of 
hirudin on the spontaneous proteolysis of CP in blood serum. Western blotting was carried out using rabbit 
anti-hCP Abs and peroxidase-conjugated goat anti-rabbit IgG. Lane 1: molecular weight protein standards; lane 
2: aliquot (2 	l) of human serum incubated at 37ºC for two weeks under sterile conditions; lane 3: as in lane 2, in 
the presence of hirudin HM2 (100 nM); lane 4: as in lane 2, in the presence of hirudin (1-47) (100 nM); lane 5: 
aliquot (2 	l) of freshly prepared human serum; lane 6: aliquot (0.2 µg) of purified hCP undergoing spontaneous 
proteolytic degradation, corresponding to lane 10 in panel A. 
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        10         20         30         40         50         60  
KEKHYYIGII ETTWDYASDH GEKKLISVDT EHSNIYLQNG PDRIGRLYKK ALYLQYTDET  
        70         80         90        100        110        120  
FRTTIEKPVW LGFLGPIIKA ETGDKVYVHL KNLASRPYTF HSHGITYYKE HEGAIYPDNT  
       130        140        150        160        170        180  
TDFQRADDKV YPGEQYTYML LATEEQSPGE GDGNCVTRIY HSHIDAPKDI ASGLIGPLII  
       190        200        210        220        230        240  
CKKDSLDKEK EKHIDREFVV MFSVVDENFS WYLEDNIKTY CSEPEKVDKD NEDFQESNRM  
       250        260        270        280        290        300  
YSVNGYTFGS LPGLSMCAED RVKWYLFGMG NEVDVHAAFF HGQALTNKNY RIDTINLFPA  
       310        320        330        340        350        360  
TLFDAYMVAQ NPGEWMLSCQ NLNHLKAGLQ AFFQVQECNK SSSKDNIRGK HVRHYYIAAE  
       370        380        390        400        410        420  
EIIWNYAPSG IDIFTKENLT APGSDSAVFF EQGTTRIGGS YKKLVYREYT DASFTNRKER  
       430        440        450        460        470        480  
GPEEEHLGIL GPVIWAEVGD TIRVTFHNKG AYPLSIEPIG VRFNKNNEGT YYSPNYNPQS  
       490        500        510        520        530        540  
RSVPPSASHV APTETFTYEW TVPKEVGPTN ADPVCLAKMY YSAVDPTKDI FTGLIGPMKI  
       550        560        570        580        590        600  
CKKGSLHANG RQKDVDKEFY LFPTVFDENE SLLLEDNIRM FTTAPDQVDK EDEDFQESNK  
       610        620        630        640        650        660  
MHSMNGFMYG NQPGLTMCKG DSVVWYLFSA GNEADVHGIY FSGNTYLWRG ERRDTANLFP  
       670        680        690        700        710        720  
QTSLTLHMWP DTEGTFNVEC LTTDHYTGGM KQKYTVNQCR RQSEDSTFYL GERTYYIAAV  
       730        740        750        760        770        780  
EVEWDYSPQR EWEKELHHLQ EQNVSNAFLD KGEFYIGSKY KKVVYRQYTD STFRVPVERK  
       790        800        810        820        830        840  
AEEEHLGILG PQLHADVGDK VKIIFKNMAT RPYSIHAHGV QTESSTVTPT LPGETLTYVW  
       850        860        870        880        890        900  
KIPERSGAGT EDSACIPWAY YSTVDQVKDL YSGLIGPLIV CRRPYLKVFN PRRKLEFALL  
       910        920        930        940        950        960  
FLVFDENESW YLDDNIKTYS DHPEKVNKDD EEFIESNKMH AINGRMFGNL QGLTMHVGDE  
       970        980        990       1000       1010       1020  
VNWYLMGMGN EIDLHTVHFH GHSFQYKHRG VYSSDVFDIF PGTYQTLEMF PRTPGIWLLH  
      1030       1040  
CHVTDHIHAG METTYTVLQN EDTKSG  
Figure 4.4 (C) Amino acid sequence of mature hCP (entry code: P00450). The peptide segments identified 
during peptide mass fingerprint analysis are underlined. 
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Nicked CP (CP*) Retains the Native Fold of the Intact Protein 
Purified intact CP was reacted with thrombin at 37°C for 2 hours, such that the amount of 
intact CP, estimated from the intensity of the 132-kDa band, was < 5% compared to that of 
CP*. Thrombin traces were eliminated from the proteolysis mixture by affinity 
chromatography on a benzamidine-Sepharose column. The completeness of the proteolytic 
reaction at the scissile bonds Arg481-Ser482 and Lys887-Val888 was checked by SDS-PAGE 
(4-10% acrylamide), showing the presence of fragments 1-481 (67 kDa band), 482-887 (50 
kDa band) and 888-1046 (19 kDa band), and the concomitant absence of intact CP (1-1046; 
132 kDa band) and that of the overlapping fragment 1-887 (116 kDa band). The persistence of 
a minor band at 72 kDa, corresponding to the overlapping fragment 482-1046, indicates that 
the peptide bond Lys887-Val888 is slightly more resistant to thrombin proteolysis than 
Arg481-Ser482 bond, consistent with the substrate specificity of thrombin which prefers an 
Arg-residue at P1 (38). 
 Size-exclusion chromatography (SEC) analysis (Fig. 4.5) indicates that intact and 
nicked CP (CP*) are eluted at the same volume of effluent, thus suggesting that the molecular 
size and global fold of CP remain unchanged after proteolysis, with an estimated molecular 
weight of about 160 kDa, in agreement with the molecular weight of CP = 132 kDa. 
Figure 4.5 Size-exclusion chromatography of intact (CP) and nicked CP (CP*  ). Aliquots (0.2 ml; 
0.5 mg/ml) of CP and CP* were loaded on a Superose-12 column eluted at flow of 0.3 ml/min, with 25mM Tris-
HCl pH 7.4, 0.15M NaCl buffer. The absorbance of the effluent was recorded at 280 nm using a 0.2cm 
pathlength detection cell. (Inset) Column calibration with protein standards (). From the calibration curve, a 
molecular weight of ~160 kDa was estimated for both CP and CP* (). 
0 5 10 15 20 25 30
0
5
10
15
20
25
A
b
s
o
rb
a
n
c
e
 a
t 
2
8
0
 n
m
 (
m
A
U
)
Volume (ml)
3.6 4.2 4.8 5.4
0.2
0.4
0.6
0.8
K
D
log (MW)
4.2 Proteolysis of Ceruloplasmin by Thrombin 
128 
Figure 4.6 Conformational characterization of intact (CP ) and nicked CP (CP*  ). (A) UV/Vis 
absorption spectra of CP and CP*. The spectra were reordered at 25±0.1°C, using a 1 cm pathlength cuvette. (B)
Fluorescence spectra of CP and CP* were obtained by excited protein samples at 280 nm with an 
excitation/emission slit of 1 and 3, respectively. CD spectra of CP and CP* in the far- (C) and near-UV (D)
region. All measurements were carried out at 25±0.2°C in 20mM Tris-HCl buffer pH 7.4, at a protein 
concentration of 0.2 mg/ml, except near-UV CD measurements (0.5 mg/ml). 
 Very similar conclusions can be drawn from UV/Vis absorption (Fig. 4.6A) and 
emission fluorescence (Fig.4.6B) spectra, indicating that the chemical environment 
surrounding copper-binding sites (i.e. UV-Vis) and aromatic amino acids (i.e. fluorescence) 
remains essentially unchanged after proteolysis. Likewise, far-UV CD spectra indicate that 
CP* retains the β-sheet secondary structure of CP (Fig. 4.6C), whereas the lower CD signal of 
CP* in the near-UV region (Fig. 4.6D) is suggestive of a looser tertiary packing in the nicked 
protein, as already observed with copper-free apo-CP (39). Overall, our results strongly 
suggest that, after 2-h proteolysis with thrombin, CP* can be essentially regarded as a 
fragment complementing system in which fragments 1-481, 482-887, and 888-1046 tightly 
interact to form a non-covalent complex possessing native-like structure. 
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Thrombin-Mediated Proteolysis of CP Hinders MPO Inhibitory Activity without Altering 
Ferroxidase Activity 
The time-course proteolysis reaction of CP with thrombin was monitored by SDS-PAGE (Fig. 
4.7A) and at each time-point the functional properties of CP/CP* were studied with respect to 
its ability to promote oxidation of Fe+2-ion and to inhibit the oxidase activity of leukocyte 
MPO (Fig. 4.7B). Aliquots of the proteolysis reactions were taken, treated with PMSF to 
irreversibly inhibit thrombin, and then tested with respect to their ferroxidase and MPO 
activities. Our data unequivocally demonstrate that the ferroxidase activity of CP is not 
affected by proteolysis; whereas inhibition of MPO is dramatically reduced during 
proteolysis, and after 2-h reaction, when the relative amount of intact CP is negligible the 
inhibition of MPO is totally abolished (Fig. 4.7B). Notably, incubation of CP with the 
catalytically inactive thrombin S195A mutant does not decrease the ability of CP to inhibit 
MPO oxidase activity. Moreover, control experiments demonstrate that thrombin does not 
alter the function of MPO in the absence of CP. These results provide clear-cut evidence that 
the inhibition of MPO can be reverted by thrombin through proteolysis of CP. 
Figure 4.7 Effect of thrombin cleavage on the ferroxidase and MPO inhibitory activity of CP. (A) SDS-
PAGE analysis of the proteolysis reaction of CP with thrombin. At the indicated time points, aliquots (10 µl) of 
the proteolysis reaction were taken ad analyzed on a 4-10% acrylamide gel. (B) Freshly purified CP (120 nM) 
was treated at 25°C with human thrombin (1.2nM) in TBS pH 7.4. At the time points as in panel A, aliquots 
were taken, thrombin was inactivated by adding an equimolar concentration of PMSF, and the ferroxidase and 
MPO inhibitory activity of hCP was determined. The ferroxidase activity (-) of CP*, generated during 
proteolysis with thrombin, was determined at 25°C by the rate of Fe+3-DMF complex formation at 310 nm in 
0.1M sodium acetate buffer pH 5.5, containing 30mM thiourea and 200mM Fe+2. The MPO inhibitory activity
(-) of the newly generated CP* was determined at 25°C by measuring the rate ABTS•+ formation at 414 nm 
in the same buffer with [MPO] = 20nM. Control measurement (
-
) was carried out in the absence of CP. 
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Probing Thrombin-CP Interaction 
The interaction of thrombin with CP was investigated by several different spectroscopic 
techniques, including dynamic light scattering (DLS) (Fig. 4.8A), fluorescence spectroscopy 
(Fig. 4.8B) and surface plasmon resonance (SPR) (Fig. 4.8C, 4.8D). To avoid proteolysis of 
CP during analysis, human thrombin was irreversibly inhibited at the active site with (D)-Phe-
Pro-Arg-choromethyl ketone (PPACK) and used in DLS measurements, whereas the inactive 
thrombin S195A mutant was used in fluorescence and SPR analyses. Notably, mutation of 
Ser195 with Ala abrogates the catalytic activity of thrombin without altering its binding 
properties [Johnson et al., 2005#37; Pozzi et al., 2013#32]. 41 
 The molecular diameter (d) of PPACK-thrombin (Thb) and CP alone were determined 
by DLS as 4. ±0.1nm and 7.5±0.1 nm (Fig. 4.8A), respectively, with a polydispersity index 
significantly higher for PPACK-thrombin (0.29) compared to that of CP (0.17). From the 
calibration curve (Fig. 4.8A, Inset) the apparent molecular weight (MW) of PPACK-thrombin 
and CP was estimated at 40 kDa and 140 kDa, respectively, in agreement with the MW of the 
two proteins (Thb = 36kDa and CP = 132kDa). Interestingly, the d-value of CP gradually 
increased after addition of Thb, from 0.5:1 to 5:1 molar ratio, together with the increase in the 
polydispersity index. At a Thb:CP molar ratio of 3:1, a d-value of 8.5±0.2nm was determined, 
corresponding to an apparent MW of about 190 kDa (Fig. 4.8A, Inset). This value is 
reasonably compatible with the formation of a 1:1 complex between two proteins, like Thb 
and CP, that both contain extended carbohydrate chains. 
 The affinity of thrombin for CP was determined quantitatively by recording the 
decrease of fluorescence intensity of CP after addition of the catalytically inactive thrombin 
S195A mutant. Fitting data points with an equation that describes the one-site binding model, 
yields an equilibrium dissociation constant, Kd, of 267±30nM (Fig. 4.8B). 
 CP-thrombin interaction was also studied by Surface Plasmon Resonance (SPR). CP 
was first immobilized on a CM5 sensor chip and then incremental concentrations of PPACK-
thrombin or S195A were injected in the mobile phase (Fig. 4.8C). The data relative to the 
binding of PPACK-thrombin were interpolated with one-site binding model, and resulted in a 
good fit, with a Kd of 56±2nM (Fig. 4.8D, -), comparable to that estimated by fluorescence 
measurements. When the same equation was used to interpolate the data of S195A binding 
(Fig. 4.8D, -), a poor fit was obtained (dashed line), with a Kd = 3.2±0.8µM. Notably, after 
interpolating the data points with the equation that describing a two-site binding model, a 
much better fit was obtained (continuous line). Analysis of binding data suggests the presence 
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of at least two binding sites on CP: a high-affinity site (Kd1 of 65±8nM) and a low-affinity 
site (Kd2 of 9.0±1.1µM). 
  
Figure 4.8 Probing CP-thrombin interaction by Dynamic Light Scattering (DLS) and fluorescence 
spectroscopy and SPR. (A) DLS spectra of isolated PPACK-thrombin (Thb: 100 µg/ml, -), isolated CP (100 
µg/ml, -), and PPACK-Thb:CP mixture (-) in a 3:1 molar ratio (3µM Thb with 1µM CP). (Inset) Plot of the 
experimental molecular diameter (d) of standard proteins versus log MW. (B) Fluorescence binding of thrombin 
S195A mutant to CP (50 nM) yields a Kd = 267±30nM. (Inset) At each S195A concentration, the fluorescence 
of CP-Thb mixture (Mix) was subtracted for the contribution of thrombin alone (Thb) at the same concentration, 
to yield the fluorescence change associated with complex formation (Mix-Thb). (C) Sensograms of CP-S195A 
interaction. (D) SPR analysis of thrombin-CP interaction and mapping of thrombin binding sites. -: binding of 
active site-inhibited PPACK-thrombin to immobilized CP; 
-
: binding of PPACK-thrombin having exosite 1
saturated with hirugen; -: binding of PPACK-thrombin having exosite 2 saturated with γ-peptide; -: 
binding of thrombin S195A mutant to immobilized CP. The data are expressed as the plot of RU at increasing 
[thrombin]. Fitting PPACK-thrombin binding data results in Kd = 56 ± 2 nM; Fitting of S195A binding data with 
eq. describing a two-site binding model, give a Kd1 = 65 ± 8 nM and a Kd2 = 9.0 ± 1.1 µM. 
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 The role of thrombin exosites in CP binding was assessed in SPR competition 
experiments (Fig. 4.8D), whereby PPACK-thrombin solutions were first incubated with 
saturating concentrations of ligands specific for exosite 1 (i.e. hirugen) or exosite 2 (i.e. 
fibrinogen γ-peptide) and then injected over the CP-bound sensor chip. The decrease in the 
SPR signal (%RU) was interpreted as an indication that the blocked exosite was involved in 
the interaction with CP. The results indicate that blockage of either one of the two thrombin 
exosites results in the reduction of RU by > 90%, such that a reliable Kd could not be 
estimated. 
Mutual Effects of Thrombin and CP Binding: 
Active Site-Blocked Thrombin Inhibits the Ferroxidase Activity of CP whereas CP does not 
Affect the Hydrolytic Activity of Thrombin 
The effect of thrombin binding on CP function was investigated by measuring the rate of Fe+2
oxidation by CP as a function of [Fe+2] at increasing concentration of PMSF-thrombin (Fig. 
4.9A, 4.9B). Covalent blockage of thrombin active-site with PMSF was necessary to prevent 
binding of the protease to potential proteolytic sites on CP surface and therefore to study the 
effect of thrombin binding on CP function independently from proteolysis. Remarkably, 
PMSF-thrombin inhibited the ferroxidase activity of CP in a concentration-dependent manner 
and Hanes-Wolff analysis of the reaction rates indicated that that PMSF-thrombin increased 
the value of Kmapp (from 57 to 138µM), without substantially affecting vmax (Fig. 4.9A). 
These findings are compatible with a competitive mechanism of CP inhibition by thrombin, 
whereby the enzyme covers the ferroxidase site of CP and competitively impairs binding of 
Fe+2 at that site. From the secondary plot of Kmapp versus [PMSF-thrombin] (Fig. 4.9B), a 
value of the equilibrium inhibition constant (KI) was determined as 220±20nM, very close to 
the Kd value of PPACK-thrombin binding estimated from fluorescence measurements (Kd = 
267±30nM). 
 The effect of CP binding on thrombin hydrolytic activity was measured by recording 
the time-course release of pNA from the chromogenic substrate S2238 in the presence of 
increasing [CP] (Fig. 4.9C). Our results indicate that the rate of pNA release is unchanged 
even at [CP] = 20µM, a concentration approximately 100-fold higher than the Kd value of 
thrombin-CP complex. This finding provides experimental evidence that, after CP binding, 
the active site of thrombin remains accessible and functional. 
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Figure 4.9 Mutual effects of thrombin and CP binding. (A) Effect of thrombin on the ferroxidase activity of 
CP. To a solution of purified hCP were added increasing concentrations of PMSF-inactivated thrombin (, 0 
nM; , 120 nM; , 360 nM). The resulting ferroxidase activity of hCP 1 yields Km
app values of 57±2, 80±3 and 
138±6 µM and Vmax values of 301±20, 302±18 and 300±25 nMh-1. (B) Secondary plot of Kmapp versus [PMSF-
thrombin]. Data fitting yields a KI = 220±20 nM. (C) Effect of CP on the hydrolytic activity of human thrombin. 
The release of pNA from the substrate S2238 (20µM) by thrombin (100pM) was measured at 37°C in the 
absence () and in the presence of 2µM () and 20µM (
) CP. As a control, the time course hydrolysis of S2238 
was carried out without adding thrombin (), in the presence of 1µM CP. 
The Synovial Fluid of Patients with Rheumatoid Arthritis (RA) Contains Proteolyzed CP, 
Apo-CP and Variable Amount of MPO and Thrombin 
Samples of synovial fluid taken from 24 patients with a history of RA were analyzed by SDS-
PAGE and Western blotting with rabbit anti-CP polyclonal Ab (Fig. 4.10A). For comparison, 
blood serum samples were also analyzed. As expected, serum CP (lane K in Fig. 4.10A) 
migrated as a single band at 132 kDa, corresponding to intact CP, with only a faint reactive 
band at 116 kDa. Conversely, CP-related species from synovial fluid samples migrated as 
multiple reactive bands at lower MW. For instance, intact CP was the predominant species in 
sample 5, even though several other reactive bands at 116, 72, 67, and 50 kDa were present. 
The latter bands were variably represented in all other samples analyzed, whereas the 132-
kDa band was missing, thus indicating that CP undergoes proteolytic degradation in the 
synovial fluid. This conclusion was confirmed by adding an aliquot (1µl) of sample n.1, 
corresponding to lane 1 in Fig. 4.10A, to a solution of purified CP. As shown by Western 
blotting analysis (Fig. 4.10B), low-molecular weight CP-species were produced over time and 
the fragmentation pattern resembled that obtained after in vitro proteolysis of purified CP 
with thrombin. Strikingly, as already shown for thrombin-mediated proteolysis of CP in vitro 
the data in Fig. 4.10D demonstrate that proteolytic degradation of CP induced by the synovial 
fluid sample n.1 is inhibited by hirudin. This finding demonstrates the involvement of 
thrombin in the proteolytic degradation of CP in the synovial fluid of RA patients. 
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Figure 4.10 Identification of proteolyzed CP in the synovial fluid of rheumatoid arthritis (RA) patients 
and quantification of MPO and thrombin in the synovial fluid of RA patients. Samples were analyzed by 
SDS-PAGE and Western blotting using rabbit anti-hCP Ab and peroxidase-conjugated goat anti-rabbit IgG. ()
Proteolyzed CP species in samples from RA patients. Lanes 1-4 and 6-12: synovial fluid samples (5	l) of RA 
patients displaying different extent of proteolytic degradation and lacking the 132 kDa band, characteristic of 
intact hCP; lane 5: representative sample (5	l) of the synovial fluids containing the 132 kDa band; lane K: blood 
plasma (2	l). (B) Proteolytic degradation of purified CP by the synovial fluid of RA patients. Lanes 1-8: freshly 
purified CP (2mg/ml; 10µl) in TBS was added with 0.5	l of synovial fluid sample corresponding to lane 1 in 
panel A. Aliquots (5µg) of the reaction mixture were taken and analyzed over time, as indicated. (C) 
Identification of apo- and holo-CP in the synovial fluid of RA patients. Lane 1: purified apo-CP (1	g), obtained 
by treating holo-CP with KCN; lane 2: purified holo-CP (1	g); lane 3 synovial fluid sample (5µl) from a RA 
patient. To prevent copper depletion, samples for electrophoresis were prepared in the absence of SDS and 
without heat treatment. Notably, apo-CP migrates faster than holo-CP. (D) Effect of hirudin on the proteolysis of 
purified CP. Lane 1: purified CP (20µg); lane 2: purified CP (20µg) added with synovial fluid sample (1µl), 
corresponding to lane 1 in panel A, after 1-h incubation at 37°C; lane 3: as in lane 2, after 12-h incubation; lane 
4: as in lane 2, in the presence of hirudin (2µg); lane 5: aliquot (10	l) of synovial fluid sample (lane 1 in panel 
A); lane 6: molecular weight protein standards. (E) Quantization of MPO and thrombin in the synovial fluid of 
RA patients. The levels of thrombin and MPO in synovial fluid samples were determined as detailed in the 
Methods. The numbers refer to the samples analyzed in panel A. Three different clusters can be identified (P, Q, 
and R), with different thrombin/MPO titers and intact CP. Cluster P (
) contains 11 samples with low titers of 
both MPO and thrombin and variable amount of intact CP, as given by the presence of the 132 kDa band; 
clusters Q () and R () contain 8 or 5 samples, with variably high titers of thrombin and MPO respectively, in 
which intact CP is absent, whereas titers are. 
A
1     2     3     4     5     6     7     8        kDa
B
0    15   30   45   60  90  120  240      min C
1       2     3      4      5       6    kDa
132
110
70
50
40
35
15D 0.0 0.5 1.0 1.5 2.0 2.5
0
500
1000
1500
2000
2500
M
P
O
 (
n
g
/m
l)
Thrombin (NIH/ml)
5
10
412
11 8
3
7
9
6
2
1
E
P
Q
R
E
4.2 Proteolysis of Ceruloplasmin by Thrombin 

135 
Notably, Western blotting analysis of the synovial fluid in RA patients revealed the presence 
of significant amount of (copper-free) apo-CP (Fig. 4.10C). However, the average total 
copper concentration (i.e. Cubound + Cufree) in the synovial fluid of the 24 patients tested was 
determined as 0.96±0.19mg/l, very close to the plasma concentration of copper in normal 
individuals (31). After dialysis of synovial fluid samples with a 3-kDa cut-off membrane, 
about 2/3 of total copper remained in the well, while the residual copper (1/3) was found in 
the dialysate. This finding demonstrates that significant copper depletion from CP occurs in 
RA patients. 
 The levels of MPO and thrombin in the synovial fluid of RA patients are reported in 
Fig. 4.10E. Although no clear trend can be delineated, three clusters (i.e. P, Q and R) can be 
identified according to the levels of MPO and thrombin. Cluster P comprises 11 out of 24 
samples, all containing very low titers of MPO and thrombin and low amount of proteolyzed 
CP, cluster P is characterized by the presence of a distinctive band at 132 kDa, corresponding 
to intact CP (i.e. sample n. 5 in Fig. 4.10A). The samples belonging to cluster Q (8 out of 24) 
display relatively high MPO and low thrombin levels. Although intact CP is missing in these 
samples (i.e. sample n. 3, 4, 8, 10, 11, 12), the presence of bands at high molecular weight is 
suggestive of reduced proteolytic activity. Cluster R contains 5 samples, all displaying high 
MPO and thrombin titers. In these samples (i.e. sample n. 1, 2, 6, 7, 9), CP extensively 
degraded, as documented by the absence of high molecular weight bands and by the 
concomitant accumulation of a 50-kDa band, considered as the end-point of proteolytic 
degradation of CP (40). 
Hirudin Treatment Ameliorates the Clinical Symptoms of Rheumatoid Arthritis 
From the group of 24 Russian patients with RA previously analyzed, 19 patients were treated 
with an ointment containing hirudin, whereas 5 patients were untreated and used as controls. 
At the end of the treatment (14 days), eight patients reported moderate pain relief, but the 
reduction of edema remained within the error margins. Notably, CP was somewhat 
proteolyzed in the synovial fluid of these patients. Strikingly, 11 patients reported cessation of 
pain, and the edema of their joints was noticeably reduced when compared to controls. 
Furthermore, much of CP in their synovial fluid was intact, as judged by the relative 
abundance of the 132-kDa band in SDS-PAGE. The remaining five untreated patients 
reported exacerbation of pain, increased swelling of the knee joint and extensive proteolytic 
degradation of CP. Although the number of patients enrolled in this study is too small to draw 
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statistically significant conclusions, the levels of intact CP in synovial fluid samples seem to 
positively correlate with hirudin treatment. 
DISCUSSION 
Structural Analysis of CP Cleavage by Thrombin 
 Along the 1046 amino acid-sequence of CP, there are many potential cleavage sites for 
thrombin (i.e. 40 Arg- and 65 Lys-residues). In addition, the sequence of the thrombin 
proteolytic sites on CP surface, i.e. PQSR481S482VPP and PYLK887V888FNP, only 
partially conform to the consensus substrate specificity reported for the protease, i.e. P4(φal)-
P3(x)-P2(Pro)-P1(Arg)P1(s)-P2(φar)-P3(Arg)-P4(φal) (38), where x stands for any amino 
acid and φal and φar are apolar aliphatic or aromatic residues. Nevertheless, CP proteolysis is 
limited exclusively at the peptide bonds Arg481-Ser482 and Lys887-Val888 (Fig. 4.11A), 
while and the resulting noncovalent complex CP*, has a native-like fold (Fig 4.5, 4.6) that is 
quite resistant to further proteolysis even at higher thrombin:CP ratio (up to 1:5) or after 
prolonged reaction time (up to 5h). 
 The unique susceptibility of CP to thrombin hydrolysis can be explained on the basis 
of the three-dimensional structure of CP (10, 11) and on the general structural requirements 
for limited proteolysis (41). Beyond substrate specificity among competing sites on the 
protein surface, in fact, limited proteolysis is dictated by the exposure of the cleavable site 
and, most importantly, by its conformational flexibility. Indeed, proteolysis occurs at exposed 
and flexible loops and rarely at sites embedded in rigid secondary structure elements (41). In 
the case of CP, >50% of the amino acid residues are embedded in β-sheets (39%) or α-helices 
(13%) and therefore are protected from proteolysis. Conversely, Arg481-Ser482 bond is in the 
loop region connecting domain 3 and 4 on the outer surface of CP, while Lys887-Val888 
bond is in the loop bridging domain 5 and 6 in the flat/basal region of the molecule (Fig. 
4.11B). Furthermore, both cleavable sites are characterized by high surface exposure and 
conformational flexibility, compared to other potentially competing segments, such that they 
are not visible in the crystallographic CP structure. Although proteolysis of CP by thrombin 
has important functional implications, our results also account for the so-called “spontaneous” 
degradation of CP occurring during prolonged storage of highly purified preparations and set 
a point to the long-lasting debate on the single-chain nature of circulating bioactive CP (42, 
43). 
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Figure 4.11 Analysis of thrombin proteolytic sites on CP structure. (A) Scheme of CP domain architecture 
and identification of thrombin proteolytic sites (indicated by arrows), as obtained from peptide mass fingerprint 
analysis. (B) Ribbon drawing of the crystallographic structure of CP (4ENZ.pdb). Left panel: side view; right 
panel: top view. β-sheets are colored in cyan, while helices are in red; copper (orange), Na+ (violet) and Ca+2
(green) ions are also shown, together with the Fe+2 ion (magenta) in the putative ferroxidase site. Unresolved 
chain segments in the X-ray structure of CP are delimited by sequence numbers, while arrows indicate thrombin 
cleavage sites. In the ferroxidase site, Fe+2 is coordinated by Glu272, Glu935, His940 and Asp1025, and is at 
~8Å form the mononuclear copper center underneath, where the copper ion is coordinated by His975, Cys1021 
and His1026.
Proteolysis has Opposite Effects on CP Functions 
 The structural integrity of CP is important for the glutathione-dependent peroxidase 
activity of the protein (44) and for CP-mediated loading of iron into ferritin (45). In 
agreement with these studies, the data shown in Fig. 4.7 indicate that limited proteolysis by 
thrombin abrogates the MPO inhibitory function of CP. However, the data also show that the 
ferroxidase activity of CP is not affected by thrombin-induced proteolysis. These opposite 
effects can be rationalized by analyzing the structure of intact CP and proposing reasonable 
mechanisms explaining how peptide bond cleavage might perturb the ferroxidase site of CP 
and its MPO binding site. 
 Considered that nicked CP* essentially retains the native-like structure of the intact 
protein (Fig 4.5, 4.6) and that the ferroxidase site in intact CP, and perhaps also in the nicked 
CP*, is separated from the scissile bonds R481-S482 and K887-V888 by about 45 and 50 Å, 
respectively, it is very unlikely that local perturbations, possibly evoked after peptide bond 
cleavage, are transmitted long-range to the ferroxidase site in such a way to alter its function. 
A
B
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Therefore, the ferroxidase activity of CP is predicted to remain unchanged after proteolysis, 
as experimentally verified (Fig. 4.7). On the other hand, the abrogation of MPO inhibition 
observed with CP* (Fig. 4.7) is nicely explained by the crystallographic structure of CP-MPO 
complex, very recently solved at low resolution (4EJX Z.pdb) (11). This structure shows that 
CP interacts with MPO through its lower flat and positively charged surface, thus hindering 
access of substrates to the deep pocket leading to MPO active site, where the heme-group is 
bound (Fig. 4.12A). In particular, the 884-890 loop containing the scissile bond Lys887-
Val888 in CP makes numerous contacts with a wide hydrophobic pocket surrounding the 
heme-group of MPO in the protein region across the N-termini of the light and heavy chains, 
thus limiting substrate accessibility. Importantly, the role of this loop in CP-MPO interaction 
has been confirmed by the synthetic peptide 883PYLKVFNPRR892, which can effectively 
inhibit the peroxidase activity of MPO (11). Of note, the other scissile bond Arg481-Ser482 in 
the 475-483 loop on CP structure is located in the upper region of the molecule and does not 
seem to participate in CP-MPO interaction. On these grounds it is conceivable that cleavage 
of the 884-890 loop in CP can dramatically alter both the stereochemical and electrostatic 
properties of this segment in such a way that free CP* looses affinity for MPO. 
Thrombin-CP Interaction 
 A major achievement of this work is that thrombin has an intrinsic affinity for CP, and 
that this affinity is only marginally related to the binding of CP at the protease active site, 
leading to CP hydrolysis. Quantitative data on thrombin-CP interaction were obtained by 
different techniques, including fluorescence, SPR and inhibition of ferroxidase activity. The 
affinity of thrombin for CP, obtained from fluorescence binding experiments of the inactive 
S195A thrombin mutant (Kd=267±30nM) (Fig. 4.9B), was identical to that deduced from 
inhibition of CP ferroxidase activity by active-site blocked PMSF-thrombin (KI=220±20nM) 
(Fig. 4.6). A comparable Kd value was obtained from SPR measurements of active-site 
blocked PPACK-thrombin to immobilized CP (Kd=56±2nM) (Fig. 4.9D). In these 
experiments a single binding site for thrombin was identified on CP structure. Conversely, 
when SPR experiments were carried out with thrombin S195A mutant, having the active site 
empty, at least two binding sites were identified on CP: a low-affinity site (Kd2=9.0±1.1µM) 
and a high-affinity site (Kd1=65±30nM), having a Kd value identical to that determined for 
PPACK-thrombin (Kd=56±nM) (Fig. 4.9D). A key aspect emerging from SPR experiments is 
that interaction is abrogated after saturating either one of the two exosites with specific 
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peptide binders (i.e. hirugen or fibrinogen γ-peptide), thus demonstrating that both thrombin 
exosites are involved in CP binding (Fig. 4.9D). 
Figure 4.12 Structural Models of complexes of CP with MPO and thrombin. (A) Crystallographic structure 
of MPO-CP complex (4EJX.pdb) (11). CP structure is shown as a color-coded surface, whereas MPO is shown 
in green. (B) Theoretical model of thrombin-CP complex. The approximate position of the catalytic site is 
indicated by an arrow. The loop regions on CP structure that are cleaved by thrombin are also indicated. The 
docking model was obtained using the HEX software, starting from the coordinates of isolated CP (4ENZ.pdb) 
and thrombin (1PPB.pdb).
 To interpret our binding data, a theoretical docking model of thrombin-CP interaction 
was generated (Fig. 4.12B, 4.13). The model clearly shows geometric and electrostatic 
complementarity between the positively charged exosites on the convex surface of thrombin 
and the large negative, concave surface in the upper region of CP molecule, where the 
ferroxidase site is located. Importantly, the model also shows that thrombin covers the 
ferroxidase site of CP and impairs substrate entrance and product release, while leaving the 
protease active site fully accessible for ligand/substrate binding. This is a key structural 
insight for explaining the observed mutual effect of CP and thrombin binding, whereby 
PMSF-thrombin competitively inhibits the ferroxidase activity of CP (Fig. 4.9A, B), whereas 
CP does not alter the hydrolytic activity of the protease (Fig. 4.9C). Finally, evaluation of 
SPR binding data in the light of the docking model allows us to propose that the high-affinity 
binding site spans the negative concave surface in the upper region of CP, whereas the low-
affinity site(s) can map in the cleavable loop regions 885-889 or 476-482. When thrombin 
active site is filled with PPACK, only the high-affinity site is available. Instead, in S195A the 
active site is empty, so both binding sites are available on CP surface. 
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Figure 4.13 Theoretical model of the ternary complex MPO-CP-Thb. The docking model was obtained using 
the HEX software, starting from the coordinates of MPO-CP complex (4JEX.pdb) and thrombin (1PPB.pdb). 
MPO interacts with the bottom, flat surface of CP which is positively charge, whereas thrombin binds to the 
upper surface of CP, which is negatively charged. The active site of the serine protease remains free and 
accessible for substrate binding.
Relevance of CP Proteolysis by Thrombin in the Pathogenesis of Rheumatoid Arthritis 
 The fragmentation pattern of purified CP, obtained after in vitro proteolysis with 
thrombin or after prolonged storage (Fig. 4.3A and Fig.4.7A), is similar to that of CP present 
in the synovial fluid of patients with rheumatoid arthritis (RA) (Fig. 4.10A). More 
importantly, the proteolytic degradation of purified CP, induced by addition of exogenous 
thrombin or of synovial fluid samples from RA patients, is effectively blocked by hirudin, a 
highly potent inhibitor that displays absolute specificity for thrombin (Fig. 4.1B and Fig. 
4.10D) (36). These observations provide strong indication that thrombin can proteolyses CP 
both in vitro and in vivo. Thrombin, however, is not the only CP cleaving protease: CP is also 
highly susceptible to digestive (i.e. trypsin and chymotrypsin), fibrinolytic (i.e. plasmin) and 
leukocyte (i.e. elastase and cathepsin G) proteases, which extensively degrade CP into small 
fragments devoid of any functional activity. Conversely, we have shown that thrombin-
mediated proteolysis is “limited” at only two sites and selectively abrogates the ability of CP 
to inhibit the oxidase activity of MPO, whereas it does not alter the ferroxidase function. 
Hence, it is possible to speculate that thrombin, at variance with other proteases, might 
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regulate via proteolysis CP function in vivo, especially in those clinical settings where the 
concentrations of CP, thrombin and MPO are increased, such as in RA. 
 RA is a widespread, chronic inflammatory disease more frequently affecting the 
synovial membrane of flexible joints (46). Even though the initiation of RA is thought to be 
driven by T lymphocytes, activation of the coagulation cascade as been proposed as an 
important nonimmunological pathway amplifying and perpetuating the features of chronic 
inflammation in RA joints (22). Increased permeability of the inflamed synovial 
microvasculature leads to extravasations of inflammatory leukocytes and clotting factors, 
such that intact extrinsic coagulation pathway has been demonstrated within the RA 
synovium, with higher expression in RA patients of tissue factor, fibrinogen (>2-fold) and 
thrombin (>7-fold) (29) compared with osteoarthritis patients. Thrombin activation leads to 
abundant deposition of fibrin, a distinctive feature of RA joints, which in turn exacerbates the 
disease either by mechanically altering the functionality of the affected joint and by forming a 
matrix onto which inflammatory leukocytes can be activated via αMβ2 integrin receptor (47). 
Activated leukocytes then start releasing proteases, inflammatory cytokynes, and MPO, which 
is the major route to the burst of ROS and RNS production, thus amplifying inflammation and 
tissue damage. In inflamed tissues thrombin induces the release of pro-inflammatory 
cytokines from monocytes and macrophages, including interleukin-6 (IL-6) (28). Besides its 
role in sustaining inflammatory processes, IL-6 also markedly increases the expression of CP 
(8), which would downregulate inflammation via MPO inhibition (19). The cellular effects of 
thrombin in RA seem to be mediated by activation of PAR1, which is abundantly expressed in 
inflamed rheumatoid synovial tissues (48). However, soft tissue inflammation and synovitis 
were reduced by only 30 or 20% in PAR1 deficient mice compared to controls (49). The 
cellular effects of thrombin in RA seem to be mediated by activation of the thrombin receptor 
PAR1, which is abundantly expressed in inflamed rheumatoid synovial tissues. 
 These results, while strongly supporting the role of the thrombin-PAR-1 axis in animal 
models of RA, also suggest that other mechanisms, different from PARs activation, may 
function to sustain inflammation and tissue damage in rheumatoid joints. In this study, we 
propose that thrombin may act as an indirect stimulator of MPO prooxidative function by 
releasing the breaks that CP exerts on the enzyme. Our data also show the concomitant 
presence of apo-CP (Fig. 8C) and higher levels of free copper in the synovial fluid of arthritic 
patients.  
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Å   Angstrom 
ABTS    2,2-azino-bis(3-ethyl benzthiazoline-6-sulphonic acid) disodium salt  
CD  Circular Dichroism 
Da   Dalton 
DLS   Dynamic Light Dcattering 
DMF    N,N-dimethylformamide  
DMSO   dimethyl sulfoxide 
EDC   N-ethyl-N-dimethylaminipropylcarbodiimide   
EDTA    Ethylene Diamino Tetracetic Acid 
ESI    Electrospray ionization 
Gdn-HCl  Guanidine Chloride 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC    High-pressure liquid chromatography 
IPTG    IsoPropyl-β-D-ThioGalactopyranoside 
LPS   Lypopolysaccharide 
MALDI  Matrix-Assisted Laser Desorption Ionization 
MS   Mass spectrometry 
MW     Molecular Weight 
NAPAP .N-(2-naphthyl-sulphonyl-glycyl)-D,L-p-amidinophenylalanyl-piperidine  
NHS   N-hydroxysuccinimide 
PABA   p-aminobenzamidine  
PEG      PolyEthylene Glycol 
PMSF   Phenylmethylsulphonyl fluoride  
PPACK  D-Phe-Pro-Arg-chloromethyl ketone 
RP   Reverse-phase 
S-2238   D-Phe-Pip-Arg-p-nitroanilide 
S-2366   pyroGlu-Pro-Arg-p-nitroanilide 
SDS    Sodium Dodecyl Sulfate 
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SDS-PAGE   SDS-PolyAcrylamide Gel Electrophoresis 
SEC   Size-exclusion chromatography 
SPR   Surface Plasmon Resonance 
TFA   Trifluoroacetic acid 
TOF   Time-of-flight 
Tris   Tris(hydroxymethyl)aminomethane 
UV   ultraviolet 
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Ala  A   Alanine 
Arg   R   Arginine 
Asp   D   Aspartic acid 
Asn   N   Asparagine 
Cys   C   Cysteine 
Gly   G   Glycine 
Gln   Q   Glutamine 
Glu   E   Glutamic acid 
His   H   Histidine 
Ile   I   Isoleucine 
Lys   K   Lysine 
Leu   L   Leucine 
Met   M   Methionine 
Phe   F   Phenylalanine 
Pro   P   Proline 
Ser   S   Serine 
Thr   T   Threonine 
Tyr   Y   Tyrosine 
Trp   W   Tryptophan 
Val   V   Valine 
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Chym T1h F1g G1f S1e G1d E1c A1b D1a C1 G2 L3 R4 
Ch-A 1 2 3 4 5 6 7 8 9 10 11 12 
Ch-B - - - - - - - - - - - - 
ProT 285 286 287 288 289 290 291 292 293 294 295 296 
Chym P5 L6 F7 E8  K9 K10 S11 L12 E13 D14 K14a T14b 
Ch-A 13 14 15 16 17 18 19 20 21 22 23 24 
Ch-B - - - - - - - - - - - - 
ProT 297 298 299 300 301 302 303 304 305 306 307 308 
Chym E14c R14d E14e L14f L14g E14h S14i Y14j I14k D14l G14m R15 
Ch-A 25 26 27 28 29 30 31 32 33 34 35 36 
Ch-B - - - - - - - - - - - - 
ProT 309 310 311 312 313 314 315 316 317 318 319 320 
            
Chym I16 V17 E18 G19 S20 D21 A22 E23 I24 G25 M26 S27 
Ch-A 37 38 39 40 41 42 43 44 45 46 47 48 
Ch-B 1 2 3 4 5 6 7 8 9 10 11 12 
ProT 321 322 323 324 325 326 327 328 329 330 331 332 
Chym P28 W29 Q30 V31 M32 L33 F34 R35 K36 S36a C37 Q38 
Ch-A 49 50 51 52 53 54 55 56 57 58 59 60 
Ch-B 13 14 15 16 17 18 19 20 21 22 23 24 
ProT 333 334 335 336 337 338 339 340 341 342 343 344 
Chym E39 L40 L41 C42 G43 A44 S45 L46 I47 S48 D49 R50 
Ch-A 61 62 63 64 65 66 67 68 69 70 71 72 
Ch-B 25 26 27 28 29 30 31 32 33 34 35 36 
ProT 345 346 347 348 349 350 351 352 353 354 355 356 
Chym W51 V52 L53 T54 A55 A56 H57 C58 L59 L60 Y60a P60b 
Ch-A 73 74 75 76 77 78 79 80 81 82 83 84 
Ch-B 37 38 39 40 41 42 43 44 45 46 47 48 
ProT 357 358 359 360 361 362 363 364 365 366 367 368 
Chym P60c W60d D60e K60f N60g F60h T60i E61 N62 D63 L64 L65 
Ch-A 85 86 87 88 89 90 91 92 93 94 95 96 
Ch-B 49 50 51 52 53 54 55 56 57 58 59 60 
ProT 369 370 371 372 373 374 375 376 377 378 379 380 
Chym V66 R67 I68 G69 K70 H71 S72 R73 T74 R75 Y76 E77 
Ch-A 97 98 99 100 101 102 103 104 105 106 107 108 
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Ch-B 61 62 63 64 65 66 67 68 69 70 71 72 
ProT 381 382 383 384 385 386 387 388 389 390 391 392 
Chym R77a N78 I79 E80 K81 I82 S83 M84 L85 E86 K87 I88 
Ch-A 109 110 111 112 113 114 115 116 117 118 119 120 
Ch-B 73 74 75 76 77 78 79 80 81 82 83 84 
ProT 393 394 395 396 397 398 399 400 401 402 403 404 
Chym Y89 I90 H91 P92 R93 Y94 N95 W96 R97 E97a N98 L99 
Ch-A 121 122 123 124 125 126 127 128 129 130 131 132 
Ch-B 85 86 87 88 89 90 91 92 93 94 95 96 
ProT 405 406 407 408 409 410 411 412 413 414 415 416 
Chym D100 R101 D102 I103 A104 L105 M106 K107 L108 K109 K110 P111 
Ch-A 133 134 135 136 137 138 139 140 141 142 143 144 
Ch-B 97 98 99 100 101 102 103 104 105 106 107 108 
ProT 417 418 419 420 421 422 423 424 425 426 427 428 
Chym V112 A113 F114 S115 D116 Y117 I118 H119 P120 V121 C122 L123 
Ch-A 145 146 147 148 149 150 151 152 153 154 155 156 
Ch-B 109 110 111 112 113 114 115 116 117 118 119 120 
ProT 429 430 431 432 433 434 435 436 437 438 439 440 
Chym P124 D125 R126 E127 T128 A129 A129a S129b L129c L130 Q131 A132 
Ch-A 157 158 159 160 161 162 163 164 165 166 167 168 
Ch-B 121 122 123 124 125 126 127 128 129 130 131 132 
ProT 441 442 443 444 445 446 447 448 449 450 451 452 
Chym G133 Y134 K135 G136 R137 V138 T139 G140 W141 G142 N143 L144 
Ch-A 169 170 171 172 173 174 175 176 177 178 179 180 
Ch-B 133 134 135 136 137 138 139 140 141 142 143 144 
ProT 453 454 455 456 457 458 459 460 461 462 463 464 
Chym K145 E146 T147 W148 T149 A149a N149b V149c G149d K149e G150 Q151 
Ch-A 181 182 183 184 185 186 187 188 189 190 191 192 
Ch-B 145 146 147 148 149 150 151 152 153 154 155 156 
ProT 465 466 467 468 469 470 471 472 473 474 475 476 
Chym P152 S153 V154 L155 Q156 V157 V158 N159 L160 P161 I162 V163 
Ch-A 193 194 195 196 197 198 199 200 201 202 203 204 
Ch-B 157 158 159 160 161 162 163 164 165 166 167 168 
ProT 477 478 479 480 481 482 483 484 485 486 487 488 
Chym E164 R165 P166 V167 C168 K169 D170 S171 T172 R173 I174 R175 
Ch-A 205 206 207 208 209 210 211 212 213 214 215 216 
Ch-B 169 170 171 172 173 174 175 176 177 178 179 180 
ProT 489 490 491 492 493 494 495 496 497 498 499 500 
Chym I176 T177 D178 N179 M180 F181 C182 A183 G184 Y184a K185 P186 
Ch-A 217 218 219 220 221 222 223 224 225 226 227 228 
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Ch-B 181 182 183 184 185 186 187 188 189 190 191 192 
ProT 501 502 503 504 505 506 507 508 509 510 511 512 
Chym D186a E186b G186c K186d R187 G188 D189 A190 C191 E192 G193 D194 
Ch-A 229 230 231 232 233 234 235 236 237 238 239 240 
Ch-B 193 194 195 196 197 198 199 200 201 202 203 204 
ProT 513 514 515 516 517 518 519 520 521 522 523 524 
Chym S195 G196 G197 P198 F199 V200 M201 K202 S203 P204 F204a N204b
Ch-A 241 242 243 244 245 246 247 248 249 250 251 252 
Ch-B 205 206 207 208 209 210 211 212 213 214 215 216 
ProT 525 526 527 528 529 530 531 532 533 534 535 536 
Chym N205 R206 W207 Y208 Q209 M210 G211 I212 V213 S214 W215 G216 
Ch-A 253 254 255 256 257 258 259 260 261 262 263 264 
Ch-B 217 218 219 220 221 222 223 224 225 226 227 228 
ProT 537 538 539 540 541 542 543 544 545 546 547 548 
Chym E217 G219 C220 D221 R221a D222 G223 K224 Y225 G226 F227 Y228 
Ch-A 265 266 267 268 269 270 271 272 273 274 275 276 
Ch-B 229 230 231 232 233 234 235 236 237 238 239 240 
ProT 549 550 551 552 553 554 555 556 557 558 559 560 
Chym T229 H230 V231 F232 R233 L234 K235 K236 W237 I238 Q239 K240 
Ch-A 277 278 279 280 281 282 283 284 285 286 287 288 
Ch-B 241 242 243 244 245 246 247 248 249 250 251 252 
ProT 561 562 563 564 565 566 567 568 569 570 571 572 
Chym V241 I242 D243 Q244 F245 G246 E247 
Ch-A 289 290 291 292 293 294 295 
Ch-B 253 254 255 256 257 258 259 
ProT 573 574 575 576 577 578 579 
In the first row the chymotrypsinogen numeration of thrombin is indicated; in the second row 
the numeration in which the first residue of the A-chain is designated as 1 is indicated.; in the 
third row the numeration in which the first residue of the B-chain is designated as 1 is 
indicated; finally, the last row show the numeration of prothrombin. 
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